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Abstract 
 
Introduction: Central nervous system (CNS) tumours and leukaemia in children are 
associated with detrimental neurocognitive outcomes across a wide range of 
cognitive domains. It is recommended these children receive regular 
neuropsychological assessment to screen for deficits that may affect their long term 
outcomes. Barriers to this include time constraints and practice effects associated 
with traditional neuropsychological assessment. CogState is a brief computerised 
neuropsychological battery which assesses the neurocognitive domains at risk in this 
population. This study aimed to evaluate the construct validity of the battery in this 
population through convergent validity with standardised neuropsychological 
measures. A secondary aim was to investigate the relationship between time since 
diagnosis and performance on the CogState battery.  
Method: A cross-sectional within subject correlation design was used to assess the 
construct validity in a sample of 37 children aged 8-16 years treated for leukaemia or 
CNS tumours. Partial correlation was used to assess the relationship between overall 
performance on the battery and time since diagnosis controlling for IQ and emotional 
distress.  
Results: One subtest of the CogState battery correlated significantly with the 
standard measure assessing the same cognitive domain, showing a large effect size. 
Four further subtests showed small to medium correlations, however these were not 
significant and confidence intervals were large. One subtest showed no clear 
correlation. No significant correlation was found between overall performance on the 
battery and time since diagnosis, however there was also no relationship between 
time since diagnosis and IQ in this sample.  
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Conclusion: This study provides some evidence for the construct validity of sections 
of the CogState battery in a paediatric oncology population. Sample characteristics 
and methodological limitations which may have affected the scope and reliability of 
results are discussed. Further research in larger samples is needed before it can be 
recommended as a standard follow up assessment.  
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1 Introduction 
1.1 Overview 
In this chapter an overview of cancer in children will be presented, focused on 
the two most common forms, leukaemia and brain tumours (BT). The evidence for 
the neuropsychological effects most commonly seen in the literature following 
treatment for these conditions will be discussed along with the literature on the 
progression of these effects over time. This is followed by a description of the 
current recommendations for clinical monitoring. A detailed review of the available 
literature on screening measures and batteries employed in a paediatric oncology 
population, used either clinically or to facilitate large scale research, will be 
presented with a critical evaluation of their strengths and weaknesses. Finally the 
CogState measure will be introduced and its potential as a screening and monitoring 
measure in this population discussed, highlighting the need for the current research to 
investigate its construct validity in this setting. The chapter ends with the research 
questions and hypotheses for this study based on this literature.   
 
1.2 Cancer in Children 
1.2.1 Prevalence and prognosis. 
Although cancer in children is much less common than in adults (Howlader et 
al., 2011) around 20,000 children are diagnosed with some form of cancer each year 
(Steen & Mirro, 2000) with 1,600 each year in UK (Scottish Intercollegiate 
Guidelines Network [SIGN], 2013). The two most common forms are leukaemias 
and central nervous system (CNS) tumours, which make up approximately half of 
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diagnoses (Stiller, 2007). It is estimated that there are 33,000 adult cancer survivors 
in the UK (SIGN, 2013).  
Acute Lymphoblastic Leukaemia (ALL) is the most common form of 
leukaemia in children in Western Europe, accounting for around 80% of cases. It is 
followed by Acute Myeloid Leukaemia (AML) which accounts for almost 20% 
(Stiller, 2009). In total the age-standardised incidence of all types of leukaemia in the 
United Kingdom is 46.7 cases per million person-years in children aged 0-14 years 
(Stiller, 2009). Overall survival rates for children diagnosed with ALL have 
improved considerably in recent decades and recent estimates of five year survival 
rates are around 90% (Hunger et al., 2012).  
There are a wide variety of different tumours affecting the brain in children 
which vary in location, histology and response to treatment. One of the most 
common is Medulloblastoma (MB), which makes up approximately 20% of all cases 
and is typically sited in the posterior fossa region of the brain. These tumours vary in 
histology and aggressiveness and those with the highest degree of dissemination are 
typically associated with the poorest prognosis (Ris & Abbey, 2010). Also common 
are low grade gliomas including Low grade Astrocytomas (LGA) and 
Oligodendrogliomas, both of which are histologically benign tumours. However they 
still require mainly surgical treatment and are associated with some late effects 
(Beebe et al., 2005; Steinlin et al., 2003).  Low grade gliomas constitute around 25% 
of paediatric brain tumour diagnoses (Ris & Abbey, 2010). Overall recent estimates 
of five year survival are around 65% for children diagnosed with CNS tumours 
(Butler & Haser, 2006). However there is a large degree of variability depending on 
the tumour location, histology and relative risk (based on factors including age and 
degree of dissemination). For example, for standard risk MB five year progression 
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free survival rates of 81-86% have been reported (Packer et al., 2006) whereas the 
corresponding rate for children with high risk MB is 40-57% (Zeltzer et al., 1999). 
Similarly for low grade gliomas survival rates are estimated at around 90% (Pollack, 
1999) whereas for high grade gliomas overall survival rate between 36-38% have 
been reported (Batra et al., 2014). 
 These survival rates, although varied, represent a large improvement over 
recent decades, largely due to improvements in treatment regimens. Therefore, 
increasing focus is now being placed on quality of life post treatment and the 
influence on late effects of both the disease and its treatment (Butler & Haser, 2006).  
 
1.2.2 Treatment. 
Treatment for ALL almost always consists of three phases, remission-
induction therapy, intensification (consolidation) therapy and continuation 
(maintenance) treatment. Therapy directed at the CNS is started very early in the 
course of treatment and given for varying lengths of time dependent on the level of 
risk. Corticosteroids, including dexamethasone, are very commonly used during the 
initial remission-induction phase. During the intensification phase chemotherapeutic 
agents including high dose methotrexate (MTX) amongst others are given (Pui & 
Evans, 2006). The most common form for treatment for ALL is intravenous 
chemotherapy combined with intrathecal chemotherapy (ITC), which is 
chemotherapy injected within the cerebrospinal fluid (Butler & Haser, 2006). ITC is 
mainly a prophylactic treatment aimed at preventing relapse. Cranial radiation 
therapy (CRT) is also used when the risk of CNS relapse is high. Periods of 12 to 18 
months of continuation therapy consisting of moderately intensive chemotherapy, 
including weekly MTX, are generally required (Pui & Evans, 2006).  
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 Treatment for CNS tumours is more variable due to the wide variation in 
location and type of tumour. Treatment for MB generally involves a combination of 
surgery and targeted or cranospinal radiation therapy (RT) and is risk-adapted so that 
more toxic treatment is only given if required by high-risk disease. Surgical 
treatments aim for gross total resection of the tumour and this is often achieved 
through incision in the cerebellar vermis (Ris & Abbey, 2010). In general RT needs 
to be given to the entire neuroaxis (cranospinal RT) with a boost to the tumour site. 
Recent protocols include the use of conformal RT which delivers the radiation in 
small doses through multiple planes to reduce the dose given to surrounding healthy 
tissue. The dose of RT is measured in grays (Gy) or centigrays (cGy). Standard 
therapy would be 5,400 cGy to the tumour site and 3,600 to the neuroaxis (Ris & 
Abbey, 2010) although more recently reduced doses have been trialled in an effort to 
reduce neurocognitive effects (Mulhern et al., 2005). Proton therapy is another recent 
advance in RT where a proton beam rather than photon beam, as in standard RT, is 
used. Protons have advantages over photons as they deposit most of their dose at the 
end of their range with almost no dose travelling further than this into healthy tissue 
meaning the treatment can be more accurately targeted (Schulz-Ertner & Tsujii, 
2007). This has been shown to greatly reduce the radiation received by surrounding 
healthy tissue (Fossati, Ricardi, & Orecchia, 2009; Stokkevag et al., 2014). However, 
this treatment is not currently available in the UK or recommended by the NHS for 
MB treatment abroad (NHS National Specialist Commissioning Team, 2011). 
Chemotherapy is often given as an adjunctive therapy. For LGA surgery is the most 
common treatment to achieve gross total resection of the tumour. Focal RT is 
sometimes given following subtotal resection but chemotherapy is not used in these 
cases (Ris & Abbey, 2010).   
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Of these treatments cranospinal RT is considered the most toxic, targeted RT 
at intermediate toxicity and surgery and chemotherapy the least toxic with regard to 
long term neuro-behavioural effects (Ris & Abbey, 2010).  
 
1.3 Neurocognitive Late Effects  
It has been reported that between 40-100% of brain tumour survivors will 
experience some neurocognitive late effects (Glauser & Packer, 1991) with figures of 
between 40% and 70% reported for ALL survivors (Ashford et al., 2010; Kunin-
Batson, Kadan-Lottick, & Neglia, 2014; Moleski, 2000). Neurocognitive late effects 
are defined as “problems with thinking, learning, and remembering among survivors 
of childhood cancer” (Mulhern and Palmer, 2003, p. 117) with late effects more 
generally meaning “long term or remote sequelae of cancer and its treatments” (Ris 
and Abbey, 2010, p. 92). #72}    
 
1.3.1 Demographic factors affecting neurocognitive outcome. 
Younger age at diagnosis and treatment has been found to be associated with 
poorer outcome, with the risk being particularly high for those under three years old 
(Caron et al., 2009; Ribi et al., 2005) indicating that the degree of maturation of the 
brain may mediate the risk associated with treatment. A reduction in the volume of 
normal-appearing white matter (NAWM) both through loss and deficient 
development, potentially connected to increased oxidative stress, has been suggested 
as a mechanism for this (Caron et al., 2009; Mulhern et al., 2001).  
Several studies have also shown a gender variation in responses to treatment with 
girls being most at risk (e.g. (Christie, Leiper, Chessells, & Vargha-Khadem, 1995; 
Peterson et al., 2008; Waber, Tarbell, Kahn, Gelber, & Sallan, 1992) although the 
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opposite pattern has also been observed (Kahalley et al., 2013). While the 
mechanism for this is unclear, recent animal studies have shown that irradiation in 
young mice effects the development of white matter significantly more in females 
than males (Roughton, Bostrom, Kalm, & Blomgren, 2013).  
 Research on the impact of socioeconomic status on neurocognitive outcome is 
mixed (e.g. (Butler et al., 2013; Kaleita, Reaman, MacLean, Sather, & Whitt, 1999; 
Rubenstein, Varni, & Katz, 1990)), however, it is generally accepted that 
sociodemographic factors can have a large impact on IQ and academic functioning 
(Vanderploeg, 1998). Mechanisms for this may include the value placed on academic 
achievement in the home and school environment and the resources available to 
support development (Nathan et al., 2007).  
 
1.3.2 Treatment factors affecting neurocognitive outcome. 
Of all the approaches used in treatment of paediatric brain tumours and 
leukaemia CRT has consistently been shown to have the strongest association with 
the poorest neurocognitive outcomes (Anderson, Godber, Smibert, & Ekert, 1997; 
Butler, Hill, Steinherz, Meyers, & Finlay, 1994; Copeland et al., 1988; Mulhern et 
al., 1999; Schatz, Kramer, Ablin, & Matthay, 2004). Whilst early whole brain 
irradiation protocols have largely been discontinued due to the evidence of their 
impact on cognitive functioning; reduced dose radiation,  targeted radiation and 
conformal radiation have still been shown to have cognitive late effects (Kiehna, 
Mulhern, Li, Xiong, & Merchant, 2006; Rubenstein et al., 1990) although they 
appear to be reduced (Mulhern et al., 1998). There is no current published evidence 
on the neurocognitive outcome following proton therapy, however clinical trial data 
in this area is being collected (Tarbell, 2005) and it has been modelled that cognitive 
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late effects (as represented by IQ) should be reduced (Merchant, 2013) due to the 
reduced radiation received by surrounding tissue with this technique, particularly in 
children who are younger at time of treatment.   
However it can be difficult to study the effects of CRT in isolation as patients 
will often also be receiving chemotherapy. For example a study into different 
strength CRT protocols found no significant differences between a 24 Gy, 18 Gy and 
no CRT group with around 22-30% of children in all groups showing a significant 
decline in IQ. One possible explanation for this was the increased dose of intrathecal 
and intravenous MTX that the children on the lower or no CRT groups were 
receiving to compensate (Mulhern, Fairclough, & Ochs, 1991). This study highlights 
both the methodological challenges in pinpointing the separate effects of treatments 
but also the potential neuro-toxicity of chemotherapy.  
The literature on the effect of chemotherapy on the developing nervous system is 
more varied than for CRT however there are several studies of children treated with 
chemotherapy alone, particularly intrathecal MTX, where declines in aspects of 
neurocognitive functioning have been found (Brown et al., 1998; Espy et al., 2001). 
A recent meta-analysis of thirteen studies of children with ALL treated with 
chemotherapy found significant mean effect sizes for deficits in a wide range of 
cognitive abilities including attention, processing speed, executive functioning and 
verbal memory although there was a significant level of variability in the results 
reflecting the varied measures and results among the studies reviewed (Peterson et 
al., 2008). In addition several studies have found a synergistic detrimental effect of 
ITC when given in combination with CRT (Riva et al., 2002; Waber et al., 1995). 
Recent studies are also finding subtle deficits following systemic MTX, previously 
thought to be relatively benign, especially where certain genetic predispositions are 
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present (Reddick & Conklin, 2010). Corticosteroids have also been shown to be 
associated with both cognitive and neurobehavioral effects both during active 
treatment (Mrakotsky et al., 2011) and at five years post diagnosis (Waber et al., 
2013), although the nature of these deficits appears to be more subtle than other  
forms of treatment.   
Surgery alone, without further CNS directed therapy has been described as the 
least toxic treatment modality (Ris & Abbey, 2010) however a number of studies 
have shown it to be associated with deficits (e.g. Carpentieri et al., 2003). Two small 
studies of children with posterior fossa tumours treated with surgery alone still 
showed impairments in the patients on measures of motor speed, attention, executive 
functions, visuo-spatial function, and expressive language when compared to 
standard norms (Levisohn, Cronin-Golomb, & Schmahmann, 2000; Rønning, 
Sundet, Due-Tønnessen, Lundar, & Helseth, 2005). 
 In summary, whilst protocols of treatment for childhood brain tumours and 
leukaemia are often multimodal and it can be difficult to pick apart the impact of the 
individual treatment components and the disease itself, there is evidence within the 
literature of neurocognitive deficits following all forms of commonly used treatment. 
The nature of these deficits does appear to vary in type and severity but based on the 
current literature children treated with any of the currently used CNS directed 
protocols should be considered to be at risk of some neurocognitive late effects from 
their treatment.   
 
1.4 Cognitive Domains Most Commonly Affected  
Early studies into cognitive late effects focused exclusively on deficits in 
intelligence and academic attainment (e.g. (Fletcher & Copeland, 1988)) and these 
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areas, particularly IQ, continue to be reported on in most outcome research. Peterson 
and colleagues’ (2008) meta-analysis of outcome studies on ALL finds a highly 
significant weighted mean effect size of 0.76 (95% CI: 0.42-1.12) for deficits in full 
scale IQ across seven studies. Similarly for brain tumour survivors a meta-analysis of 
32 studies including 1096 participants reported a weighted Hedges g effect size of -
0.83 (95% CI: -0.65—1.00) (Robinson et al., 2010). However, some studies which 
report on IQ and broader neurocognitive abilities have shown that in some cases total 
IQ can be within the normal range even though specific deficits in areas such as 
immediate memory and processing speed are present (Anderson et al., 1997).  
Several more specific areas of neuropsychological functioning have now been 
investigated in addition to IQ and academic achievement. Recent studies have 
suggested that primary deficits in the core processes of attention and concentration, 
working memory and processing speed may underlie academic problems and more 
general intellectual deficits (Campbell et al., 2007; Mabbott, Penkman, Witol, 
Strother, & Bouffet, 2008; Schatz et al., 2004). Aspects of these processes have been 
conceptualised as part of the executive functions (Anderson, Anderson, Northam, 
Jacobs, & Mikiewicz, 2002; Mulhern & Palmer, 2003) with additional difficulties 
such as cognitive flexibility, goal setting, planning and organisation of behaviour 
also included in this term. In addition to the above difficulties deficits have also 
frequently been reported in visual perceptual and psychomotor abilities (Butler & 
Haser, 2006; Nathan et al., 2007). All of these areas are most strongly associated 
with the non-dominant hemisphere, with language related deficits less common apart 
from in children treated at a very young age (Butler et al., 2013). This may be 
understood as a lateralized dysfunction, however, this pattern of discrepancy is a 
common finding in children and from a developmental perspective may actually be 
22 
 
better interpreted as the developing brain compensating to preserve verbal over non-
verbal abilities (Baron, 2004). Such neuroplasticity has been reported in studies of 
unilateral lesions in children which indicate that if the area of the cortex traditionally 
responsible for language is damaged this function is reorganised and taken on by 
areas which would typically be responsible for visuo-spatial skills to the detriment of 
the later (Goodman & Yude, 1996; Vargha-Khadem, Isaacs, & Muter, 1994). A 
consequence of this plasticity in brain development in children can be “sleeper” 
effects where late emerging abilities such as executive functioning are subtly 
compromised by much earlier insult and subsequent reorganisation (Warner-Rogers, 
2013), although these effects may also in part reflect deficits in later emerging 
abilities becoming more apparent as the brain develops.  Such late emerging effects 
are consistent with the pattern of late effects seen in this population where greater 
deficits may be seen several years after treatment in areas such as executive 
functioning (e.g. Copeland, Moore, Francis, Jaffe, & Culbert, 1996).   
 Each of the cognitive constructs mentioned above will now be considered in 
turn beginning with Attention. 
 
1.4.1 Attention. 
 Attention is not a unitary construct but rather a collection of inter-related 
functions. Several models of attention have been proposed, each subdividing 
attention into multiple component processes. Posner and Peterson (1990) propose 
three inter-related systems; orienting, mediated by posterior brain regions including 
the posterior parietal lobe and responsible for directing spatial attention; selection, 
related to the anterior cingulate and responsible for conscious target selection; and 
alerting or sustained attention which has been hypothesized to be linked to right 
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anterior prefrontal regions and represents being able to sustain continued responding 
over time in the absence of engaging stimuli. Preliminary support for this model has 
been reported (Swanson et al., 1998) however other authors report a different 
neuroanatomical division. Jain, Brouwers, Okcu, Cirino, and Krull (2009) describe 
three overlapping attentional systems with different neural substrates; an anterior 
attentional system which mediates the ability to shift attention along with other 
functions related to executive control; a posterior attention system particularly 
involved in filtering and focusing on incoming information and a subcortical 
information system involved in the maintenance of attention over time. They do also 
acknowledge the importance of executive functioning skills in the maintenance of 
attention highlighting that the three systems do not operate independently from each 
other.  The importance of anterior brain regions, particularly in attentional control 
systems is supported by neuroimaging studies (D'Esposito et al., 1995). Clinically the 
subdomains of selective or focused attention, divided attention, sustained attention or 
vigilance and alternating attention or attentional control are most commonly referred 
to (Baron, 2004), although there is some overlap with models of executive 
functioning which would typically include the concept of attentional control. 
Attentional abilities develop gradually over childhood and into adolescence with 
visual selective attention developing earliest and being established around 5-6 years 
old, focused attention developed at around 7 years and sustained attention continuing 
to develop into adolescence (Baron, 2004). {Posner, 1990  
 Within the literature on paediatric oncology neurocognitive late effects there 
is strong evidence for deficits in attention. Robinson et al. (2010) performed a meta-
analysis on studies of brain tumour survivors and from the nine studies which 
included at least one measure of attention (n=226) they found a large effect size of 
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g=-1.22 for attention deficits. In a similar review for ALL survivors {Campbell, 2007 
#130} a medium effect size of g=-0.57 was calculated from 15 studies (n not 
reported). However, due to the varied methodologies of the studies included in these 
reviews it is not possible to ascertain the specific aspects of attention which are most 
at risk. In studies which do report more specific assessments, deficits in focused 
attention and sustained attention have been most consistently reported (Dennis, 
Hetherington, & Spiegler, 1998; Mulhern et al., 2001; Reddick et al., 2003).  
Jain et al. (2009) studied the relative impact on the anterior (attention 
shifting), posterior (focused attention) and subcortical (sustained attention) attention 
systems in a large sample of 103 long term ALL survivors and found that deficits 
were mediated by both gender and intensity of treatment; with higher treatment 
intensity related to significantly poorer sustained attention and girls performing more 
poorly than boys in this area. Significant difficulties in attention shifting were also 
seen in the girls. This pattern of sustained attention and attention shifting being most 
at risk replicates a pattern seen in other studies of ALL survivors treated later in 
childhood (Lockwood, Bell, & Colegrove, 1999).  
Several studies have suggested that the volume and integrity of white-matter 
in the brain is related to attentional performance (Reddick et al., 2006; Reddick et al., 
2003). For example Reddick et al. (2006) investigated the relationship between 
attention and white-matter volume in children treated for ALL with either 
chemotherapy alone or chemotherapy and CRT. They found significant deficits in 
measures of attention on the Conners Continuous Performance Task (Conners, 1992) 
which were significantly correlated with reduced volumes of white-matter. 
 The area of memory and learning will be considered in the next section.  
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1.4.2 Memory and learning. 
Memory is a highly faceted construct with numerous classifications and 
explanatory models. The basic processes of memory are the encoding, storage 
(consolidation) and retrieval (recall or recognition) of information. Learning 
describes the acquisition of knowledge via this system. Types of memory can be 
defined in a number of ways (Lezak, Howieson, & Loring, 2004). The basic 
distinction of explicit or declarative memory and implicit or nondeclarative memory 
is agreed on by most theorists (Wright & Limond, 2004). Explicit memories, i.e. 
memories of facts and events of which one is explicitly aware, are most often 
assessed clinically. They are held in the working memory system, for short term 
storage and manipulation of information, and may then be encoded into long term 
memory. The most influential model of working memory was put forward by 
Baddeley and Hitch (1974) and proposes that it is made up of specialised ‘buffer’ 
systems for visuospatial or phonological information (short term or immediate 
memory) which are controlled by a ‘central executive’. These distinctions are well 
supported by a wide range of data from experimental studies on adults, 
neuropsychological studies and brain imaging studies (Gathercole, 1998). Working 
memory is often included as an aspect of executive function, although the immediate 
memory aspect of it is also heavily dependent on attention (Lezak et al., 2004). Long 
term memory describes the storage and retrieval of information over longer periods 
of time. It can be further divided into memory for events (episodic memory) and 
facts (sematic memory). Types of memory can also be defined by the modality of the 
information to be remembered i.e. visual or verbal. Clinically memory assessments 
typically distinguish immediate and delayed memory, working memory, visual and 
verbal memory, recognition and recall, and learning although there is inconsistency 
26 
 
across measures (Baron, 2004). Working memory abilities develop qualitatively in 
the first seven years of life with evidence that rehearsal does not form part of the 
phonological loop until this age (Gathercole, 1998). Quantitative improvement in 
memory continues into early adolescence, for example memory span (the number of 
unrelated items that can be held in short term memory) has been shown to increase 
from between 2-3 items at age four to around six items at age twelve (Gathercole, 
1998). (Baddeley & Hitch, 1974) 
Several areas of the brain are known to be vital for memory function 
including the hippocampus and the medial temporal lobe (Lezak et al., 2004). The 
role of connections between these areas and areas of the frontal lobes, including the 
orbitofrontal/ventromedial prefrontal cortex in the Papez circuit, in memory 
processes are also being increasingly understood (Simons & Spiers, 2003). This 
highlights that memory function involves several distributed processes and can be 
impacted on by diffuse axonal injury as well as localised lesions. The role of the 
cerebellum in working memory, through its interactions with the frontal cortex via 
the cerebello-thalamo-cerebral pathways (Salmi et al., 2009), is becoming 
increasingly apparent. 
Within the paediatric oncology literature memory deficits are frequently 
reported for both BT and ALL survivors, although the aspect of memory studied is 
variable and results are not fully consistent. In their meta-analysis of studies looking 
at BT patients Robinson et al. (2010) compiled results on verbal memory, visual 
memory and working memory (although this was placed in the category of executive 
functioning in this review) however enough data to calculate a weighted effect size 
was only available for the verbal memory category. In this area a large mean effect 
of g=-1.14 was found indicating significant deficits although there was significant 
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heterogeneity in effect sizes across the nine studies indicating that moderating 
variables such as treatment dose may influence the amount of deficit seen. This 
amount of variability in the results between studies is not unexpected given the 
heterogeneity of samples included in the review. In the equivalent meta-analysis for 
ALL patients (Campbell et al., 2007) verbal memory was found to have a small mean 
effect size of g=-0.39 and visual memory a medium effect size of g=-0.62. Working 
memory was not considered in this analysis. After accounting for CRT which 
consistently leads to worse outcomes in this group, these results were not 
significantly heterogeneous suggesting that this is a robust and generalizable finding 
across the studies.  (Conklin et al., 2013) (Howarth et al., 2014) 
Individual studies which have looked specifically at working memory have 
demonstrated impairments in this area and have begun to investigate the biological 
basis for this. Conklin et al. (2013) have found that groups of brain tumour survivors 
perform significantly worse on two non-standardized computerised measures of 
working memory (verbal and visual) than sibling controls or solid tumour controls. 
Howarth et al. (2014) used the same tasks to investigate the role of genetic 
polymorphisms in the COMT gene, involved in dopamine levels in the prefrontal 
cortex, in performance. Their results suggest a potential role in verbal but not visual 
working memory however the direction of the result was inconsistent with the wider 
COMT literature and needs further investigation. Robinson et al. (2010) investigated 
the neural substrates of working memory in a small sample of ALL survivors using 
functional neuroimaging. They found a trend for ALL survivors to perform less 
accurately than controls on an n-back task as difficulty increased which was 
associated with greater activation of the dorsolateral prefontal cortex and anterior 
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cingulate cortex than controls, suggesting that greater levels of energy and effort is 
required in the survivor group to complete the same task.   
 The next cognitive construct to be reviewed will be executive functioning. 
  
1.4.3 Executive function. 
Executive function is an “umbrella term” for high-level cognitive functions 
required to identify, work towards and achieve personal goals and to modify actions 
in relation to those goals (Burgess & Simons, 2005). Processes associated with 
executive function by theorists include anticipation, goal selection, planning, 
initiation of activity, self-regulation, mental flexibility, deployment of attention, and 
utilization of feedback (Anderson et al., 2002). Several models of executive function 
have been proposed to account for how these processes interact including the 
Supervisory Attentional System (Norman & Shallice, 1986) and Anderson’s 
developmental model (Anderson et al., 2002) derived empirically from factor 
analysis of outcome parameters of executive function test batteries. This model 
highlights the role of attentional control over information processing, cognitive 
flexibility and goal setting abilities.  
Executive function development begins in early childhood with selective 
attention skills starting in the first year followed by information processing around 
the second, cognitive flexibility around the third and goal setting in the fourth year 
(Anderson et al., 2002; Garon, Bryson, & Smith, 2008). There is a critical period for 
development between 7 and 9 years with skills rapidly improving during this time 
period. In contrast between the ages of 11 to 17 years old the developmental 
trajectory is comparatively flat across all domains (Anderson, Anderson, Northam, 
Jacobs, & Catroppa, 2001) although some development continues into young 
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adulthood, (Anderson et al., 2002) making it one of the last cognitive skills to reach 
maturity. This development follows the pattern of progressive neuronal myelination 
in the brain (Barnea-Goraly et al., 2005) a process which is disrupted by CNS 
directed therapies.  
Neuropsychological case studies (e.g. (Stuss & Benson, 1986)), imaging 
studies (Jurado & Rosselli, 2007) and examination of neural architecture and 
connectivity (Royall et al., 2007) support the role of the prefrontal cortex in 
executive function. The circuitry involves dispersed regions of cortex and sub-
cortical structures meaning damage to these areas, or circuits in the form of diffuse 
white matter damage, can produce deficits in executive function without direct 
damage to the prefrontal cortex (Stuss & Levine, 2002; Vaquero, Gomez, Quintero, 
Gonzalez-Rosa, & Marquez, 2008).  
 The literature on executive function deficits as a late effect of treatment for 
childhood brain tumour or leukaemia is variable due to methodological differences 
and small sample sizes. However there is strong evidence that a substantial subset of 
children experience difficulties in this area following both brain tumours of all 
diagnoses and leukaemia. A meta-analysis of 15 studies including a measure of 
executive function (five different measures were reported measuring varied areas of 
executive function) in children treated for ALL found a small to moderate effect size 
of -0.46 for deficits in this area (Campbell et al., 2007). The most consistent evidence 
is for processes associated with cognitive flexibility (Riva et al., 2002; Spiegler, 
Bouffet, Greenberg, Rutka, & Mabbott, 2004) although deficits in all theorised 
aspects of executive function have been observed (Wolfe, Madan-Swain, & Kana, 
2012). Younger age at treatment appears to be a particular risk factor for later 
executive function deficits (Campbell et al., 2009; Riva et al., 2002) consistent with a 
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developmental model that suggests early CNS insult would interrupt the normal 
development of these processes.   
  In the next section the construct of processing speed will be reviewed.  
 
1.4.4 Processing speed. 
Processing speed is a core cognitive function which describes the ease and 
speed with which an individual completes cognitive operations (Kahalley et al., 
2013), registering and integrating information across multiple distributed brain 
networks (Turken et al., 2008). Processing speed has been described as a key 
cognitive resource that underlies ability in a wide range of cognitive domains and 
measures of processing speed correlate strongly with other general measures of 
cognitive ability (Li et al., 2004). Within the literature on the effect of CRT on IQ 
there is evidence to support a mediating role for processing speed abilities in 
understanding the impact of CRT on working memory, which then subsequently 
mediates the relationship of CRT and IQ (Schatz, Kramer, Ablin, & Matthay, 2000). 
This supports the fundamental role of processing speed in higher order functions. 
Processing Speed develops throughout childhood and adolescence following an 
exponential function with large increases in ability during younger childhood 
becoming smaller with age (Kail, 1991).  
Processing speed is a widely distributed function associated with the integrity 
of white matter tracts within the whole brain, particularly with superior longitudinal 
fasciculus which sub-serves fronto-parietal integration (Turken et al., 2008). 
Evidence from a neuroimaging study in children treated for brain tumours and ALL 
found decreased levels of axonal integrity and myelination in patients compared to 
controls in a number of areas including the body of the corpus callosum and the right 
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inferior fronto-occipital fasciliculus which was correlated with measures of speed of 
processing (Aukema et al., 2009) providing further evidence of the importance of 
white matter tracts in this area.  
Processing speed deficits are commonly reported in the literature on 
neurocognitive late effects in a paediatric oncology population (Nathan et al., 2007) 
and are particularly highly correlated with CRT (Mabbott et al., 2008; Schatz et al., 
2000). A meta-analysis of eleven studies of children treated for ALL found a 
medium effect size of g=-0.52 for deficits in information processing (Campbell et al., 
2007). Deficits in this area have been found to be significant even when estimates of 
general ability are within the normal range (Kahalley et al., 2013) and other cognitive 
processes such as attention and working memory are largely intact (Mabbott et al., 
2008). As such they are likely to be missed by more general batteries which do not 
investigate this area specifically.  
The final area of neurocognitive processing commonly affected in this 
population, visual perceptual and psychomotor abilities, will be considered in the 
next section.  
 
1.4.5 Visual perceptual and psychomotor abilities.  
Visuospatial, visuoperceptual and visuomotor abilities relate the integration 
and interpretation of visual information and the translation of this into a motor 
response. These nonverbal abilities are an integral part of all commonly used general 
intelligence measures (Baron, 2004) and develop rapidly during the first two years of 
life but continue to be refined over the first decade (Johnson, 2005).   
The role of the primary visual cortex, the posterior parietal cortex and inferior 
temporal cortex in the dorsal processing stream and ventral processing stream 
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respectively is well defined, as are connections to the primary motor cortex (Johnson, 
2005). More recently the role of the cerebellum in visuomotor processing has been 
investigated (Van Braeckel & Taylor, 2013).  
Within the paediatric oncology literature the relatively greater deficits 
commonly seen on measures of performance IQ relative to verbal IQ can be 
interpreted as being reflective of visual perceptual difficulties (Nathan et al., 2007). 
The strongest evidence of visuoperceptual, visuospatial and visuomotor deficits is in 
children treated for BT particularly those in the posterior fossa. A meta-analysis of 
children treated for all types of BT (Robinson et al., 2010) reported large effect sizes 
for deficits in both psychomotor (g=-1.43) and visual perceptual skill (g=-1.14). 
Levisohn and colleagues (2000) studied 19 children with posterior fossa tumours 
treated only with surgery and found deficits in visual spatial function in 7 of these, 
and marked impairment in fine motor functioning in 14. Although this is a small 
study, the fact that the participants were assessed following surgery only highlights 
the role of the cerebellum in these functions as any treatment related damage would 
have been specific to this area rather than the more defuse impacts of both RT and 
chemotherapy. However, damage to the cerebellum is not limited to those with 
tumours in this area. Horska et al. (2010) found impaired performance on visual-
spatial and fine motor tasks in ten children with a variety of tumour locations and one 
with ALL treated with CRT, which was correlated with cerebellar vermis volume. A 
meta-analysis of studies of children treated for ALL found a small but significant 
effect size (g=-0.34) for psychomotor skills deficits (based on 14 studies) and a 
medium effect size (g=-0.57) for visuospatial skill deficit (Campbell et al., 2007).  
More broadly Dockstader et al. (2013) have shown that slowed activation of both 
visual and motor cortices, along with atypical neuronal patterns reflective of 
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increased top down control, is associated with poorer performance on a visual-motor 
reaction time task in children treated with CRT for posterior fossa tumours relative to 
controls. They relate their findings to slower information processing speed in general 
in these children which they report indicates these cognitive functions are 
interdependent. (Dockstader et al., 2013) 
 
1.5 Change in Neurocognitive Effects Over Time 
Within the field of paediatric oncology it has been commented recently that 
there is a “striking dearth of longitudinal data which track and characterise the 
evolution of neurocognitive and behavioural functioning that may unfold during and 
after treatment” (Noll et al., 2013, p. 1049). However, the longitudinal studies that 
have been done suggest that there is a decline in abilities relative to peers over time. 
The largest studies have been done on children treated with radiotherapy and 
chemotherapy for MB and are limited to assessment of IQ and academic functioning. 
Ris and colleagues have studied two samples of this type (2001; 2013). In their first 
study 43 children completed between two and five assessments up to four years post 
RT (although due to large drop-out rates only data up to three years is considered 
here) and an average drop in Full Scale IQ of 4.3 points per year was found. More 
recently they reported on a larger sample of 110 children following a similar 
treatment protocol who were assessed up to six years after RT, although almost half 
of this sample completed only baseline assessment and therefore did not contribute to 
the full model. In this study there was an average drop in Full Scale IQ of 1.9 points 
per year. This sample were significantly older than the previous one at time of 
treatment which may account for some of the difference in the decrease found. 
Mulhern et al. (2005) found a similar magnitude of decline (-1.59 points per year) in 
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their sample of 111 MB patients with significantly greater rates of decline for those 
younger at diagnosis or treated with more aggressive therapy.  
All of these studies had the methodological problems inherent in such 
longitudinal research including drop out and variety in the age appropriate measures 
needed to cover the time span. However, they have used robust statistical analysis to 
account for this where possible and the finding that IQ declines over time appears to 
be a robust one, in this specific group of patients at least.  It has been neatly 
demonstrated in another longitudinal study in this population of children treated with 
RT for MB (Palmer et al., 2001) that these declines represent a failure to keep up 
with the rate of progression of their peers rather than a loss of function, as raw scores 
on the IQ measures were still found to significantly increase over time, even though 
there was a significant decline in scaled scores. This highlights the ongoing 
developmental impact of late effects of treatment, where the impact is to divert 
children from the standard developmental trajectory rather than statically impair 
performance.  
 These studies assume linearity in the rate of decline of IQ scores however this 
may not be the case. Spiegler et al. (2004) report that in their sample of 34 children 
the rate of decline was not linear, being most rapid in approximately the first five 
years post treatment and attenuating over time.  
For children with ALL less longitudinal data is available. One study (Krull et 
al., 2013) reports on a sample of 102 survivors treated with CRT and chemotherapy 
and assessed between one and ten years after completing treatment (retrospective 
data gained from medical files) and then again at a median interval of 28.5 years post 
treatment. They found initial significant deficits in Full Scale IQ and Performance IQ 
and significant declines in Verbal IQ (-10.31 points) and Full Scale IQ (-4.75 points) 
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at follow up. They report that these deficits at follow up were significantly related to 
current measures of sustained attention and reading but not processing speed, 
exective function or memory although no details of how these constructs were 
measured is given. Interestingly only 48% of their sample showed a significant 
decline but they did not find any significant association between that decline and 
demographic variables such as CRT dose, age at diagnosis or gender suggesting that 
it is difficult to predict which children will significantly decline over time in 
advance.  
 Far fewer longitudinal studies have considered specific cognitive functions in 
addition to global measures of IQ.  Decline in performance has been seen in visual-
motor functioning, memory, executive functioning and fine motor functioning in one 
small study of posterior fossa tumour patients (Spiegler et al., 2004). Copeland et al. 
(1996) studied non-irradiated patients with leukaemia or non-CNS tumours at both 
three years post treatment and between five and 11 years post treatment. Their results 
are varied finding no significant declines at three years and a significant decline in 
the 5-11 year group only on executive function tests with perceptual IQ and tactile-
spatial skills significantly improving. Some further support for declining 
performance over time in specific neurocognitive functions can be found in cross-
sectional studies which have found significant correlations between time since 
diagnosis or treatment and assessment scores, although these data are also variable. 
Mulhern et al. (2001) report significant correlations between time since CRT and 
verbal memory in a study of 42 MB patients, but no such correlation for sustained 
attention. Edelstein et al. (2011) also found a significant association between time 
since diagnosis for working memory and global functioning in their sample of 20 
MB patients who were assessed between 6.5 and 42.2 years since diagnosis, but no 
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such associations for processing speed, executive function, immediate or delayed 
memory or motor dexterity. Further research is needed looking specifically at 
defined neurocognitive functions to further understand how they change over time 
since treatment and how this relates the more global failure to acquire the skills 
measured in IQ tests at the same rate as peers.  
(Copeland et al., 1996; Edelstein et al., 2011; Ris, Packer, Goldwein, Jones-Wallace, 
& Boyett, 2001; Ris et al., 2013) 
1.6 Summary of Neurocognitive Deficit Literature  
In summary, whilst the literature on neurocognitive late effects is variable, 
most likely due to small samples which are heterogeneous for disease, age of 
diagnosis, treatment and assessment method, there is evidence for deficits in 
attention, working memory, verbal memory, visual memory, executive functions, 
processing speed, visuomotor and visuoperceptual abilities in a significant proportion 
of children treated for BT and leukaemia. These deficits have been found, although 
not consistently, following all currently used treatment methods and in meta-analyses 
the effect sizes range from small to very large. There is good evidence that IQ 
declines over time, due to a failure to keep pace with peers, and some evidence of 
decline in more specific cognitive functions over time.  
Several studies (Anderson et al., 1997; Horska et al., 2010; Mabbott, 
Noseworthy, Bouffet, Rockel, & Laughlin, 2006; Mulhern et al., 2001; Riva et al., 
2002) have suggested these deficits are mediated by damage to the existing white 
matter in the brain as well as significantly less development of NAWM. This 
developmental impact may help to explain why some deficits only become 
pronounced several years after the completion of treatment (Copeland et al., 1996). 
Given that the prefrontal and frontal lobes have a comparatively greater volume of 
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white matter than other areas of the brain, are among the last areas of the brain to 
mature, and immature oligodentrites are thought to be more vulnerable to injury that 
mature cells (Mulhern et al., 2004), it follows that areas of cognition hypothesised to 
be mediated by these areas, such as attention, working memory and executive 
function, and diffuse functions like processing speed, are particularly affected, and 
especially so in younger children (Caron et al., 2009; Mahone, Prahme, Ruble, 
Mostofsky, & Schwartz, 2007). Other markers of injury have also been observed 
including cortical atrophy, enlarged ventricles, breakdown of the blood brain barrier, 
microvascular occlusion and calcifications in cortical grey matter. Basal ganglia and 
cellular and subcellular damage is also believed to occur however a full 
understanding of the precise mechanisms of damage requires further research 
(Mulhern et al., 2004).  
 
1.7 Impact of Neurocognitive Late Effects 
Research into the impact of neurocognitive late effects on survivors of 
childhood cancers has indicated wide ranging detrimental effects. A recent study by 
Kunin-Batson et al. (2014) found that deficits in verbal cognitive abilities and visual-
motor integration skills were significant predictors of poor quality of life in the areas 
of school and physical abilities in a large sample of children treated for ALL with 
chemotherapy (including corticosteroids) only. Deficits in executive functioning 
abilities have been found to significantly predict poor parent-reported social skills in 
childhood brain tumour survivors (Wolfe et al., 2013). Selective attention deficits 
have been shown to significantly predict health-related quality of life one year after 
diagnosis in a mixed sample of children treated for brain tumours (Penn et al., 2010). 
Qualitative research with young adult brain tumour survivors has shown that 
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concerns over cognitive decline and poor social skills, along with the impact on 
future education and vocational opportunities, are prevalent in this group 
(D'Agostino & Edelstein, 2013). More broadly, poor neuropsychological 
performance has been associated with lower educational level, earnings in later life, 
chance of being married and health related quality of life (Ness et al., 2008).  
 
1.8 Recommendations for the Assessment of Neurocognitive Consequences 
Given this literature, several bodies including the Children’s Oncology Group 
(COG), the National Institute for Health and Clinical Excellence (NICE), and the 
Scottish Intercollegiate Guidelines Network (SIGN) recommend neuropsychological 
assessment as a routine part of long term follow up for survivors of childhood cancer 
at risk of neurocognitive late effects. COG recommends a baseline assessment at 
entry into long term follow up as a minimum, and additional assessments at times of 
transition or if any difficulties arise (Nathan et al., 2007). NICE recommend access 
to neuropsychological services for all patients, particularly those with CNS tumours, 
and highlight the importance of such assessments in guiding schooling and later 
career decisions (National Institute for Health and Clinical Excellence [NICE], 
2005). It is recommended in the guideline that “all children and young people with 
CNS malignancies have access to a neuro-rehabilitation service, even years after 
treatment” (p. 69) and this recommendation now forms a quality standard for 
children and young people with cancer (National Institute for Health and Clinical 
Excellence, 2014). Neuro-rehabilitation is defined as “A care package including 
services that will take into account the effects of the cancer and its treatment on 
neurological, physical, psychological and academic function, recognising that these 
effects can become more evident over time.” (NICE, 2014 p. 28) meaning that 
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accurate and repeatable neuropsychological evaluation will need to form an integral 
part of this care package.  
The SIGN recommendations highlight that those children who have received 
CRT are especially at risk of neurocognitive late effects and should therefore be 
assessed prior to treatment and annually thereafter to monitor change over time 
(SIGN, 2013), with lifelong follow up currently recommended as best practice for 
brain tumour patients. However, these recommendations should be considered a 
minimum and given evidence that suggests early intervention has considerable 
benefits (Nathan et al., 2007) more frequent assessment may be clinically useful.  
 In addition to recommendations for cognitive assessments to form a routine 
part of clinical follow up, their importance in research and clinical trials has also 
been highlighted. The COG blueprint for research in the area of behavioural science 
(Noll et al., 2013) has stated that neurocognitive assessments should be included in 
all trials of contemporary paediatric cancer therapies with known or suspected 
adverse effects on the CNS, citing benefits of this including for the child as discussed 
above; gathering additional long term outcome data; and providing an additional 
outcome measure to help clinicians choose between treatments with similar medical 
outcomes.  
(National Institute for Health and Clinical Excellence, 2014) 
1.8.1 Limitations in meeting recommendations. 
It is acknowledged that these recommendations are currently not being fully 
implemented (Nathan et al., 2007; Noll et al., 2013). There are several barriers to this 
including the time and therefore cost involved in a full neuropsychological 
assessment combined with limited resources in the form of clinic space and 
appropriately qualified staff. Tonning Olsson, Perrin, Lundgren, Hjorth, and 
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Johanson (2013) report that in their study of 132 paediatric brain tumour patients in 
Sweden only 48% were referred for neuropsychological evaluation in spite of most 
of the non-referred group having significant risk factors for, or reports of, cognitive 
impairment. They suggest this low level of referral may have been due to the paucity 
of neuropsychological services available in Sweden at the time of the study although 
the reasons for referral or non-referral in each case were not stated. Whilst referring 
to a different health care system this study highlights that organisational factors and 
limited resources may have a significant impact on the assessment and rehabilitation 
of children at risk of cognitive impairment following treatment for cancer. In the UK 
NICE (2005) acknowledge that “Both professionals and parents/carers have 
identified a significant lack in formal psychological input … which represents a 
significant area of unmet need” (p. 75), indicating that similar resource issues are a 
factor in the ability of health services in the UK to meet current recommendations in 
this area.  In multi-site research, data accrual levels of <30% for neurocognitive data 
are common (Noll et al., 2013). (Tonning Olsson, Perrin, Lundgren, Hjorth, & 
Johanson, 2013) 
1.8.2 Potential for screening instruments to increase assessment. 
 The utilization of brief cognitive screening instruments that can be more 
easily incorporated into the routine follow up of these patients has the potential to 
increase the numbers of children receiving assessment for potential cognitive late 
effects. Such a screen would need to be time efficient and sensitive to the areas of 
cognitive deficit most commonly highlighted in the literature to date (Noll et al., 
2013) which are  summarised above. Educational evaluations are not adequate for 
detecting these deficits (Nathan et al., 2007) and functional measures have been 
found to be insensitive to serious cognitive shortcomings (Rønning et al., 2005).  
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1.9 Current Literature on Screening Assessments 
To determine the current literature on screening assessments or batteries in a 
paediatric oncology population a detailed review of the literature was conducted in 
February 2014. Inclusion criteria were original papers describing a screening 
assessment or battery of assessments designed for the routine evaluation of children 
treated for cancer in clinical practice or consistent use in research. Web of 
Knowledge (all databases incorporating Medline) was searched using the search 
terms: ("neuro-oncology" OR oncology OR cancer) AND (Child* OR Paediatric OR 
Pediatric) AND (neuropsycholo* OR "cognitive functioning" OR 
neurocognitive) AND (assessment OR screen*) all within the Topic field. No limits 
were placed on year of publication, language was limited to English. Lemmization 
was turned on. Meeting reports and abstracts were excluded. One hundred and fifty 
two results were returned and titles and abstracts were reviewed to determine the 
relevance to the search question. Twelve articles were found to meet the inclusion 
criteria reporting on eleven different screening measures or batteries. Information on 
the studies is presented in Table 1 together with a critical evaluation based on three 
main factors; comprehensiveness of the measure/battery with reference to the 
literature on the range of neurocognitive deficits seen in this population; 
generalizability of the sample and rigour of the evaluation (i.e. evidence of the 
validity, reliability, acceptability and feasibility in this population).  
 
1.9.1 Informant report measures. 
 Six of the studies evaluated single informant report measures, five of which 
were parent report (Howarth et al., 2013; Lai, Butt, et al., 2011; Lai, Zelko, et al.,  
 
 
Table 1 
Studies Examining Cognitive Screening Measures or Batteries in a Paediatric Oncology Population 
Reference Sample 
size 
Diagnosis Age 
range 
Mode of 
assessment 
Screening 
measures 
Cognitive 
domains covered 
Time to 
complete 
Critical Evaluation of Results  
Corklin et 
al. 2013 
24 BT treated 
with 
conformal 
RT 
13-18 
years 
Computerized 
Battery 
“ImPACT” 
(age modified 
for 
adolescents) 
Speed Click 
Word Memory 
Design Memory 
X’s and O’s 
Symbol match 
Colour Match 
Four Letters 
Word memory – 
delay 
Design memory-
delay 
Reaction time 
Visual and verbal 
learning and 
memory 
Spatial working 
memory 
PS 
Divided attention 
Delayed 
recognition 
memory  
Approx 45 
minutes 
Comprehensiveness: High, but no 
measure of executive functioning 
other than working memory  
Generalizability: Narrow age band 
included, excluded IQ<70, did not 
include other at risk groups (eg ALL 
or other treatment types)  
Rigour: Comparison to Solid tumour 
and sibling control groups matched 
for age and gender but not IQ 
Provides some of evidence criterion 
validity for limited subtests. No 
correction for multiple comparisons. 
Some evidence for convergent 
validity from additional 
computerised measures of 
recognition memory and working 
memory only. Some evidence of 
clinical predictive validity but limited 
by small sample size.  
 
Embry et 
al. 2010 
 
 
 
159 MB 2-21 
years 
Battery of 
standard 
neurocognitive 
assessment 
measures 
Age appropriate 
versions of 
Vocabulary, 
BD, SS, coding, 
DS, logical 
Intelligence, 
Attention, PS, 
WM, EF, Verbal 
and Visual 
memory, 
60 minutes Comprehensiveness: High in 
general, but more limited for younger 
children (<4 years).  
Generalizability: Limited to MB but 
broad age range.  
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Reference Sample 
size 
Diagnosis Age 
range 
Mode of 
assessment 
Screening 
measures 
Cognitive 
domains covered 
Time to 
complete 
Critical Evaluation of Results  
Embry et 
al. cont. 
“ALTE07C1” memory, Face 
and spatial 
memory, CVLT. 
Parents: BASC-
II, BRIEF, 
ABAS-II and 
PedsQL 4.0 
Behavioural/ 
Social emotional 
function, adaptive 
function 
Rigour: Used measures with 
established reliability and predictive 
validity but not evaluated in this 
population. Evidence of acceptability 
and feasibility from high 
participation rate (96% time 1, 95% 
time 2).  
 
         
Gross-King 
et al. 2008 
12 Not fully 
reported: 
received 
“treatment 
involving 
CNS” 
Not 
fully 
reported 
Battery of 
Standard 
neuropsycholo
gical measures 
WRAT-3 
reading subtest, 
WISC-III DS, 
SS and Coding 
subtests 
 
Estimated IQ, 
WM, PS 
Not fully 
reported; 
WRAT-3 
reading 
took 15-30 
minutes  
Comprehensiveness: Low; no 
measure of visual or verbal memory, 
sustained attention, selective 
attention or EF. 
Generalizability: Unclear due to 
poor reporting but very small sample 
size.  
Rigour: No evaluation of 
acceptability, reliability, practice 
effects for serial testing, construct 
validity or criterion validity in this 
sample. Qualitative descriptions of 
feasibility.     
 
Howarth et 
al. 2013 
 
 
 
 
 
50 BT treated 
with 
conformal 
RT 
8-18 
years 
Parent report BRIEF-WM 
scale 
 
WM Not 
reported 
Comprehensiveness: Low as 
specific to working memory and low 
sensitivity and specificity.  
Generalizability: Excluded IQ<70, 
did not include other at risk groups 
(e.g. ALL or other treatment types)  
Rigour: Comparison to Solid tumour 
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Reference Sample 
size 
Diagnosis Age 
range 
Mode of 
assessment 
Screening 
measures 
Cognitive 
domains covered 
Time to 
complete 
Critical Evaluation of Results  
Howarth et 
al. cont. 
and sibling control groups matched 
for age and gender and controlled for 
IQ provides evidence criterion 
validity. Limited evidence of 
construct validity from correlation 
with digit span backwards and self-
ordered search tasks but low 
sensitivity and specificity to detect 
difficulties (.4 and .56 respectively). 
Some evidence of feasibility and 
acceptability from high participation 
rate (82%). 
 
Kieffer et 
al. 2012 
29 Cerebellar 
BT 
(Astrocytom
a and MB) 
6-11 
years 
Teacher report Deasy-Spinetta 
questionnaire 
Learning 
difficulties, 
Socialization,  
Disturbing 
Behaviour 
Not 
reported 
Comprehensiveness: Limited due to 
general nature of constructs 
measured.  
Generalizability: Limited as only 
included cerebellar BT patients and 
excluded those in special education. 
Narrow age range. 
Rigour:  Qualitative report of 
acceptability. Evaluation of factor 
structure of measure which reveals a 
lack of reliability. Some evidence of 
criterion validity for learning 
difficulties factor. Some evidence of 
construct validity for learning 
difficulties factor.  
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Reference Sample 
size 
Diagnosis Age 
range 
Mode of 
assessment 
Screening 
measures 
Cognitive 
domains covered 
Time to 
complete 
Critical Evaluation of Results  
Krull et al. 
2008 
 
240 Varied – 
consecutive 
sample in 
Long term 
survivors 
clinic 
6-18 
years 
Battery of 
standard 
neuro-
psychological 
measures 
“DIVERGT” 
DS,  
Grooved Peg 
Board Test 
Verbal Fluency 
Test 
TMT 
WM 
Psychomotor 
speed and fine 
motor dexterity 
Attention 
switching 
EF  
 
 
20-30 
minutes 
Comprehensiveness: Reasonable 
but no measure of visual or verbal 
memory or learning, PS, sustained or 
focused attention.  
Generalizability: Broad age range. 
All diagnoses included in 
consecutive clinic sample, so high 
generalizability to standard clinic 
Rigour: High. Evidence of test-retest 
reliability (average 1 year), 
discriminative and predictive 
validity. Evidence of feasibility and 
acceptability from high recruitment 
rate (estimated 82%) 
 
Lai et al. 
(2011a, 
2011b) 
 
 
 
 
 
 
 
 
 
 
 
 
1409 General 
population 
sample 
(including 
23 BT) 
7-17 
years 
Parent report 
“pedsPCF” 
Item bank of 43 
items used as 
full 
questionnaire 
and in 
Computerized 
Adaptive 
Testing (CAT) 
“Perceived 
Cognitive 
Functioning” 
Including 
Memory retrieval, 
attention/concentr
ation and working 
memory 
Less than 2 
minutes 
(using 
CAT) 
 
Comprehensiveness: Developed in 
the context of a BT population to 
cover difficulties most commonly 
seen. However final scale does not 
explicitly cover all areas.  
Generalizability: Assessed in a 
general population sample with a 
subset of BT (and other neurological) 
patients. Needs further assessment in 
paediatric oncology setting to 
determine generalizability.  
Rigour: Strong evidence for internal 
consistency of the scale and 
correlation of CAT to full scale. 
Some evidence for criterion validity. 
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Reference Sample 
size 
Diagnosis Age 
range 
Mode of 
assessment 
Screening 
measures 
Cognitive 
domains covered 
Time to 
complete 
Critical Evaluation of Results  
Lai et al. 
cont. 
Some evidence of construct validity 
from CBCL. No evaluation of 
relationship between ‘perceived’ 
cognitive functioning and ‘measured’ 
cognitive functioning.  
 
Msall et al. 
(2010) 
76 MB <36 
months 
Parent report ASQ, Pediatric 
Independence 
Measure (WEE 
FIM), Motor 
Quotient, 
CLAMS and 
additional 
questions on 
health, 
developmental 
and adaptive 
status 
Gross motor, Fine 
Motor, Problem 
Solving, Personal 
-Social, Self-care, 
mobility, social-
cognition, 
communication 
30 minutes Comprehensiveness: Functionally 
comprehensive for this age range 
Generalizability: Specific diagnosis 
and age range studied limits 
generalizability.  
Rigour: Some elements of the screen 
used well validated instruments but 
also unclear use of additional 
questions. Stated con-current 
neuropsychological evaluation but no 
data presented to support construct 
validity. Report of high feasibility 
and acceptability but unsupported.  
 
Patel et al. 
(2007) 
 
 
 
 
 
 
 
 
70 BT 6-16 
years 
Parent report Child 
Behavioural 
Check List 
Attention 15 minutes Comprehensiveness: Limited to 
attentional difficulties only 
Generalizability: Wide age range 
but did not include other at risk 
groups (e.g. ALL) and based on 
retrospective data which may over 
represent survivors at risk of 
cognitive impairment.  
Rigour: Evaluated construct validity 
relative to objective measures of 
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Reference Sample 
size 
Diagnosis Age 
range 
Mode of 
assessment 
Screening 
measures 
Cognitive 
domains covered 
Time to 
complete 
Critical Evaluation of Results  
Patel et al. 
cont.  
attention providing some limited 
evidence of construct and criterion 
validity. However the attention scale 
was not a significant predictor of 
attention dysfunction and the social 
problems scale showed poor 
sensitivity and specificity (52% and 
26% respectively).  
 
Pejnovic et 
al. (2012) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
59 Varied – 
consecutive 
sample of 
patient who 
would 
receive 
CNS-
directed 
therapy 
 
0-16 
years 
<3 years: 
Parent report 
>3 years: 
Battery of 
standard 
neuropsycholo
gical measures 
and 
standardised 
questionnaires 
(including 
parent report) 
“Trackwell” 
 
<3 : Vineland 
adaptive 
behaviour scales 
>3: Coding, SS, 
Sentence 
Repetition, DS, 
Visual attention, 
sky search, 
telephone 
search, Beery-
Buktenica 
Development 
Test of visual-
motor 
integration,  
Statue, TMT, 
Category 
fluency, 
COWAT, 
Phonological 
Processing, 
PS, WM, 
Selective 
attention 
Visuomotor 
integration and 
motor co-
ordination 
Cognitive 
flexibility 
Verbal Fluency 
Reading 
Spelling 
Maths 
Behaviour 
EF  
Mean 49.4 
minutes  
SD 12.8 
Range 30-
75 
 
Comprehensiveness: High but no 
measure of visual or verbal memory 
or learning or sustained attention. 
Less comprehensive for younger 
children 
Generalizability: Broad age range. 
Targeted recruitment to population 
most at risk. Assessed at diagnosis so 
unclear if the battery would be 
feasible with children post treatment 
where more difficulties likely to be 
evident.  
Rigour: Good evidence of feasibility 
within a defined model. Compared to 
a control group, but unmatched for 
age (smaller age range) or ability. 
Acceptability high assessed by both 
participant and researcher. Added 
value assessed compared to medical 
notes. No report of validity or 
reliability in this paper.  
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Reference Sample 
size 
Diagnosis Age 
range 
Mode of 
assessment 
Screening 
measures 
Cognitive 
domains covered 
Time to 
complete 
Critical Evaluation of Results  
Pejnovic et 
al. cont. 
subtests of 
WIAT 
>8: Self report 
BASC-2 
Parents: PEDS, 
BASC-2 and 
BRIEF 
 
Quigg et al. 
2013 
30 Varied - All 
new 
oncology 
except 
benign 
haematology 
4-48 
months 
Parent report Ages and Stages 
questionnaire 3rd 
Edition 
Communication 
Gross Motor 
Fine Motor 
Problem solving 
Personal-social  
10-15 
minutes 
(estimated) 
Comprehensiveness: Functionally 
comprehensive for this age range 
Sensitivity of questionnaire only 72% 
so may miss subtle difficulties. No 
objective measurement included. 
Generalizability: Suitable for very 
young, but narrow age range. 
All oncology diagnoses included, 
consecutive sample, so high 
generalizability to standard clinic 
Rigour: Did not corroborate 
identified ‘at risk’ or ‘delayed’ 
children with objective assessment so 
no evidence of validity in this 
population. 
Some evidence of feasibility through 
high rates of completion and follow 
up to 12 months.  
Note. BT = brain tumour; RT = radiotherapy; PS = Processing Speed; MB = Medullablastoma; WM = working memory; EF = Executive function; BD = 
block design task from Weschler tests; SS = Symbol search task from Weschler tests; DS = Digit Span task from Weschler tests; CVLT = Calafornia Verbal 
Learning Test; BRIEF = Behaviour Rating Inventory of Executive Function; BASC-II = Behaviour Assessment System for Children 2nd Edition; ABAS-II = 
Adaptive Behaviour Assessment System 2nd Edition ; CNS = Central Nervous System; WRAT-3 = Wide Ranging Achievement Test 3rd Edition; WISC-III = 
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Weschler Intelligence Scale for Children 3rd Edition; WIAT = Weschler Individual Achievement Test; TMT = Trail Making Test; COWAT = Controlled Oral 
Word Association Task; CLAMS = Clinical Linguistic and Auditory Milestone Scale ; PEDS = Parent’s Evaluation of Developmental Status; ASQ = Ages 
and Stages Questionnaire 
4
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2011; Msall, 2010; Patel, Lai-Yates, Anderson, & Katz, 2007; Quigg, Mahajerin, 
Sullivan, Pradhan, & Bauer, 2013) and one was teacher report (Kieffer et al., 2012). 
Quigg et al. (2013) and Msall et al. (2010) reported on measures designed for use 
with young children aged 48 months and under. Whilst these measures are 
functionally comprehensive for this age range they are inherently limited as screens 
for use in the general clinic population by being inappropriate for older children. In 
addition the Ages and Stages Questionnaire used by Quigg et al. showed low 
sensitivity for difficulties so may be of limited use even in this age range.  Howarth 
et al. (2013) and Patel et al. (2007) report on well validated measures for use with a 
much wider, although older, age range; the Behaviour Rating Inventory of Executive 
Function (BRIEF) and Child Behaviour Check List (CBCL) respectively. However 
there are several limitations with using these measures as stand-alone screens. Firstly 
as informant report measures they can only provide information on difficulties 
“perceived” by the rater rather than objectively “observed” impairments. Whilst 
informant report measures can provide very useful additional information it is 
recommended they are included as part of a broader battery (Baron, 2004). Secondly 
both measures are limited in focus to single cognitive construct and therefore do not 
cover the broad range of relevant areas. In addition Patel et al. (2007) found the 
CBCL to be a poor predictor of attention dysfunction and to lack sensitivity and 
specificity for social problems limiting its usefulness further. Similarly the BRIEF 
working memory scale also showed very low sensitivity and specificity for 
impairments seen on objective tasks indicating that, whilst it may provide additional 
information to these tasks, it should not replace them. Kieffer et al. (2012) assessed 
the usefulness of the Deasy-Spinetta questionnaire, a teacher report measure, as a 
screening tool. However, as it is both very general in the constructs it covers and 
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lacks reliability in its factor structure it appears it is of limited value. The most 
promising of the standalone informant report measures is the ‘pediatric perceived 
cognitive function item bank’ (pedsPCF) reported on by Lai and colleagues (2011a, 
2011b). This 43 item bank was developed to cover the full continuum of the 
constructs of cognitive functioning in a paediatric brain tumour population and 
shows promising statistical properties based in a very large general population 
sample. Using the bank with computerized adaptive testing (CAT) means that it can 
take as little as two minutes to get as reliable an estimate of cognitive functioning as 
from completing the full scale, which would make this approach highly feasible to fit 
into routine clinic follow up. However, whilst a broad range of cognitive areas were 
theoretically included in the item bank, factor analysis of the normative data most 
strongly supports a single factor (a requirement for CAT) and therefore subtle 
deficits in individual areas may not be adequately probed by the scale. In addition no 
data are yet available on the construct validity of the scale relative to standard 
objective measures and so the relationship between ‘perceived’ cognitive function 
and ‘observed’ cognitive function is unclear. With further evaluation this may be a 
useful tool to get a general assessment of cognitive functioning with very little input 
of professionals’ time, which could then identify those in need of a more 
comprehensive assessment.   
 
1.9.2 Batteries of standard neuropsychological measures. 
 Four studies report on the use of batteries of standard neuropsychological 
measures as screening tools (Embry et al., 2012; Gross-King, Booth-Jones, & 
Couluris, 2008; Krull et al., 2008; Pejnovic et al., 2012). Gross-King and colleagues 
(2008) used a very brief battery consisting of the Wide Ranging Achievement Test, 
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version 3 (WRAT-3) reading subtest to provide an estimate of IQ and three subtests 
of the Wechsler Intelligence Scale for Children, version 3 (WISC-III); Digit Span to 
measure verbal working memory, Symbol Search to measure processing speed and 
Coding to measure visual-motor speed in their very small study. It is hard to draw 
any conclusions from the lack of data presented however the battery itself is very 
limited in scope and therefore a poor candidate for a widespread screening tool.  
Krull et al. (2008) evaluated a battery assessing executive function, attention 
and psychomotor speed using established neuropsychological measures which took 
30 minutes to administer and was found to have good test-retest reliability (r=0.72) 
and predictive validity for IQ, reading ability and mathematical ability in a varied 
and generalizable sample. However it does not include measures of visual or verbal 
learning or memory, processing speed and sustained or focussed attention and 
therefore does not cover all the areas known to be affected in these patients.  
Pejnovic et al. (2012) reported on a comprehensive battery which included 
standardised measures of processing speed, selective attention, working memory, 
psychomotor function, executive function, behaviour and reading, spelling and maths 
which took a mean of 49.4 minutes (SD 12.8) to administer. They also included a 
validated parent report measure for use when the patient was under three years old, 
however, limited data on this group is presented. The main battery was shown to be 
acceptable to families and feasible for use in this clinical population but reliability 
and validity data were not presented so it is not possible to evaluate these aspects or 
consider the screen rigorously tested at this stage.  
Embry et al. (2010) evaluated a comprehensive battery of measures drawn 
from widely available and generally well validated assessments aiming to increase 
the collection of neurocognitive data in clinical trials. Their battery covers a very 
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wide age range of 2-21 years and therefore uses several different measures of the 
same construct for different age groups. Whilst this is a pragmatic approach it does 
increase the variability in the battery as a whole, potentially increasing the 
measurement error. They report that the battery took 60 minutes to complete and, 
within the context of a research study aimed at collecting complete data, they 
achieved very high participation rates indicating that this is acceptable to families.  
 All of these batteries reduce their administration time by using single subtests 
from larger standard measures. Whilst this has the advantage of enabling a broad 
range of constructs to be assessed in a brief battery it may reduce the reliability of the 
assessment. It also requires the availability of several measures to extract the subtests 
from, which may increase the cost of such a screening tool if they are not already 
available. Whilst several studies reported the administration time of the battery none 
reported on time taken to score the assessments which can also equate to a significant 
amount of the clinicians’ time. Standard neuropsychological measures need to be 
administered by suitably qualified professionals and are often subject to practice 
effects which generally preclude retesting within a year. This limits the flexibility of 
using these batteries to track change over shorter time frames, or at times of 
transition if these fall between yearly assessments.  
 
1.9.3 Computerized measures. 
 One study by Conklin et al. (2013) has evaluated a computerized screening 
tool.  The ImPACT battery is a well validated adult measure previously used 
following mild brain injuries. It includes measures of divided attention, visual and 
verbal learning and memory, spatial working memory, processing speed and reaction 
time (a measure of psychomotor speed) but lacks any broad measures of executive 
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function. The version used in this study was modified to make it suitable for 
adolescents (13-18 years) by elaborating and simplifying the instructions, however, 
the age range covered is still narrow compared to other screens in this review and the 
age range of children seen in follow up clinics. Participants in the study were 24 
children treated for BT with conformal CRT, along with solid tumour and sibling 
control groups. The results demonstrated criterion validity on some of the outcome 
measures reported (four of the eight accuracy measures and all speed measures) and 
convergent construct validity for verbal and visual memory tasks (with small to 
medium effect sizes r=.25-.30) but not working memory tasks. Construct validity 
was not assessed for divided attention, processing speed, and psychomotor speed. 
The small sample included in this study is fairly specific in both diagnosis and 
treatment and may therefore not be representative of the full population of children at 
risk of cognitive late effects. Advantages of computerized assessment over standard 
assessment measures noted by the authors include the accuracy with which 
processing speed can be measured and the reduced level of expertise and therefore 
cost needed to administer the battery. They claim that the battery has also been 
shown to have limited practice effects meaning it can flexibly be used to track 
change over time.  
 
1.9.4 Conclusion of detailed literature review. 
 This detailed review of the literature shows that whilst several potential 
screening batteries have been evaluated in this population none could be considered 
fully comprehensive, or rigorously tested in a sample that is easily generalizable.  
Informant report measures have the advantages of being inexpensive, quick 
and easy to administer but they are often limited in scope or very general in the 
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constructs they measure which limits their usefulness in a general clinic. The 
relationship between perceived and observed deficits is also unclear meaning that 
equivalence between these measures and standard neuropsychological assessments 
cannot be assumed. Therefore, whilst such measures can potentially add useful 
information to a screening battery, they should not replace other more specific 
assessments.  
 The batteries of standard measures which have been investigated are able to 
provide more specific and detailed information and are comparatively quick to 
administer compared to a full length neuropsychological assessment. An advantage 
of using measures which are familiar to practicing psychologists in the clinic setting 
may be that these batteries would be fairly easy to incorporate into practice. However 
they also retain the disadvantages of traditional assessment including high levels of 
expertise needed to administer and score them and lengthy gaps needed between 
assessments to prevent practice effects.  
 Computerised assessment can potentially limit the effects of many of these 
problems. The ImPACT battery could be administered by a wider range of 
professionals without expert knowledge or training, is less affected by practice 
effects and can assess a wide range of constructs in a single measure. However it has 
currently only been assessed in a narrow segment of the paediatric oncology 
population and still lacks some evidence of the criterion and construct validity which 
needs to be demonstrated before it could be used in general practice. It also lacks a 
broad measure of executive function, and may therefore miss more subtle cognitive 
deficits which may be increasingly evident as treatment approaches continue to 
improve.  
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 Therefore, whilst recent progress has been made in this areas, there is still a  
need for further comprehensive, sensitive and repeatable screening batteries which 
could be used with a large proportion of the population seen in paediatric oncology 
late effects clinics or clinical trials.    
 
1.10 CogState 
CogState is a brief computerized neurocognitive battery designed to assess 
psychomotor function, processing speed, visual attention, vigilance (sustained 
attention), working memory, visual learning and memory and executive function 
(Collie, Maruff, McStephen, & Darby, 2003; Pietrzak et al., 2008). It is formed of 
simple experimental psychology paradigms such as n-back tasks; forced choice 
reaction time tasks etc. which have been shown to provide robust measures of 
cognitive constructs and have been widely used in neuroimaging and cognitive 
psychology research (e.g. (Cohen & Leckman, 1994; Salthouse & Davis, 2006; 
Squire & Kandel, 2000). These tasks have then been modified to make them 
applicable and acceptable in clinical use and sensitive to change over time (Pietrzak 
et al., 2009). The battery makes use of non-verbal and culturally neutral stimuli in 
order to make it familiar and acceptable to individuals from diverse cultural and 
social groups (Maruff et al., 2009). It has been shown to demonstrate virtually no 
practice effects in adults or children after the second administration (Falleti, Maruff, 
Collie, & Darby, 2006; Mollica, Maruff, Collie, & Vance, 2005) allowing for 
repeated administration to accurately assess any change over time. Its computerised 
administration allows for accurate collection of data and automated scoring which 
facilitates the collection of consistent data across different sites (Collie et al., 2007).  
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1.10.1 Psychometric properties in other populations.  
CogState was originally developed specifically to assess cognitive change 
over repeated assessment (Collie et al., 2003) and has been assessed in a wide variety 
of settings. The largest studies investigating construct validity and criterion validity 
have been samples of healthy adults and adults with schizophrenia, mild traumatic 
brain injury (TBI) and AIDs dementia complex (Cysique, Maruff, Darby, & Brew, 
2006; Maruff et al., 2009; Pietrzak et al., 2009; Yoshida et al., 2011). Strong 
correlations with standard measures of the same cognitive constructs were found in 
healthy adults and patients with chronic schizophrenia (r’s=.49-.83) supporting the 
construct validity of CogState in these groups (it was not investigated in the other 
groups). The effect sizes for the magnitude of the deficits when comparing controls 
to patient groups were large (d=-.60 to -1.80) and in the Pietrzak et al. study 
comparable to the battery of standard neuropsychological measures used indicating 
that CogState is sensitive to impairments in these groups and performs as well as 
standard measures in detecting them. 
CogState has also been investigated for use with children. It has been used in 
healthy samples (Mollica et al., 2005; Thomas, Reeve, Fredrickson, & Maruff, 2011) 
and been shown to have good test-retest reliability and the same limited practice 
effects as in adults, making it potentially very useful for assessing change over time 
in the context of a developing CNS. Subtests from the CogState battery, particularly 
the Groton Maze Learning Task, have been used in a number of studies with children 
from paediatric populations including children with ADHD (Mollica, Maruff, & 
Vance, 2004; Snyder, Maruff, Pietrzak, Cromer, & Snyder, 2008) cerebral malaria 
(Bangirana et al., 2009); poor motor coordination (Rigoli et al., 2013); HIV (Boivin 
et al., 2010) and in-utero exposure to cocaine (Mayes, Snyder, Langlois, & Hunter, 
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2007) which provide some evidence of criterion validity in these populations. 
However specific studies of criterion validity have not been done and there is 
currently no published evidence of construct validity for the paediatric battery.  
 
1.10.2 Potential for use in the paediatric oncology population. 
To date there are no published studies using CogState in the paediatric 
oncology population. One study (Ichimura et al., 2010) has used four subtests of the 
Japanese version of the adult CogState battery with adult patients who have received 
surgery only for posterior fossa lesions including brain tumours. They found the 
battery to be more sensitive to subtle cognitive difficulties than standard measures 
(which exhibited practice effects).  
COG have recently highlighted the potential of computerised assessments, 
specifically CogState, over traditional neuropsychological measures, as “a time-
efficient approach to facilitate collection of psychometrically robust data” (Noll et 
al., 2013 p. 1051) both in order to follow children over time to investigate the time 
course of deficits and to screen children to identify those in need of further 
comprehensive assessment. Currently the paediatric CogState battery is embedded in 
one COG trial of high risk ALL patients. However they acknowledge that studies 
which link the CogState battery to traditional measures are still needed to “provide 
critical data related to the validity of brief computerized measures” (p. 1051).     
 
1.11 Psychometric Theory of Validity 
Psychometric theory states that assessments should be reliable, valid, 
standardised and free from bias (Rust, 2012). Within this, validity refers to the extent 
to which an assessment is fit for purpose i.e. does it measure what it claims to 
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measure in a sensitive and specific way? There are many different types of validity 
including face validity (the extent to which an assessment is acceptable as a measure 
of what it claims to measure); predictive validity (the extent to which performance on 
a measure is predictive of other measures of functioning) and criterion validity (the 
extent to which a measure differentiates between groups specified by a particular 
criterion). Construct validity relates to the extent to which a measure taps the 
construct it is claiming to assess. It can be determined in a number of ways. 
Convergent (or concurrent) validity is one way of assessing construct validity and 
relates to the correlation between the measure which is being evaluated and 
established measures of the same construct (Rust, 2012).  
 
1.12 Summary and Rationale for Current Study 
In summary, neurocognitive late effects are common in the paediatric 
oncology population where treatment is directed at the CNS. Although the use of 
CRT has been consistently connected to poor neurocognitive outcomes there is 
evidence of deficits following all commonly used treatment methods. Deficits have 
been found in the areas of attention (especially selective and sustained attention), 
memory (especially visual and verbal immediate memory and working memory), 
processing speed, executive functioning (especially cognitive flexibility) and visual-
percetual and visuomotor processing. There is evidence that global deficits, 
measured by IQ, deteriorate over time due to a failure to keep pace with the cognitive 
development of peers. It is recommended that all children at risk of these deficits be 
screened at least annually and at times of transition to ensure that any difficulties are 
picked up early and can be addressed. Currently this recommendation is not being 
consistently followed likely due to the cost, expertise and time required to carry out 
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these assessments. In response to this, brief screening measures and batteries have 
been developed however none of the batteries in the current literature have been 
shown to be ideal for this task to date. CogState is a brief computerised 
neurocognitive screening battery which has been identified to show promise as a 
screening instrument in this population. However, currently there is no evidence of 
its validity in a paediatric oncology setting. Therefore, the current study primarily 
aims to begin to assess the construct validity of the paediatric CogState battery by 
determining its concurrent validity with standard neuropsychological measures. In 
addition a secondary aim is to add to the currently limited literature on change in 
specific neurocognitive functions over time by investigating the relationship between 
time since diagnosis and performance on the CogState battery.   
 
1.13 Research Questions and Hypotheses 
The primary research questions are: 
1. Does CogState demonstrate adequate construct validity in a population of children 
who have survived a brain tumour or leukaemia when compared to a standard 
neuropsychological battery?  
 
The standard battery used in this study is made up of neuropsychological tests 
and subtests chosen to assess the same neurocognitive constructs which the CogState 
battery reports that it covers. The battery is made up of the Grooved Peg Board 
(Klove, 1963), the Trail Making Test (TMT) A and B (Reitan, 1958, 1971), the 
Symbol Search and Digit Span subtests from the Weschler Intelligence Scale for 
Children version four (WISC-IV) (Wechsler, 2003), the Map Mission and Score! 
subtests from the Test of Everyday Attention for Children (TEA-Ch) (Manly, 
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Robertson, Anderson, & Nimmo-Smith, 1999) and the Dot Location subtest from the 
Children’s Memory Scale (CMS) (Cohen, 1997) and the Behaviour Rating Inventory 
of Executive Function (BRIEF) (Gioia, Isquith, Guy, & Kenworthy, 2000). The 
properties of these tests and the reasons they were selected are discussed further in 
the Method chapter.  
Both batteries cover most of the areas of neurocognitive functioning shown by 
previous research to be often affected by childhood cancer and its treatment. If 
CogState is a valid assessment of these areas in this population several hypothesis 
can be made about which of its subtests will correlate with which standard 
neuropsychological tasks: 
Hypothesis 1:  The Detection task of the Cogstate battery measures psychomotor 
function and processing speed and will be positively correlated with performance on 
the Grooved Peg Board task and the WISC-IV Symbol Search subtest. 
Hypothesis 2: The Identification task of the Cogstate battery measures visual 
attention and vigilance and will be positively correlated with performance on the 
Map Mission and Score! subtests of the TEA-Ch.  
Hypothesis 3: The One-Card Learning Task of the CogState battery measures visual 
learning and memory and will be positively correlated with performance on the CMS 
Dot location subtest. 
Hypothesis 4: The Continuous Paired Associate Learning Task of the CogState 
battery measures visual learning and memory and will be positively correlated with 
performance on the CMS Dot location subtest. 
Hypothesis 5: The One-Back Task of the CogState battery measures working 
memory and will be positively correlated with performance on the WISC-IV Digit 
Span subtest.  
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Hypothesis 6: The Groton Maze Learning Task of the CogState battery measures 
executive function, including cognitive flexibility, and will be positively correlated 
with performance on TMT B and the BRIEF total score.  
 
2. Given the research showing intellectual performance declines over time since 
treatment (e.g. (Spiegler et al., 2004)) is there a relationship between time since 
diagnosis and performance on the CogState battery? 
Hypothesis 7: Time since diagnosis will be negatively correlated with overall 
performance on the CogState battery.  
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2 Method 
2.1 Overview 
 In this chapter the methodology employed in the study will be described. This 
includes a description of the design of the study, the sample and recruitment, the 
measures used with a focus on their psychometric properties, the testing procedure, 
ethical considerations involved in the study and it will end with a description of the 
plan of analysis.  
 
2.2 Design 
The construct validity of the CogState battery was investigated using a within 
subject correlational design. Each participant completed both the CogState battery 
and a battery of standard neuropsychological subtests which have been shown in 
previous research to measure the same cognitive constructs as the CogState tasks are 
designed to measure. Subtests of standard measures were used rather than indices or 
composite scores in order to facilitate evaluating the full CogState battery within a 
time scale that could feasibly be completed in one research visit. Whilst this may 
have reduced the reliability in the measures this method was chosen in order to limit 
variation in results due to environmental factors that two visits would have entailed, 
reduce burden on participants and increase the feasibility of the study. Performance 
on each pair of corresponding subtests was correlated.  The study was cross sectional 
as all measures were completed at a single time point.  
The relationship between time since diagnosis and overall performance on the 
CogState battery was also investigated using a cross sectional correlation design. IQ 
and mood have been shown in the literature to affect performance on 
neuropsychological assessments (Baron, 2004) therefore data were collected on these 
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variables to facilitate a partial correlation analysis should they be shown to correlate 
significantly with performance in this study.  
It could be argued that a longitudinal study following the same participants over 
time would be a more powerful and valid way to assess the relationship between time 
since diagnosis and performance on the CogState battery. However, the time 
constraints of the current study meant it was unfeasible to consider this design for 
this project.  
 
2.3 Participants 
2.3.1 Population of study. 
 Children who had received a diagnosis of a brain tumour or a leukaemia were 
chosen as the study participants. This is because these are the most common 
malignancies in children and have been shown most often in the literature to 
experience neurocognitive deficits following their cancer treatment (Butler & Haser, 
2006). Whilst it is acknowledged that this variety in diagnoses resulted in a 
heterogeneous sample it was decided that limiting the sample to one specific 
diagnosis would be detrimental to the study for several reasons. Firstly the literature 
indicates that the most significant cognitive deficits are seen following certain types 
of brain tumour (Ris & Abbey, 2010) however these populations are so small that to 
recruit from this single diagnosis would significantly reduce the pool of potential 
participants and result in the study becoming unfeasible. Secondly, if only patients 
with leukaemia were included, brain tumour patients likely to have more severe 
cognitive impairments and who are therefore more likely to require 
neuropsychological assessment would be excluded and the clinical efficacy of the 
study would be reduced. In addition, the within subject correlational design used to 
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address the first research question mitigates to an extent the effect of having a 
heterogeneous sample on the power of the analysis. A strength of using a 
heterogeneous sample when considering the utility of the CogState battery as a 
screening instrument for use in general clinics was the increased generalizability of 
the results to clinical settings.   
 The participants had all completed the active part of their treatment prior to 
taking part in the study, defined as being off active therapies for brain tumour 
patients and at least in maintenance therapy for ALL patients This was to ensure that 
the results do not reflect the immediate cognitive effects of undergoing stressful 
hospital treatment and to avoid the additional stress of asking patients and their 
families to take part in research during an acutely difficult time for them.  
 
2.3.2 Inclusion and exclusion criteria. 
Participants were between 8 and 16 years of age inclusive. This age range 
was chosen to cover the widest age range seen in the paediatric oncology clinics as 
possible whilst maintaining a requirement for one battery of assessments.  
Participants were required to have received a diagnosis of a brain tumour or 
leukaemia, with stable disease as determined by the primary physician and checked 
by the Principle Investigator in each recruitment site. This included being off active 
therapies for brain tumour survivors and at least in maintenance therapy or off 
therapy for children with leukaemia. English was required to be the participant’s 
primary language to ensure that all assessments could be understood.  
Patients were excluded if they had a pre-existing neurodevelopmental or 
genetic disorder or history of head injury to ensure as far as possible that any 
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cognitive deficits found in the study were as a result of the cancer and its treatment 
alone.   
Patients with sensory or motor impairment severe enough to prevent testing 
were excluded to ensure that all participants were able to complete the full battery. 
Examples of impairments which led to exclusion from recruitment included not 
having the use of one hand or visual impairment severe enough to require large print 
written material at school.  
Patients who had been assessed within the last year using any of the 
neuropsychological tests in the standard battery were also excluded to prevent 
practice effects.  
 
2.3.3 Sample size. 
Sample size calculations were performed using G. Power 3.1 (Faul, 
Erdfelder, Buchner, & Lang, 2009). For the first research question the expected 
effect size was determined by taking the average correlation between the CogState 
subtests used in this study and the standard neuropsychological comparator tests in 
two large studies validating CogState in adult clinical populations (Maruff et al., 
2009; Pietrzak et al., 2009). The correlation coefficients in these studies range from 
0.49-0.83 with a mean of 0.52. Using this value with a power of 0.8 and an alpha 
level of 0.05 for a two-tailed test gives a sample size of 26 for a correlation analysis.  
For the second research question the estimated effect size was taken from 
Mulhern et al. (2001) who found a Pearson’s product moment correlation of -0.46 for 
time since CRT and estimated full scale IQ in sample of patients with a 
medulloblastoma. Using this effect size with a power of 0.8 and an alpha level of 
0.05 for a two-tailed test gives a sample size of 32 for a correlation analysis.  
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 Given these power calculations the study aimed to recruit a minimum of 32 
patients.  
 
2.4 Recruitment Procedure 
Paediatric oncology care in the region is organised by the East of England 
Children and Young People’s Cancer network. In this model Addenbrooke’s 
Hospital (part of Cambridge University Hospitals NHS Foundation Trust) co-
ordinates the cancer treatment of all paediatric (0-16 years) cancer patients in the 
region and is the Principle Treatment Centre (PTC). All diagnostic and treatment 
decisions are made at this hospital and it also co-ordinates late effects and 
psychosocial care. There are ten other hospitals in the region which are designated 
Paediatric Oncology Shared Care Units (POSCUs) and which provide some aspects 
of the patient’s care closer to their home.  
The Clinical Psychologists providing input to the paediatric oncology 
multidisciplinary teams at Addenbrooke’s Hospital and two local POSCU’s; The 
Norfolk and Norwich University Hospital (NNUH) and The Queen Elizabeth 
Hospital King’s Lynn (QEHKL), were approached with initial information about the 
project and asked if their department would be interested in taking part. These 
centres were chosen due to their geographical proximity and to facilitate a wide 
range of time since diagnosis in the potential participants approached during the 
recruitment period, since patients who are in long term follow up are only seen 
approximately annually at the PTC. All three centres responded positively and 
following gaining ethical approval, local research governance approval was sought to 
recruit participants from each centre. As all patients in the region are known to the 
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PTC care was taken when recruiting from all sites to ensure that the family had not 
been previously approached by another team.  
Potential participants meeting the inclusion and exclusion criteria were 
identified by the paediatric oncology team in each hospital. They were then 
approached by a member of the clinical team to provide them with initial information 
about the study and obtain consent to be contacted by the researcher (see Appendices 
A-E). This occurred either during a routine clinic visit or by posting the invitation 
letter and consent form to potential participants and following up with a telephone 
call to ensure they have received the information and obtain verbal consent to be 
contacted by the researcher.   
Once consent to contact was received, the researcher contacted the family to 
arrange a convenient and suitably quiet time and location to meet to answer any 
further questions they had and obtain appropriate consent/assent for the study (see 
Appendices F-I). Provided consent/assent was obtained the study measures were also 
completed at this visit.  
In total 37 participants were recruited to the study; 9 through QEHKL, 16 
through NNUH and 13 through Addenbrooke’s hospital.  
 
2.5 Assessment Measures  
The assessment battery completed by each participant was made up of the 
CogState battery and a Standard battery including a range of standardised tests and 
subtests and one informant report questionnaire measure. These standard measures 
were chosen to match the relevant CogState task based on a combination of factors. 
These included established psychometric properties in the relevant area of cognition 
which the CogState task is described as measuring, described in the test manual or 
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wider literature and summarised below; prior use in adult validity studies of 
CogState (Cysique et al., 2006; Maruff et al., 2009; Pietrzak et al., 2009; Yoshida et 
al., 2011); general use in clinical settings and availability to the researcher. Not all 
factors were satisfied for each measure with some, such as availability to the 
researcher needing to be prioritised. Table 2 lists the neurocognitive domain and 
related tests for both batteries. In addition a brief IQ measure, the Wechsler 
Abbreviated Scale of Intelligence (WASI) and a brief self-report questionnaire 
measure of mood, the Paediatric Inventory of Emotional Distress (PI-ED) were 
administered to account for potential confounding variables. Two unstandardized 
questionnaires regarding demographic information and the acceptability of the 
CogState battery were also completed.  
 
Table 2  
Neurocognitive Domains Measured by Subtests in the CogState and Standard 
Batteries  
Note. BRIEF = Behaviour Rating Inventory of Executive Function, CMS = 
Children’s Memory Scale, TEA-Ch = Test of Everyday Attention for Children. 
WISC-IV=Wechsler Intelligence Scale for Children Fourth Edition  
 
Neurocognitive 
Domain 
CogState Tasks Standard Neuropsychological 
Tasks 
Psychomotor function Detection Task Grooved peg board 
Processing speed WISC-IV Symbol Search Subtest 
   
Visual attention Identification Task  TEA-Ch Map Mission Subtest 
Vigilance TEA-Ch Score! Subtest 
   
Visual learning and 
memory 
One Card Learning Task 
Continuous Paired Associate 
Learning Task 
CMS Dot Location Subtest 
 
   
Working memory One Back Task WISC-IV Digit Span Subtest 
   
Executive function Groton Maze Learning Task Trail Making Test-B  
BRIEF Global Executive 
Composite 
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Each element of the battery will now be outlined further in detail including its 
psychometric properties and administration.    
 
2.5.1 CogState Battery (Pietrzak et al., 2009).  
2.5.1.1 Description. 
CogState is a brief computerized neurocognitive battery formed of simple 
standardised experimental psychology paradigms such as n-back tasks and forced 
choice reaction time tasks etc. which have been shown to provide robust measures of 
cognitive constructs in experimental settings. These tasks have then been modified to 
make them applicable and acceptable in clinical use and sensitive to change over 
time (Pietrzak et al., 2009). The battery makes use of non-verbal and culturally 
neutral playing card stimuli, abstract shapes and mazes and has been shown to 
demonstrate virtually no practice effects in adults or children (Falleti et al., 2006; 
Mollica et al., 2005) allowing for repeated administration to assess any change over 
time. Its computerised administration allows for accurate collection of data and 
automated scoring. 
For this study six tasks were used covering the neurocognitive functions most 
commonly found to be affected by childhood cancer and its treatment as described in 
the Introduction. A description of the tasks, the constructs that the test publisher 
describes them as measuring, and their primary outcome measures can be found in 
Table 3.  
The measure was provided without charge under license for research 
purposes by CogState Inc. 
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Table 3 
CogState Subtest Descriptions 
Subtest 
(primary cognitive 
constructs measured) 
Abbreviation Description Primary Outcome 
Variable 
Detection Task 
(Psychomotor 
function, processing 
speed) 
DET The participant must 
press the “yes” key as 
soon as the single card 
in the centre of the 
screen flips over. In 
the 10-16 years battery 
a joker is used. In the 
8-9 years battery a 
smiling face is used.  
Speed of 
performance 
(Log10 
transformation of 
mean reaction 
time) 
Identification Task 
(Attention/Vigilance) 
IDN The participant must 
respond “yes” if the 
card presented is red 
and “no” if it is black 
as soon as it flips over. 
In the 10-16 years 
battery a joker is used. 
In the 8-9 years battery 
a smiling face is used. 
Speed of 
performance 
(Log10 
transformation of 
mean reaction 
time) 
One Card Learning 
Task 
(Visual recognition 
memory) 
OCL The participant must 
respond “yes” if they 
have seen the card 
presented before in 
this subtest and “no” if 
they have not. There 
are four target cards 
which repeat nine 
times during task. In 
the 10-16 years battery 
standard playing cards 
are used. In the 8-9 
years battery coloured 
numbers and symbols 
are used.  
Accuracy of 
performance 
(Arcsine 
transformation of 
proportion of 
correct responses)  
One Back Memory 
Task 
(Working memory) 
OBK The participant must 
respond “yes” if the 
current card is the 
same as the previous 
card and “no” if it not. 
In the 10-16 years 
battery standard 
playing cards are used. 
In the 8-9 years battery 
Speed of 
performance 
(Log10 
transformation of 
mean reaction 
time) 
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coloured numbers and 
symbols are used. 
Continuous Paired 
Associate Learning 
Task 
(Visual associate 
learning and 
memory) 
CPAL After a learning phase 
during which all the 
shapes are visible the 
participant must chose 
the matching shape 
from a choice of eight 
hidden locations (six 
hiding shapes and two 
decoy). They continue 
choosing on each trial 
until the correct shape 
is found.  
Total Errors 
Groton Maze 
Learning Task 
(Executive 
functioning 
including problem 
solving, reasoning 
and error 
monitoring)  
GMLT The participant must 
find the correct path 
through a 10x10 grid 
from a starting point to 
a target following 
three rules. For the 10-
16 years battery the 
previous steps taken 
are hidden, for the 8-9 
years battery they 
remain visible. Five 
trials are presented 
with the same 29 step 
path on each occasion.  
Total Errors 
(Summed across 
the five trials; 
Total Rule Break 
Errors is an 
alternative 
variable) 
 
2.5.1.2 Psychometric properties.  
Test-retest reliability of the CogState subtests used in this study has been 
reported as between .84 and .91 in a sample of 300 healthy young adults (Collie et 
al., 2003). The construct and criterion validity of the subtests has been well 
established in adult samples. An early version of the battery including the DET, IDN 
and OBK tasks was studied in 62 adults with HIV and 21 control subjects (Cysique 
et al., 2006) providing good evidence of criterion validity in this sample and some 
evidence of construct validity although the results were at times contradictory. 
Maruff et al. (2009) report on a sample of 215 healthy adults who were administered 
the DET task, IDN task, OBK task and OCL task and comparator 
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neuropsychological tasks including the Grooved Peg Board task and the Trail making 
task amongst others. Pearson’s Product-Moment correlations ranged from .79 to .81 
for tasks measuring similar constructs providing evidence for convergent validity. 
Divergent validity was also shown with unrelated tasks not showing significant 
correlations. The above tasks and the GMLT were also administered to 120 healthy 
control subjects in a study reported by Pietrzak et al. (2009) with correlations 
between .45 and.75 found with comparator tasks measuring the same cognitive 
construct. Both studies investigated the criterion validity of the CogState battery by 
comparing the performance of healthy controls to patient groups (adults with 
schizophrenia, mild TBI and AIDs dementia) on both the Cogstate and standard 
comparator batteries. In both studies the patient groups showed comparable 
significantly worse performance on both batteries. Yoshida and colleagues (2011) 
investigated the Japanese version of the CogState battery including the DET, OBK, 
CPAL and GMLT in a sample of 40 patients diagnosed with schizophrenia and 40 
controls finding at least partial evidence for the construct validity of all of these tasks 
except the CPAL (p=.25-.34).   
In children sections of the battery have been used in both healthy samples 
(Thomas et al., 2011), and a variety of samples of children from paediatric 
populations (Bangirana et al., 2009; Boivin et al., 2010; Mayes et al., 2007; Mollica 
et al., 2005) and have been shown to provide comparable information to standard 
neuropsychological tests although construct validity has not been specifically 
assessed. There are no published data on the CogState battery in paediatric oncology 
populations.  
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2.5.1.3 Administration. 
 This six task CogState battery was administered in approximately 20 minutes 
using a Toshiba Satelite Pro C850 1K4 laptop computer. The participant was guided 
through the tasks by on screen instructions with further verbal instructions from the 
researcher supervising the testing. Practice periods were presented prior to the CPAL 
and GMLT to ensure the participant understood the instructions before beginning the 
scored portion of the test. On the other tasks particular attention was given to the 
participant’s first few responses and the instructions of the test were repeated if 
necessary. Responses to the DEC, IDN, OCL and OBK tasks were made using 
simple keyboard strokes. An external mouse was used for the CPAL and GMLT. 
Participants were encouraged to be as quick and accurate as possible in their 
responses. An error sound was heard each time the participant made a mistake. The 
scores generated by the CogState subtests include measures of reaction time and 
errors made as described in Table 3. Age standardised scores are provided for the 
four card based tasks (DEC, IDN, OCL and OBK) however as the CPAL and GMLT 
are at an earlier stage of development in the paediatric battery robust standardised 
scores are not available for these subtests and raw data was be used in the analysis. In 
addition a summary score of performance on the four standardised subtests can be 
calculated.  
 
2.5.2 Standard battery. 
The subtests used to form the standard battery are described below, grouped 
by the measures they are taken from. A summary of the subtests which make up the 
battery, in the order they were completed, can be found in Table 4. 
 
75 
 
Table 4 
Standard Battery Subtest Descriptions 
Subtest 
(primary cognitive 
constructs measured) 
Abbreviation Description Primary Outcome 
Variable 
Grooved Peg Board 
(psychomotor speed, 
and dexterity) 
GPB Participants place 25 
grooved pegs into 
matching holes using 
first their dominant 
hand and then their 
non-dominant hand. 
Eight year olds only 
place 10 pegs. 
Time to 
completion 
(dominant hand 
only) 
Symbol Search 
(processing speed) 
SS Participants scan search 
groups of five symbols 
for either of two target 
symbols marking “yes” 
if there is a match and 
“no” if there is not. As 
many items as possible 
are completed in 120 
seconds.  
Total correct 
minus total 
incorrect 
converted to 
Scaled Score 
Map Mission 
(selective/focused 
visual attention) 
MM Participants must circle 
as many target symbols 
on the map as they can 
in 60 seconds ignoring 
distractor symbols. 
Total identified 
converted to 
Scaled Score 
Score! 
(auditory sustained 
attention) 
- Participants listen to 10 
sequences of sounds 
presented on a tape 
between nine and 15 
sounds in length. They 
must count the length of 
each string. 
Total correct 
converted to 
Scaled Score 
Dot Location 
(visual/spatial short 
term memory and 
learning) 
DL Participants must place 
chips on a response grid 
from memory to 
replicate the stimulus 
pattern shown. Three 
learning trials and an 
immediate memory trial 
are completed.   
Total correct 
across all four 
trials converted to 
Scaled Score 
Digit Span 
(auditory short term 
memory including 
working memory) 
DS Participants must repeat 
strings of numbers of 
increasing length 
presented verbally. 
Forwards and 
Backwards conditions 
Total correct 
across all trials 
converted to 
Scaled Score. 
(Longest Digit 
Span Backwards 
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are included. Two trials 
are completed per string 
length. If the participant 
fails both trials the test 
is stopped. 
is an alternative 
outcome variable 
specific to the 
Backwards 
condition) 
Trail Making Test 
(Executive function 
including attentional 
control, inhibitory 
control and cognitive 
flexibility) 
TMT In the A condition 
participants must join 
numbers scattered 
across a page by a 
single line in ascending 
order. In the B 
condition they must 
alternate between 
connecting numbers in 
ascending order and 
letters in alphabetical 
order.  
Time to 
competition 
(TMT-B only) 
 
 
2.5.2.1 Wechsler Intelligence Scale for Children – 4th Edition (WISC-IV; 
Wechsler, 2003).  
2.5.2.1.1 Description. 
This standard test of intellectual function for children aged 6-16 years is 
widely used and well validated. The full test is made of up four indices; Verbal 
Comprehension, Perceptual Reasoning; Processing Speed and Working Memory. 
Two subtests, taken from the last two of these indices, the Symbol Search subtest and 
the Digit span subtest, were used to provide a standardised measure of processing 
speed and working memory respectively. 
 Symbol search is a pencil and paper task which required the child to follow a 
simple set of instructions to visually scan a group of symbols looking for the 
presence of a target symbol. It does not become progressively more difficult as the 
task progresses but does require quick accurate responses to score highly and 
therefore is strongly reliant on processing speed. In addition it has been described as 
requiring short-term visual memory, visual-motor co-ordination, cognitive flexibility, 
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visual discrimination and concentration to complete successfully(Flanagan & 
Kaufman, 2009; Sattler, 2001). The Symbol Search subtest was chosen to match the 
DET task in preference to the Coding subtest, the other component of the Processing 
Speed Index as it is less dependent on fine motor control, although use of a pencil is 
still required, and therefore is more similar to the limited motor responses required 
by the DET task.   
Digit span is a widely used measure of working memory designed to measure 
auditory short-term memory, sequencing skills, attention and concentration, in 
addition to the strong working memory component in the backwards condition 
especially (Flanagan & Kaufman, 2009; Groth-Marnat, 2009; Sattler, 2001). It was 
chosen as the measure of working memory as performance on this subtest on its own 
has been found to correlate well with the full WISC-IV working memory index 
(r=.86) and it has been included in a short form of the WISC-IV as the most 
psychometrically sound representative of the working memory subtest (Crawford, 
Anderson, Rankin, & MacDonald, 2010). Whilst it is auditory in modality, rather 
than visual like the OBK task, it was chosen to match this task due to its ease of 
administration, and sound psychometric properties covering the age range of the 
study sample.  
 
2.5.2.1.2 Psychometric properties. 
The WISC-IV battery as a whole was standardized on a large American 
sample of 2,200 children aged between 6-16 years, with the UK edition subsequently 
standardized on a sample of 780 children (Wechsler, 2003). In these samples the 
subtests used in this study showed good evidence of reliability. Average split-half 
reliability for Digit span across all age bands was .87 which is good. As split-half 
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reliability is not appropriate for processing speed measures test-retest reliability is 
given as the main measure of reliability for Symbol Search and was found to be .79 
which is acceptable. Evidence for validity is presented from a number of sources. 
The internal structure of the test supports the underlying construct validity of each 
subtest, with Digit Span correlating most highly with the other measure of working 
memory in the battery (e.g. r=.49 with Letter-Number sequencing) and Symbol 
search correlating most highly with the other measures of processing speed (e.g. 
r=.53 with Coding). Criterion validity has been established in a number of special 
group studies also described in the technical manual. Performance on Digit span and 
Symbol Search were significantly poorer in a group of 89 children diagnosed with 
Attention Deficit Hyperactivity Disorder (ADHD) consistent with the literature 
suggesting children with ADHD perform worse on measures of processing speed and 
working memory in spite of overall IQ scores within the normal range (Doyle, 
Biederman, Seidman, Weber, & Faraone, 2000). The Symbol Search subtest was 
shown to significantly distinguish between children with both open and closed TBI 
giving evidence that it is sensitive to the difficulties in processing speed often seen in 
this group (Williams, Weiss, & Rolfhus, 2003). 
 
2.5.2.1.3 Administration. 
Symbol Search is a pencil and paper subtest. Participants were required to 
determine whether one of two target symbols were present in a group of five search 
symbols for each item. The participant completed as many items as they could in 120 
seconds. Instructions were given verbally by the examiner as well as being 
demonstrated and the participant completed two practice items before starting the 
test. The Digit span subtest required participants to verbally repeat back strings of 
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numbers of increasing length spoken to them by the examiner. In the forwards 
condition the numbers were repeated exactly as heard. In the backwards condition 
the numbers must first be mentally reversed by the participant before being given. 
Two trials were completed at each number string length. If the participant gets a least 
one trial correct they progress to the next length of number string. The participant’s 
raw score was calculated by totalling the number of correct strings given on all trials 
across both the forwards and backwards conditions and converted into an age 
standardised scaled score. Approximately 10 minutes was required to complete both 
subtests. 
 
2.5.2.2 Children’s Memory Scale (CMS; Cohen, 1997).  
2.5.2.2.1 Description. 
 The CMS is a test of memory standardised for use in individuals 5-16 years 
of age. It assesses memory in three domains; auditory/verbal, visual/nonverbal and 
attention/concentration. For this study the Dot location subtest from the 
visual/nonverbal index was used to provide a measure of visual learning and memory 
as it comprises three learning trials and an immediate recall trial. Dehn (2008) 
describes it as a measure of visual-spatial short term memory and learning. The Dot 
location subtest was chosen to measure this domain due to these features of 
combining a spatial memory task with learning processes thereby covering the both 
cognitive domains reported to be measured by the OCL and CPAL tasks in the 
CogState battery. Alternative measures which could have been used include the 
Visual Learning subtest of the Wide Range Assessment of Memory and Learning 
(Sheslow & Adams, 1990) which has a similar format of presentation of visual 
information over several learning trials, or the Continuous Recognition Memory Test 
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(Hannay & Levin, 1989; Hannay, Levin, & Grossman, 1979) which has a very 
similar format to the OCL task of CogState however normative data is not available 
for this measure for the full age range covered in this study.  
  
2.5.2.2.2 Psychometric properties. 
 The Children’s Memory Scale was standardised on a representative sample of 
1000 children from the US. Using this sample split-half and test-retest reliability data 
was calculated. The Dot Location subtest has a split-half reliability of .76 and a test 
re-test reliability of .81 which are both good. Practice effects on the battery were 
shown to be up to one standard deviation indicating that it is not suitable for retesting 
within a short period of time.  
 Validity of the scale is supported by internal factor analysis supporting the 
presence of three factors; auditory/verbal, visual/non-verbal and 
attention/concentration. The Dot location subtest is within the visual/non-verbal 
factor and correlates more strongly with other sub-tests in this factor aiming to assess 
similar visual memory constructs than those in other factors. The scale also shows 
moderate to high correlations with the Wechsler Memory Scale –III (Wechsler, 
1997) and moderate correlations with the Wide Range Assessment of Learning and 
Memory –II (Sheslow & Adams, 2003). Clinical validity studies presented in the 
manual indicate that the scale is sensitive to memory impairments in children with 
TBI and brain tumours compared to normal controls. It is criticized for having strong 
floor effects in the youngest children as average scaled scores can be achieved for 
chance responding (Baron, 2004), however for the age range used in this study this is 
less of a problem.  
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2.5.2.2.3 Administration.  
 The Dot location subtest is administered by the examiner using a stimulus 
book and response grid and chips. Participants are shown a stimulus of eight dots (six 
for eight year olds) randomly located on a page for five seconds. The stimulus is then 
removed and the participant is required to replicate the locations of the dots on their 
response grid (4 squares by 4 squares for 9-16 year olds, 4 squares by 3 squares for 8 
year olds) using the chips. This is repeated three times. A distractor stimulus is then 
shown and replicated before the participant is asked to replicate the first stimulus 
from memory. The score on all four trials is totalled and an age based standard score 
is calculated. This subtest was completed in approximately 7 minutes.  
 
2.5.2.3 Trail Making Test A & B (TMT; Reitan, 1958, 1971). 
2.5.2.3.1 Description.  
The Trail Making Test Parts A & B, is a well-established and widely used 
measure of executive functioning particularly attention shifting, inhibitory control 
and cognitive flexibility (Kelly, 2000; Lezak et al., 2004). It was originally 
developed as part of the Army Individual Test Battery (Army Individual Test 
Battery, 1944) before being incorporated into the Halstead-Reitan 
Neuropsychological Test Battery (Halstead, 1947; Reitan, 1958), and later adapted 
for children (Reitan, 1971). It has been shown to be sensitive to general frontal lobe 
dysfunction (Pontius & Yudowitz, 1980; Stuss et al., 2001) although it has 
limitations in localizing the dysfunction (Lezak et al., 2004). This test was chosen as 
it assesses aspects of executive functioning similar to those reported to be captured 
by Total Errors and Rule Break Errors variables of the GMLT, and it has been used 
in previous adult construct validity studies (Cysique et al., 2006; Maruff et al., 2009). 
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The test is quick to administer with minimal equipment required making it suitable 
for assessment in participants homes and it is freely available. The Delis-Kaplan 
Executive Function System (D-KEFS) (Delis, Kaplan, & Kramer, 2001) includes a 
version of the Trail Making Test with more robust normative data covering the age 
range included in this study however unfortunately it was unavailable for use. An 
alternative measure with more face validity in terms of comparison with GMLT 
could have been a maze task such as Porteus Maze Task (Porteus, 1959) however 
normative data covering whole sample age range is not available for this measure.  
 
2.5.2.3.2 Psychometric properties. 
Normative data for the TMT is available for children aged 7-13 from a 
sample of 392 children separated into one year brackets (Anderson et al., 1997). For 
adolescents normative data is available from a sample of 100 (mean age = 15.9 years, 
SD = 0.98) separated by gender (Barr, 2003). Older normative data is available for 
this age range from (Knights, 1966) and (Fromm-Auch & Yeudall, 1983) separated 
into age bands. For consistency with the normative data for the younger age range 
this data was used.  
Test re-test reliability data for the TMT is variable but has been shown to be 
acceptable in an adolescent sample for Part B (r=.65), and to be good in some adult 
samples (Dikmen, Heaton, Grant, & Temkin, 1999; Levine, Miller, Becker, Selnes, 
& Cohen, 2004).  
Evidence for the validity of the TMT as a measure of attentional abilities and 
more specifically executive functions including cognitive flexibility and attentional 
control is given by its moderate correlation with other measures of these areas 
including the Wisconsin Card Sorting Test (WSCT) and the Paced Serial Attention 
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Test (PASAT) seen in a number of studies (Kortte, Horner, & Windham, 2002; 
O'Donnell, Macgregor, Dabrowski, Oestreicher, & Romero, 1994) although this has 
not been replicated by all studies (Ardila et al., 2000). There is evidence that the 
TMT is sensitive to neurocognitive deficits including close-head injury with diffuse 
axonal damage (Felmingham, Baguley, & Green, 2004).  
 
2.5.2.3.3 Administration. 
 The TMT is a timed pen and paper test completed in two parts. Part A 
requires the participant to draw a line connecting numbered circles scattered across 
the page in ascending numerical order. Part B requires them to alternate between 
numbers in ascending numerical order and letters in alphabetical order in the 
sequence they connect. Instructions for both parts of the test were given following 
those provided by (Strauss, Sherman, & Spreen, 2006). Both parts were completed as 
all published test instructions include both sections and Part A familiarises the child 
with the general concept of the task before moving on to the more complicated 
instructions of Part B. A short practice of each test to illustrate the instructions was 
given before the full test. Children under 15 completed an intermediate version with 
15 circles in each part whilst children over 15 completed the adult version which has 
25 circles in each part. If the child makes a mistake this is immediately pointed out 
by the examiner and they must correct the mistake before proceeding. The outcome 
variable which was used for further analysis was the time taken to completion on 
Part B with longer times indicating worse performance. On average 5 minutes was 
needed to complete both parts of the test.  
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2.5.2.4 Test of Everyday Attention for Children (TEA-Ch; Manly, Robertson, 
Anderson, & Nimmo-Smith, 1999).  
2.5.2.4.1 Description. 
 The TEA-Ch is a test of attention standardised for use with individuals aged 
6-15 years 11 months. The Map Mission subtest was used to provide a standardised 
measure of visual selective attention. This subtest was conceptually derived from 
selective attention measures in the adult measure, the Test of Everyday Attention 
(TEA) (Robertson, Manly, Andrade, Baddeley, & Yiend, 1997; Robertson, Ward, 
Ridgeway, & Nimmo-Smith, 1994). The Score! subtest was used to provide a 
standardised measure of vigilance (sustained attention). It is a children’s version of a 
well validated approach to assessing sustained attention in adults, also found in the 
TEA (Robertson et al., 1994; Wilkins, Shallice, & McCarthy, 1987). These two 
subtests were chosen out of the full TEA-Ch battery because they are brief to 
administer, simple to understand, have adequate psychometric properties and cover 
visual attention and vigilance, the two aspects of attention measured by the IDN task 
of the CogState battery. Alternative measures of vigilance are relatively limited, but 
one of the most often used in research is the Connor’s Continuous Performance Test 
(Conners, 1992) which is a computer based task that requires participants to press a 
button in response to any letter apart from X. It has a wide range of outcome 
variables and has normative data for ages 4 to adulthood, however, it requires around 
14 minutes to administer, significantly longer than the Score! subtest, is not 
commonly used in clinical practice and was unavailable at the time of testing.  
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2.5.2.4.2 Psychometric properties. 
The TEA-Ch was standardized on a large sample of Australian children aged 
between 6 and 15 years 11 months. Reliability was assessed using test-retest 
correlations where a suitable range in the data was available and percentage 
agreement in scores (within one standard deviation for first and second testing) 
where there was a ceiling effect. The Map mission subtest has a reliability coefficient 
of .65 which is acceptable. The Score! subtest has a percentage agreement of 76.2%.  
Structural equation modelling of the full TEA-Ch battery supports a good fit 
for a three factor model; selective attention, attention control/switching and sustained 
attention. This measure of internal consistency within the battery supports the 
construct validity of the two subtests used in this study as measures of selective 
attention (Map Mission) and sustained attention (Score!). In addition when compared 
to other measures of attention the Map Mission subtest correlates significantly with 
the Stroop task (Trenerry, Crosson, DeBoe, & Leber, 1989), a measure of selective 
attention and the Score! subtest correlates significantly with the Matching Familiar 
Figures Test (Arizmendi, Paulsen, & Domino, 1981), a task which assesses 
impulsivity.  
The TEA-Ch has also been assessed in a sample of 18 children with TBI 
(Manly et al., 1999) and significant difference in performance, compared to the 
control sample, was found on the Map Mission subtest at the α=0.001 level 
indicating it is sensitive to impairment. Performance on the Score! subtest was not 
significantly different between the groups in this small sample.  
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2.5.2.4.3 Administration. 
 The Map Mission subtest required the child to search a map and find as many 
target symbols as they could in one minute. The Score! subtest required the child to 
listen to a tape recording and keep track of how many ‘scoring’ sounds they hear. It 
is a task that has little intrinsic interest and is therefore a good measure of how well 
the child is able to sustain attention for a period of time. Approximately 10 minutes 
was required to administer both subtests.  Both subtests are scored on the basis of the 
number of targets correctly identified and these raw scores are then converted into 
age scaled scores on the basis of gender specific normative data. As there is no 
equivalent measure of attention for children aged 16 years (the adult version of this 
measure having 18 years as its lower cut off) the normative data for the age group 15 
years -15 years 11 months was used to standardise the data of 16 year old 
participants.  
  
2.5.2.5 Grooved Pegboard (Klove, 1963).  
2.5.2.5.1 Description. 
The grooved pegboard is a test of manual dexterity which assesses speed and 
accuracy of hand eye co-ordination. Participants are required to rapidly place small 
pegs into holes under time constraints. It has been widely used in research and 
industrial settings and is included in several neuropsychological test batteries 
(Yancosek & Howell, 2009). It was used in this study to provide a measure of 
psychomotor function and was chosen as it has been used in previous adult validation 
studies of the CogState battery (Cysique et al., 2006; Maruff et al., 2009) and found 
to correlate significantly with the DET task.  
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2.5.2.5.2 Psychometric properties. 
Normative data are  available for the grooved peg board for ages eight to 14 
years in age bands of one year divided by hand and statistically “smoothed” to 
provide consistent standard scores from age level to age level ((Knights, 1970) cited 
in (Baron, 2004)). Normative data for 15 and 16 year olds divided by hand are 
available in the test manual as part of a group of 172 15 to 19 year olds (Lafayette 
Instruments, 2002). Reliability data are reported  from a large adult study (Ruff & 
Parker, 1993) which show test-retest reliability to be good (dominant hand r=.72, 
non-dominant hand r=.74, p<.01).  
A recent MRI study in adults with brain tumours (Otten et al., 2012) provides 
construct validity evidence for the Grooved Peg Board test showing that performance 
on the task is correlated to connectivity between different motor areas of the brain 
and in those participants showing reduced connectivity performance was 
significantly different from controls.  The test has also been used with children with 
learning disabilities showing a similar pattern or performance to adults with brain 
injury (Rourke, Yanni, MacDonald, & Young, 1973).  
 
2.5.2.5.3 Administration. 
 The grooved peg board is a practical test which requires the participant to 
place 25 small metal pegs, with a rounded side and a grooved side into 25 similarly 
shaped but randomly orientated holes on a response board. This means the 
participant must rotate the peg before placing it in the hole. The task is completed 
twice, once using only the dominant hand and once only the non-dominant hand. The 
time taken to complete each trial is recorded. Age and gender based means and 
standard deviations are available allowing the calculation of z-scores. Only the 
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dominant hand score was used in the primary analyses. This test took approximately 
five minutes to complete.  
 
2.5.2.6 Behaviour Rating Inventory of Executive Function (BRIEF; Gioia et 
al., 2000)). 
2.5.2.6.1 Description. 
The BRIEF, an 86-item informant rated questionnaire, was used to provide a 
measure of executive function. It comprises eight clinical subscales which form two 
index scores and can be combined to give a global score (Global Executive 
Composite). The Inhibit, Shift and Emotional control subscales form the Behavioural 
Regulation index. The Initiate, Working Memory, Plan/Organise, Organisation of 
Materials and Monitor subscales form the Metacognition Index. Given the broad 
range of areas of executive function covered by the BRIEF, and the fact that it is 
tapping into behaviour by the child in their normal environment over a long time 
period, it provides information of high ecological validity of a type that is very 
difficult to obtain from direct psychometric testing in a structured environment. The 
measure was included in this battery for this reason, in order to assess the 
relationship between the GMLT and a more ecologically valid assessment of 
executive function than that provided by the TMT-B.   
   There are two versions of the BRIEF, one for parents and one for teachers. 
Whilst inter-rater reliability between the two versions has been found to only be 
moderate it is consistent with the different environmental settings observed. 
Equivalence was found between mother’s and father’s ratings. In this study only the 
parent form was completed by either the mother or father of the child depending on 
who was present at the testing session.  
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2.5.2.6.2 Psychometric properties. 
The BRIEF was standardised on a large representative American sample of 
1419 parent respondents (and 720 teacher respondents) of children aged between 5 
and 18 years old. The internal consistency of the scale is reported as between 0.80-
0.98 in the different parent, teacher and clinical or non-clinical samples. Test-retest 
reliability for the parent normative sample was r=.81 over an average interval of two 
weeks and for the clinical sample was r=.79 over an average interval of three weeks 
indicating that the test is stable.  
Evidence to support this scales validity comes from correlations with the 
ADHD-Rating Scale-IV (DuPaul, Power, Anastopoulos, & Reid, 1998), Child 
Behaviour Checklist (Auchenbach, 1991) and Behaviour Assessment for Children 
(Connors, 1989; Reynolds & Kamphaus, 1992) which indicate that whilst the BRIEF 
is measuring similar constructs (i.e. subscales looking at the same construct were 
highly correlated) it also adds significantly different information. The Inhibit and 
Working Memory scales were able to distinguish children diagnosed with ADHD 
from controls and preliminary studies in the manual suggest it is sensitive to 
executive difficulties in children with TBI and frontal lobe lesions among a range of 
other conditions.  
 
2.5.2.6.3 Administration. 
 The BRIEF is a parent completed rating scale in which the parent is asked to 
respond to 86 statements about children’s behaviour by rating on a three point scale 
how often their child has had problems with the behaviour in the last six months. 
Printed instructions were given on the record form as well as verbally by the 
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examiner before the parent completed the scale to encourage the importance of 
accurate reporting. Parents were encouraged to ask for help if they had problems 
completing the questionnaire and all questionnaires were checked for completion. 
One parent completed the scale whilst the child was completing the CogState battery. 
On average parents took between 10 and 15 minutes to complete the measure. Age-
standardise T-scores can be calculated for each index and the overall score. Only the 
Global Executive Composite score was used in the main correlation analysis. As 
there are several subscales of interest (including Inhibit, Shift, Working Memory and 
Monitor) which fall into both of the index scores (BRI and MI) the GEC score was 
chosen in preference to the subscale scores and index scores to limit the number of 
correlations conducted whilst including the widest possible information on executive 
function provided by the measure.  
  
2.5.3 Confounding variable measures. 
2.5.3.1 Wechsler Abbreviated Scale of Intelligence (WASI;Wechsler, 1999).  
2.5.3.1.1 Description. 
The two subtest version of this abbreviated test of intellectual function was 
used to provide a brief measure of IQ. The two subtests included are Vocabulary and 
Matrix reasoning. The Vocabulary subtest provides a good measure of crystallized 
intelligence and general intelligence. The Matrix Reasoning subtest is a measure of 
non-verbal fluid reasoning and general intellectual ability. A second edition of the 
WASI has recently been published and given the Flynn effect (Flynn, 1987b) of the 
inflation of IQ scores over time it would have been preferable to use this measure, 
however it was unavailable at the time of testing.   
91 
 
Brief measures of intelligence have been criticized for failing to provide a 
broad range of clinically useful information that can be obtained from a broader 
battery (Baron, 2004). However, in this instance the aim of using the measure is 
simply to obtain a brief indication of overall ability level to allow for consideration 
of it as a potential confounding factor, given the correlation between IQ and 
performance on other neuropsychological measures (e.g. (Duncan, 1995).  Brief 
measures have been shown to do this well (see psychometric properties) in a way 
which is time efficient, which is of primary importance in the present case in order to 
keep the battery as a whole feasible for the child to complete in one session.  
 
2.5.3.1.2 Psychometric properties  
The WASI has been standardised for ages 6-89 years on a large 
representative American sample (n=2245) including 1100 children. Reliability of the 
two-subtest version calculated using the split half method is reported as ranging 
between .92 and .95 in the child sample with an average of .93 which is very good. 
Test-retest reliability at a mean re-test interval of 31 days was an average of .87 in 
the child sample indicating the test is stable. Inter-rater reliability of the scoring of 
the Vocabulary subtest, which requires some judgement on the part of the examiner 
was .98 indicating it can be scored very reliably.  
Validity of the WASI two-subtest short form is supported by a strong 
correlation (.81) with the WISC-III, a more comprehensive assessment of 
intelligence in a sample of 176 children aged 6-16 years. It has been shown to be 
sensitive to deficits in clinical groups including children with learning disabilities 
and TBI when compared to matched controls.  
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2.5.3.1.3 Administration. 
 The two subtests were administered to the participant by the examiner in the 
order Vocabulary followed by Matrix Reasoning. The Vocabulary subtest required 
participants to orally define a series of words which become progressively more 
difficult. The words are presented in written form as well as being said to the 
participant by the examiner. The Matrix Reasoning subtest involved the participant 
choosing the most appropriate pattern to complete a grid or series from five options 
presented visually in a stimulus book. On average 20 minutes was needed to 
complete both subtests.  
 
2.5.3.2 Paediatric Inventory of Emotional Distress (PI-ED; O'Connor, Carney, 
House, Ferguson, & O'Connor, 2010).  
2.5.3.2.1 Description. 
 This 14-item self report measure is validated for use with children aged 7-17 
and provides a measure of emotional distress (cothymia) over the previous week. It 
was developed as a paediatric version of the Hospital Anxiety and Depression scale 
(Zigmond & Snaith, 1983) and therefore retains the aim of that scale to avoid items 
about symptoms which may be due to either depression and anxiety or physical 
disease e.g. dizziness or tiredness, often included in other measures of depression and 
anxiety. This makes it particularly suitable for use in this study with a paediatric 
oncology population. It was included in the battery to provide a measure of 
emotional distress in order to investigate whether this is a confounding variable in 
performance on the neuropsychological tests in this study as evidence from the 
literature suggests low mood and anxiety can impair performance (Douglas, Porter, 
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Knight, & Maruff, 2011; Elderkin-Thompson et al., 2003; Emerson, Harrison, 
Everhart, & Williamson, 2001).  
 
2.5.3.2.2 Psychometric properties. 
 The PI-ED was standardised in large school based sample of 1108 children 
aged between 7 and 17 years old, and a sample of 117 paediatric outpatients. Split-
half reliability was found to be .83 in this sample for the overall cothymia factor, 
with test-retest reliability as .81 indicating that the measure is internally consistent 
and stable. Validity was investigated by analysing the correlation with the Beck 
Anxiety Inventory – Youth (BAI-Y) and Beck Depression Inventory – Youth (BDI-
Y) scales with a correlation coefficient of .69 indicating that the measures are all 
tapping into strongly related constructs.  
  
2.5.3.2.3 Administration. 
The PI-ED was completed by the participant with supervision from the 
examiner to ensure they understood the instructions. One sample question was 
completed prior to moving on to the main portion of the measure to give the child the 
chance to practice using the four point response scale of ‘Always’, ‘A lot of the 
time’, ‘Sometimes’ and ‘Not at all’. The measure took approximately 5 minutes to 
complete.  
 
2.5.4 Un-standardised questionnaire measures.  
2.5.4.1 Demographic questionnaire (Appendix J). 
 Participants and their parents were asked their age, gender and parental level 
of education, diagnosis, treatment received, time since diagnosis and time since 
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treatment finishing. For those participants still on maintenance treatment details of 
this were collected. 
 
2.5.4.2 Acceptability questionnaire (Appendix K). 
 This questionnaire covered the acceptability of the testing procedure using 
the CogState battery by asking participants to rate the battery as a whole on 3 point 
Likert scales regarding difficulty, fatigue, distress, length, enjoyment and interest 
based on the protocol used by Pejnovic et al. (2012). A summary question asking 
participants if they would be happy to complete the tasks again was also included as 
was a question asking if they have any further comments they would like to make 
about the tasks. This questionnaire was analysed as part of an integrated service 
based research project (see Appendix L). 
 
2.6 Assessment Procedure 
The CogState battery, standard neuropsychological battery and paper 
questionnaire measures were completed by the child, and their parent where 
applicable, during a single study visit. Visits took place in the child’s home at a table 
in at least a relatively undisturbed environment. The CogState battery was 
administered first followed by the acceptability questionnaire to allow for the 
acceptability of the battery to be assessed without interference from the other tasks. 
Following this the questionnaire measures and WASI were completed and then the 
standard neuropsychological battery. This order was the same for every participant. 
This is due to the fact that it is not recommended that the CogState subtests be 
counterbalanced to address order effects due to the risk of proactive interference 
between tasks which use similar stimuli (OCL and OBK). As such, to maintain 
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consistency in the presentation of both batteries the standard battery was also 
presented in a fixed order as described in Table 2. A break was offered to the child 
following completion of the WASI and additional breaks could be requested as 
required by the child or were suggested by the researcher if needed to maintain the 
arousal level of the child. 
 
2.7 Ethical Considerations 
2.7.1 Ethical approval. 
Appropriate NHS Ethical approval and local Research and Development 
approval was sought prior to the study commencing (see Appendices M-P).  
 
2.7.2 Use of children in research and potential burden to participants.  
 As this study involves participants under 16 years old the Medical Research 
Council Ethics Guide on involving children in research (Medical Research Council, 
2004) were considered. This guidance states that “research involving children should 
only be carried out if it cannot feasibly be carried out on adults” (p.13). This study 
aimed to validate a measure already validated in adult populations for use with a 
particular child population. It was therefore not possible to carry out the study 
without the use of child participants. The MRC Ethics guide also emphasises the 
importance of assessing the risk to the child participants and the potential benefits 
and harm resulting from participation. This study involved only procedures such as 
questioning and observing the child’s performance on cognitive assessments. It was 
considered unlikely that this would result in any harm to the child beyond potential 
boredom and tiredness however if psychological distress was seen to be caused by 
the testing procedure it was stopped immediately, the cause of the distress discussed 
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and appropriate support identified. This occurred on one occasion resulting in the 
testing session being terminated, further support identified in the form of an 
upcoming clinic visit the next week, feedback being sent to the clinical team with the 
consent of the family and the participant being excluded from the analysis. The 
potential benefits for the children participating included a brief assessment of their 
neuropsychological functioning which may have informed further assessment based 
on the clinical judgement of their clinical team. More prominently it was hoped that 
by validating a brief and easily administered neurocognitive assessment tool in this 
population it may become part of standard clinical practice and therefore contribute 
to meeting the recommendation of the Children’s Oncology Group (Nathan et al., 
2007) that all at risk children receive some neuropsychological evaluation.   
 
2.7.3 Informed Consent. 
 Informed consent was sought for all study participants. For participants aged 
8-15 years consent was sought from a person with parental responsibility and assent 
was sought from the child. For participants aged 16 years consent was sought from 
them with consent also being sought from their parent regarding the questionnaire 
measures they completed. If a child and their parent did not agree on taking part in 
the study the child was not recruited as the cooperation of both parties was required 
to complete the study measures, however this situation did not occur.  
 
2.7.4 Coercion. 
 Potential participants were initially approached by members of the clinical 
team with whom they were familiar. It was made clear that it was their choice if they 
would like to be contacted by the researcher or not and that there were no adverse 
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consequences if they decided they would not like to take part. There was an 
opportunity to ask questions to the researcher at the visit prior to the consent/assent 
forms being signed. It was also made clear that participants could withdraw their 
consent/assent at any time without giving a reason.  
 
2.7.5 Access to appropriate follow up. 
 With the family’s consent a brief report of the child’s performance on the 
standard neuropsychological measures and the measure of emotional distress was 
sent to the child’s clinical team via the principal investigator for each of the three 
paediatric oncology services taking part in the study. It was the responsibility of the 
clinical team to determine if further testing or follow up was required based on the 
child’s scores on the research measures. The three paediatric oncology services 
approached to take part in the study indicated that they were able to provide 
appropriate follow up as required. Families were informed that they may be 
approached by their clinical team regarding follow up if the team thought this was 
required.  
 
2.7.6 Confidentiality. 
 Participant’s details were passed to the researcher only once they had given 
their consent for this to happen. Each participant was given a unique participant 
number and all assessment information was coded with this number and stored 
separately to identifiable information and consent forms to ensure anonymity of 
assessment results.  
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2.7.7 Protection of information. 
 All paper information generated during the study was stored securely in 
locked filing cabinets at the University of East Anglia (UEA). A locked briefcase 
was used to transport data. All electronic information was stored on password 
protected UEA computer systems and an encrypted memory stick for use on other 
computers. Data were not saved to any other computer. Data will be stored for a 
minimum of 5 years as per UEA and NHS protocols and will then be securely 
disposed of.  
 
2.8 Plan for Data Analysis 
Data will be entered into SPSS for analysis. Assumptions of parametric tests 
will be checked. All data will be transformed into z-scores for ease of comparison 
across the different subtests as suggested by Crawford (2013) where suitable 
normative data is available. Where higher scores indicate poorer performance z-
scores will be multiplied by -1 to aid interpretation so that across all tests higher 
values indicate better performance. Raw data will be used for the Continuous Paired 
Associate task and the Groton Maze Learning task as no suitable normative data is 
available. 
For the first research question regarding construct validity the six a priori 
hypotheses will be investigated using Pearson’s product moment correlations to 
determine the size and significance of each relationship (if assumptions for 
parametric tests are met, Spearman’s rho if the data is non parametric). This will 
involve nine separate comparisons and significance tests will be adjusted for multiple 
comparisons using the Holm method (Wright, 1992) to reduce the risk of type 1 
errors. The Holm method is a modification of the Bonferroni correction which 
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maintains the experimentwise error rate of α but is considered less conservative and 
was selected for this reason. It follows a sequential procedure in which the 
uncorrected p values are ordered by size and tested, beginning with the smallest 
value, with each p value compared to α/(n-i +1) where i is the position in the 
sequence, rather than α/n as in a standard Bonferroni correction. Once a non-
significant result is obtained all larger p values are deemed non-significant.  
Additional exploratory analysis of components of the standard tests will conducted if 
indicated.  
The second research question will also be investigated using Pearson’s 
product moment correlations to determine the size and significance of the 
relationship between months since diagnosis and a summary score of overall 
performance on the CogState battery (if assumptions for parametric tests are met, 
Spearman’s rho if the data is non parametric). IQ and total score on the PI-ED will 
also be correlated with the CogState summary score and if this relationship is 
significant then a subsequent partial correlation analysis will be carried out to 
remove the effect of the co-variant.   
Acceptability of the testing procedure will be descriptively reported giving 
proportions of respondents rating the tasks positively, neutrally and negatively. 
Feasibility will be reported as the percentage of eligible patients completing the 
CogState assessment and the mean length of time to complete and score the battery. 
This data forms part of a separate but integrated service based research project the 
results of which are presented in Appendix L.  
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3  Results 
3.1 Overview 
 In this chapter the results of the study are presented in five parts. First an 
overview of the clinical and demographic characteristics of the sample is given. This 
is followed by a description of the preliminary analysis of the data including 
accounting for issues in the data and investigating the distribution of each variable. 
The third and fourth sections address the two main research questions and associated 
hypotheses in turn. The final section provides a summary of the results.  
 
3.2 Demographic and Clinical Characteristics of the Sample 
 Thirty-seven participants were included in the study aged between 8 years 6 
months and 16 years 11 months. The demographic and clinical details of the sample 
are presented in Table 5.  
Table 5 
Demographic and Clinical Characteristics of the Sample  
Participant Characteristic Whole Sample (n=37) 
Gender n (%) 
    Male 
    Female 
 
16 (43) 
21 (57) 
Age at testing (years) 
    Mean 
    SD 
    Range 
 
12.7 
2.4 
8.5-16.9 
Age at diagnosis (years) 
    Mean 
    SD 
    Range 
 
5.5 
3.6 
0.5-15.6 
Time since diagnosis (years) 
    Mean 
    SD 
    Range 
 
7.1 
3.6 
0.25-13.25 
Diagnosis n (%) 
    Acute Lymphoblastic Leukaemia 
    Other Leukaemia 
    CNS Tumour 
 
27 (73) 
2 (5) 
8 (22) 
Treatment n (%)a  
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Participant Characteristic Whole Sample (n=37) 
    Surgery 
    Chemotherapy (inc. ITC) 
    Radiotherapy 
    Corticosteroids 
    Other 
7 (19) 
30 (81) 
2 (5) 
26 (70) 
3 (8) 
Maintenance treatment at time of testing n (%) 
    Yes 
    No 
 
4 (11) 
33 (89) 
Parental Level of Education n (%) 
    None 
    GCSE/O Level 
    A-level or equivalent 
    Undergraduate 
    Post Graduate 
 
1 (3) 
12 (32) 
11 (30) 
11 (30) 
2 (5) 
WASI Two-subtest IQ (standard score)b 
    Mean 
    SD  
    Range 
 
101.50 
14.86 
78-135 
PI-ED total scorec 
    Mean 
    SD 
    Range 
 
12.05 
5.89 
3-28 
Note. CNS=Central Nervous System, IT=intrathecal chemotherapy  
a Up to three treatments were recorded for each participant. 
b WASI = Wechsler Abbreviated Scale of Intelligence; Standard scores have a mean 
100 and a standard deviation of 15  
cPI-ED = Paediatric Inventory of Emotional Distress; Clinical cut off is 10 for males 
and 11 for females 
  
A significant majority (75%) of the sample had a diagnosis of leukaemia with 
only 22% having been treated for a variety of brain tumours. Whilst leukaemias are 
more prevalent in the population of children and young people treated for cancer 
accounting for around 31% of 0-19 year olds diagnosed with any form of cancer in 
America as of January 2011 verses 18% for CNS tumours (Howlader et al., 2011), 
the proportions in this study do not fully reflect this clinical picture (if the 
recruitment had been fully representative 63% of the sample would have a diagnosis 
of leukaemia and 37% would have a diagnosis of a CNS tumour). A number of 
factors, including survival rates, severity of motor and sensory late effects, and 
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current service provision of neuropsychological assessment may account for this 
discrepancy and will be discussed further in the next chapter.  
General intellectual ability in the sample as measured by the WASI two-
subtest short form does not differ significantly from the normative mean suggesting 
that on this brief global measure there is no significant impairment in functioning 
compared to typically developing peers. This contrasts with some other studies using 
similar mixed diagnosis samples (e.g. Krull et al., 2008) where the mean Full Scale 
IQ was 91.9 (SD 16.09)) and may reflect the low use of radiation treatment in the 
sample. Of note, performance on the more specific neuropsychological measures in 
the standard battery, described below, does indicate some significant levels of 
impairment in the sample, especially on measures of executive function, which are 
not reflected in the brief global IQ assessment. Table 6 presents the performance on 
these standard measures, and the CogState tasks, expressed as standard scores with a 
mean of 100 and standard deviation of 15 for ease of interpretation. In addition the 
number of children scoring ≥1SD below the mean on each task is indicated.   
Overall scores on the PI-ED exceed the clinical cut off indicating the 
presence of clinically significant levels of emotional distress within the sample. 
Specifically 8 of the male participants (50%) and 15 (71%) of the female participants 
met or exceeded the clinical cut off score.  
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Table 6 
Clinical performance on the Standard Battery and CogState battery 
Note. BRIEF GEC=Behaviour Rating Inventory of Executive Function General 
Executive Composite, TMT-B = Trail Making Test –B  
* p≤.05 **p≤.001 both One-sample t-test 
†p≤.05 †† p≤.001 both One-sample Wilcoxin Signed Rank test 
 
3.3 Preliminary Analysis 
3.3.1 Missing data.  
 Data were missing in two variables in the standard battery. Two participants 
were unable to complete the Score! subtest due to technical difficulties with the 
audio equipment needed for this test. One participant did not complete the TMT-B 
subtest due to the materials being unavailable at the time of testing. Participants with 
missing data points were excluded pairwise from the relevant analysis so as to ensure 
maximum use of the available data.  
3.3.2 CogState auditory feedback. 
 Due to a technical difficulty with the hardware running the CogState 
programme, which was subsequently resolved, the first six participants completed 
the CogState battery with no auditory feedback. Visual feedback was still present 
Task Mean SD Median 
Number ≥1SD below 
the mean (%) 
Standard Battery     
    Grooved Peg Board 79.15 31.95 86.05†† 18 (49) 
    Symbol Search 99.10 15.15 100.00 10 (27) 
    Map Mission 90.85* 19.20 89.95 14 (38) 
    Score! 89.95** 15.15 89.85 17 (46) 
    Dot Location 100.45 14.25 100.00 10 (27) 
    Digit Span 90.40 11.55 85.00†† 19 (51) 
    TMT-B 81.85 30.45 94.15† 16 (43) 
    BRIEF GEC 83.65** 20.70 82.00 22 (59) 
CogState     
    Detection 103.90 14.70 103.30 3 (8) 
    Identification 103.30 17.25 103.75 6 (16) 
    One Card Learning                              
t    (outlier removed) 
100.60 19.95 107.05 9 (25) 
    One Back 98.20 18.60 101.95 7 (19) 
    Composite 100.9 15.00 99.55 3 (8) 
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within each task which were otherwise completed in the same way as the other 31 
participants who had auditory feedback. To determine if this difference in 
administration significantly affected the results obtained on the primary outcome 
variables the group means for each group (sound and no sound) were compared with 
an independent t-test. Homogeneity of variance assumptions were not violated. No 
significant differences in mean were found for any of the six variables (p= 0.19-0.96) 
indicating that the distribution of results was not affected by the presence or absence 
of auditory feedback. Unequal group sizes can impact on the robustness of the 
independent t-test, however the impact is to increase the likelihood of Type 1 errors 
therefore this would not affect the conclusion from this test. Therefore the entire 
sample has been retained for the remaining analysis and no further distinction will be 
made between those participants who received auditory feedback and those who did 
not.   
3.3.3 Descriptive statistics and tests for normality.  
Prior to analysis the distribution of each variable was assessed using 
descriptive statistics for central tendency (mean and median), variance (range and 
standard deviation) and for adherence to a normal distribution (skew and kurtosis). In 
addition normality was assessed by visual inspection of histograms and box plots and 
by calculating the Kolmogrov-Smirnov statistic (D). As the CogState primary 
outcome variables are provided as transformed distributions further transformations 
of the data to meet the assumptions of parametric analysis were not considered. 
Outliers were examined individually as described below to determine if they should 
be excluded from the analysis due to extraneous factors affecting the score. This 
should only be done if there is good reason to believe the score is not representative 
of the sample under test (Field, 2009). 
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For clarity, the signs of the z-scores have been reflected where necessary so 
that lower scores indicate poorer performance on all variables. Where raw scores 
were used in the analysis this was not possible and the impact of this on the direction 
of the relationship is discussed below where applicable.  
3.3.3.1 CogState. 
The descriptive data for the primary outcome variable for each of the four 
CogState subtests with sufficient normative data to allow z-scores to be calculated 
are displayed in Table 7, along with a composite score derived from the mean of 
these four subtests z-score for each participant.  
Table 7  
Descriptive Statistics for the CogState Subtests with z-score Distributions 
  Range    Skew  Kurtosis 
Variable n Min Max Median M SD  SE   SE 
DET (log10 
reaction time) 
37 -1.65 2.11 0.22 0.26 0.98 -0.05 0.39  -0.64 0.76 
IDN (log10 
reaction time) 
37 -2.09 2.87 0.25 0.22 1.15 0.14 0.38  -0.22 0.76 
OCL (arcsine 
square root 
accuracy) 
37 -10.21 2.83 -0.03 -0.24 2.13 -2.87 0.39  12.97 0.76 
OCL (outlier 
removed) 
36 -3.35 2.82 0.47 0.04 1.33 -0.10 0.39  0.37 0.77 
OBK (log10 
reaction time) 
37 -3.64 3.19 0.13 -0.12 1.24 -0.29 0.39  1.85 0.76 
Composite 37 -2.95 2.03 -0.03 0.06 1.00 -0.64 0.39  1.06 0.76 
Note. DET=Detection, IDN=Identification, OCL=One Card Learning, OBK=One 
Back 
 
 The DET (D(37)=0.08), IDN (D(37)=0.07) and OBK (D(37)=0.10) subtest z-
score distributions are not significantly different from the normal distribution (all 
p>0.05) and therefore suitable for parametric analysis. The Composite score 
distribution was also not significantly different from normal (D(37)=0.09). The OCL 
z-score distribution is significantly different from normal, (D(37)=0.184, p<0.01) 
with significant negative skew and leptokurtosis meaning the assumptions of 
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normality have been violated. Inspection of the boxplot revealed one extreme outlier 
in the data (z=-10.21). Examining this case in more detail showed there was no error 
in data recording but that this participant’s testing session had taken place amid 
unavoidable moderate levels of distraction. Given this and the fact that the score on 
this subtest was inconsistent with the participants performance on the CPAL task 
(also measuring visual learning and memory) it was decided that this data point 
should be excluded from the analysis. Following the removal of this outlier the 
distribution of the One Card Learning task was no longer significantly different from 
normal (D(36)=0.09, p>0.05) and suitable for parametric analysis.   
 Suitable normative data are not currently available for the Continuous Paired 
Associate Task or the Groton Maze Learning Task due to low numbers. Therefore 
the raw data was used in the main analyses. As different versions of the GMLT are 
presented in the 8-9 year old battery and the 10-16 year old battery this data is 
presented separately. Descriptive data for these two subtests are presented in Table 8.  
Table 8 
Descriptive Statistics for the CogState Subtests Using Raw Data in the Primary 
Outcome Variable 
Note. CPAL=Continuous Paired Associate Learning, GMLT=Groton Maze Learning 
Task 
 
 The Groton Maze Learning Task total errors variable distribution is not 
significantly different from the normal distribution for either age range (8-9 years 
D(8)=0.14; 10-16years D(29)=0.11). However the Continuous Paired Associate 
  Range    Skew  Kurtosis 
Variable n Min Max Median M SD  SE   SE 
CPAL 
(errors) 
37 1 71 8 14.27 15.31 2.54 0.39  7.36 0.76 
GMLT 8-9 
years (total 
errors) 
8 34 76 50 51.13 13.92 0.69 0.75  0.41 1.48 
GMLT 10-16 
years (total 
errors) 
29 45 82 63.5 61.37 11.84 0.30 0.75  0.03 1.48 
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Learning task accuracy variable distribution is significantly positively skewed and 
leptokurtic with analysis indicating it is significantly different from the normal 
distribution (D(37)=0.193, p<0.05). Inspection of the histogram and stem and leaf 
plot reveal two significant outliers. Examining these cases in more detail did not 
reveal any data errors or particular difficulties in the testing session. Of note the two 
outliers were obtained by the two youngest children in the sample (8 years 6 months 
and 8 years 8 months). However there was deemed to be no justifiable reason to 
remove these data points therefore they were retained and non-parametric analysis 
was used for this variable.  
3.3.3.2 Standard battery. 
 Descriptive statistics for the z-score distribution of each variable from the 
standard battery are presented in Table 9.  
Table 9 
Descriptive Statistics for the Primary Outcome Variables in the Standard Battery 
Note. BRIEF GEC = Behaviour Rating Inventory of Executive Function General 
Executive Composite, D = Dominant, DL=Dot Location, DS = Digit Span, GPB = 
Grooved Peg Board, SS = Symbol Search, TMT-B = Trail Making Test-B 
 
 Of these variables five (WISC Symbol Search, D(37)=0.14; TEA-Ch Map 
Mission, D(37)=0.08, TEA-Ch Score!, D(35)=0.13; CMS Dot location, D(37)=0.13; 
and BRIEF GEC, D(37)=0.12) were not significantly different from the normal 
distribution (all p>0.05) and suitable for parametric analysis. The distributions of 
three variables were found to be significantly different from the normal distribution. 
  Range    Skew  Kurtosis 
Variable n Min Max Median M SD  SE   SE 
GPB (D-hand) 37 -8.8 1.54 -0.93 -1.39 2.13 -1.87 0.39  4.34 0.76 
SS 37 -2.0 2.0 0.00 -0.06 1.01 -0.02 0.39  -1.02 0.76 
MM 37 -3.0 1.67 -0.67 -0.61 1.28 -0.22 0.39  -0.52 0.76 
Score! 35 -2.67 1.33 -0.67 -0.67 1.01 0.14 0.40  -0.63 0.78 
DL 37 -2.0 1.67 0.00 0.03 0.95 -0.18 0.40  -0.82 0.76 
DS 37 -1.67 1.33 -1.00 -0.64 0.77 0.62 0.39  -0.36 0.76 
TMT-B 36 -7.44 1.36 -0.39 -1.21 2.03 -1.41 0.39  1.86 0.77 
BRIEF GEC 37 -4.40 0.80 -1.20 -1.09 1.38 -0.52 0.39  -0.38 0.76 
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The Grooved Peg Board dominant hand distribution (D(37)=0.16, p=0.02) was 
significantly negatively skewed and leptokurtic. Inspection of the boxplot revealed 
one extreme outlier (>3xIQR) and two further outliers in the data. Examination of 
these individual cases did not reveal any data errors or difficulties in the testing 
session therefore there was considered to be no justifiable reason to remove them. 
The WISC Digit Span distribution (D(37)=0.19, p<0.01) was significantly positively 
skewed however no outliers were identified on the boxplot. The TMT-B distribution 
(D(36)=0.19, p<0.01) was significantly negatively skewed and leptokurtic. 
Inspection of the boxplot revealed two outliers in this variable. Examination of these 
cases revealed no data errors and no particular difficulties in the testing sessions, 
with these scores being consistent with the impairment shown in the BRIEF GEC 
(both >2SD below the mean). Therefore it was decided that there was no justification 
to remove these data points. As a result non-parametric analysis was used for 
correlations involving these variables.  
3.3.3.3 Confounding variables. 
 Descriptive statistics for the two potentially confounding variables relevant to 
research question two; IQ as measured by the WASI two sub-test version and 
emotional distress as measured by the PI-ED, are presented in Table 10. 
Table 10 
Descriptive Statistics for IQ and the PI-ED  
Note. PI-ED = Paediatric Inventory of Emotional Distress 
 Both variables were found to be normally distributed (IQ, D(37)=.13, p>.05; 
PI-ED, D(37)=.10, p>.05), and therefore suitable for parametric analysis.  
  Range    Skew  Kurtosis 
Variable n Min Max Median M SD  SE   SE 
IQ z-score 37 -1.47 2.33 -.067 .10 .99 .38 .39  -.87 .76 
PI-ED total 
score 
37 3 28 11.88 12.05 5.89 .33 .39  -.12 .76 
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3.4 Primary Research Question 1: Does CogState demonstrate adequate 
construct validity in a population of children who have survived a brain 
tumour or leukaemia when compared to a standard neuropsychological 
battery? 
 Both batteries cover the main areas of neurocognitive functioning shown by 
previous research to be most often affected by childhood cancer and its treatment. If 
CogState is a valid assessment of these areas in this population several hypotheses 
can be made about which of its subtests will correlate with which standard 
neuropsychological tasks. Each of these hypotheses will now be considered in turn. 
Where both variables met the assumptions of parametric analysis Pearson product-
moment correlation (r) was used to investigate the relationship between them. Where 
either of the variables violated the assumptions of parametric analysis Spearman’s 
Rho (rs) was used. In addition 95% bootstrap confidence intervals (1000 samples, 
simple sampling and percentile method) are reported for each correlation. 
Scatterplots of all of the correlations below are presented in Appendix Q.  
In the data analysis plan nine correlations were planned to address these 
hypotheses with the significance level adjusted using the Holm correction to reduce 
the risk of Type 1 errors. Given the need to analyse the data from the Groton maze 
learning task in two separate age bands due to the lack of appropriate normative data, 
two further comparisons are required reducing the significance level further. Further 
unplanned correlations between components of the standard tests and the CogState 
subtests are considered exploratory and are not included in this correction. Given the 
relatively conservative nature of this adjustment specific p values are reported to 
allow consideration of relationships which may be significant at the standard α = .05 
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level. All probabilities are two-tailed. Correlation coefficients constitute an effect 
size, describing the strength of the relationship between the variables (Field, 2013). 
They are reported in full and described following the convention of Cohen (Cohen, 
1992) as 0.1 being small, 0.3 medium and 0.5 large.   
 
3.4.1 Hypothesis 1: The Detection task of the Cogstate battery measures 
psychomotor function and processing speed and will be positively 
correlated with performance on the Grooved Peg Board task and the 
WISC-IV Symbol Search subtest. 
 Performance on the Detection task as measured by the primary outcome 
variable of reaction time (Log10 tranformation) was found to be not significantly 
positively related to performance on the Grooved peg board dominant hand, rs = .33, 
p = .05, 95% CI [-.01, .58] or the Symbol Search subtest, r = .28, p = .10, 95% CL [-
.03, .59] at the corrected α-level. Both relationships represent a moderate effect size 
and for the GPB the relationship is significant at α=0.05, however the 95% 
confidence intervals for both correlations include zero indicating that this result is 
not robust. Therefore the hypothesis that it is a valid measure of psychomotor 
function and processing speed in a paediatric oncology population based on its 
correlation with the GPB and SS tasks does not appear to be supported based on this 
data. This is in contrast to the available literature on the construct validity of the 
adult battery and possible reasons for this disparity will be discussed in the next 
chapter.    
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3.4.2 Hypothesis 2: The Identification task of the Cogstate battery measures 
visual attention and vigilance and will be positively correlated with 
performance on the Map Mission and Score! subtests of the TEA-Ch.  
Performance on the Identification task as measured by the primary outcome 
variable of reaction time (Log10 tranformation) was found to be significantly 
positively correlated with performance on the Map mission subtest, r = .47, p 0.003, 
95% CI [.33, .75]. This relationship has a large effect size. The relationship with the 
Score! Subtest (n = 35) was not significant but still represents a moderate effect size, 
r = .32, p = .06, 95% CI [.01, .58]. Therefore the hypothesis that the Identification 
task is a valid measure of visual attention in a paediatric oncology population is 
supported based on its correlation with the Map Mission task and the hypothesis that 
it is a valid measure of vigilance is partially supported based on its correlation with 
the Score! task.  
 
3.4.3 Hypothesis 3: The One-Card Learning Task of the CogState battery 
measures visual learning and memory and will be positively correlated 
with performance on the CMS Dot location subtest. 
Performance on the One Card Learning task as measured by the primary 
outcome measure of accuracy (arcsine square root transformation) was not 
significantly correlated with overall performance on the Dot location subtest, r = .19, 
p = .26, 95% CI [-0.13, 0.43]. This result indicates that evidence for the construct 
validity of the One-Card Learning task as a measure of visual learning and memory 
in a paediatric oncology population is not provided based on its convergent validity 
with the Dot location subtest in this sample. This is in contrast to the available 
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literature on the One-Card Learning task in adult populations and potential 
contributing factors will be considered in the next chapter.   
 
3.4.4 Hypothesis 4: The Continuous Paired Associate Learning Task of the 
CogState battery measures visual learning and memory and will be 
positively correlated with performance on the CMS Dot location subtest. 
 Performance on the Continuous Paired Associate Learning task as measured 
by the primary outcome variable of total errors was not significantly related to 
performance on the Dot location subtest, rs = -.33, p = .04, 95% CI [-0.57, -.02] 
however this analysis does reveal a medium effect size for the relationship which is 
significant at the uncorrected level and the confidence intervals do not include zero 
indicating that some level of negative correlation is a robust finding, although the 
range in size is very large. The correlation is negative rather than positive but this is 
due to the fact that higher scores on the CPAL task reflect poorer performance 
therefore the underlying relationship is in the expected positive direction. Based on 
this analysis there is some evidence in support of hypothesis that the CPAL task is a 
valid measure of visual learning and memory in a paediatric oncology population 
through convergent validity with the Dot location test.  
 
3.4.5 Hypothesis 5: The One-Back Task of the CogState battery measures 
working memory and will be positively correlated with performance on 
the WISC-IV Digit Span subtest.  
 Performance on the One-back task as measured by the primary outcome 
variable of reaction time (Log10 transformation) was not significantly positively 
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correlated with performance on the Digit Span subtest although a small to medium 
positive relationship was found, rs = .23, p = .17, 95% CI [-.12, .53].  
  The WISC-IV Digit Span subtest is made up of both forwards and backwards 
conditions which tap more specifically into efficiency of attention and working 
memory respectively (Baron, 2004). Given the hypothesis specifically relates to 
working memory it was decided to further investigate this hypothesis by using 
Longest Digit Span Backwards (LDSB) as the outcome variable for the Digit Span 
Subtest. Means and standard deviations for this measure separated into one year age 
groups are given in the WISC-IV manual (Wechsler, 2003) allowing the calculation 
of age corrected z-scores. The distribution of these scores was found to be not 
significantly different from normal, M =-.28, SD =.66, D(37) = .10, p>.05, therefore 
Pearson’s product-moment correlation analysis was used. The relationship between 
LDSB and the One-Back task is significant and has a medium effect size, r = .37, p = 
.042, 95% CI [-.07, .60]. However the 95% confidence intervals for this correlation 
are wide and include zero meaning that this finding is not robust. 
 Based on this analysis there is some evidence in support of the hypothesis 
that the One-Back task is a valid measure of working memory in a paediatric 
oncology population based in its convergent validity with the Digit Span subtest but 
with limited confidence. 
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3.4.6 Hypothesis 6: The Groton Maze Learning Task of the CogState battery 
measures executive function, including cognitive flexibility and will be 
positively correlated with performance on TMT-B and the BRIEF total 
score.  
 Performance on the Groton Maze Learning Task (GMLT) was measured by 
the primary outcome total errors, using the raw data as suitable normative data was 
not available in order to calculate age corrected z-scores. High scores on this variable 
indicate poorer performance, therefore negative correlations indicate a positive 
relationship. As the task had alternate forms in the battery presented to the 8-9 year 
olds and the 10-16 year olds these scores cannot be considered to come from the 
same distribution and therefore were considered separately.  
For participants aged 10-16 years (n = 28), although a small to medium 
relationship was found between GMLT and TMT-B it was in the opposite direction 
to expected and non-significant, rs = .19, p = .33, 95% CI [-.12, .60]. For participants 
aged 8-9 years (n = 8) a significant relationship with a large effect size was found 
between performance on the GMLT and Trails B in the expected direction, rs = -.86, 
p = 0.007. 95% CI [-1.00, -.29]. However, as this sample size is very small this result 
should be treated with caution.   
The relationship between performance on the GMLT and the BRIEF Global 
Executive Composite (GEC) score for participants aged 10-16 years (n=29) was not 
significant, rs = .14, p = .47, 95% CI [-.18, .46]. However for participants aged 8-9 
years (n=8) a relationship with a large effect size was found in the expected 
direction, although not significant in this small sample and of questionable reliability 
given this and the wide confidence intervals rs = -.60, p = 0.12, 95% CI [-.92, .15].  
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Given that the BRIEF GEC is a generalised measure of many aspects of 
executive functioning it was decided to investigate if significant relationships were 
present between the GMLT total errors variable and selected subtests from the 
BRIEF measuring aspect of executive function which are more specifically targeted 
in the GMLT including monitoring, working memory, cognitive flexibility and 
inhibition (Pietrzak et al., 2008). Given the small numbers, these analyses were not 
performed in the 8-9 age group. In the 10-16 year age group correlations were 
calculated between GMLT total errors variable and the more specific measure 
GMLT rule break errors variable and the Inhibit, Shift, Working Memory and 
Monitor subtests of the BRIEF. No significant relationships were found at α-level 
0.05.  
Therefore, these specific analyses do not appear to provide support for the 
validity of the version of the GMLT in the 10-16 year old battery as a measure of 
executive function based on its convergent validity with either Trails-B or the 
BRIEF. However, the converse it true for the 8-9 year old age group, where this 
analysis provides some evidence of a strong relationship between the measures 
indicating that this version of the task may be a valid measure of executive function 
in this population, although this conclusion is based on a very small sample size and 
should be treated with caution. This unexpected pattern of results will be considered 
further in the discussion.  
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3.5 Primary research question 2: Given the research showing intellectual 
performance declines over time since diagnosis (e.g. Spielger et al., 2004) is 
there a relationship between time since diagnosis and performance on the 
CogState battery? 
Based on this research question one hypothesis was made which is considered 
below.  
3.5.1 Hypothesis 7: Time since diagnosis will be negatively correlated with 
overall performance on the CogState battery.  
This hypothesis was investigated by analysing the correlation between time 
since diagnosis (months) and the CogState composite score derived from four of the 
six tasks included in the CogState battery; DET, IDN, OCL and OBK. Two tasks, 
CPAL and GMLT, were not able to be included in the composite score due to the 
current lack of robust normative data for these subtests meaning that valid z-scores 
could not be calculated. As a result of this the composite score does not include any 
measures that claim to assess executive functioning. The composite score was 
calculated by taking the mean of the participant’s z-scores across the four tasks 
included following the procedure detailed by the test publisher (A. Schembri, 
personal communication, May 20th, 2014).   
As IQ and mood have been shown in the literature to correlate with 
performance on neuropsychological tasks (Baron, 2004) these variables were 
investigated as potential confounding factors in the relationship between time since 
diagnosis and performance on the CogState battery. The two-subtest short form of 
the WASI was used to provide an estimate of IQ. The PI-ED self-report 
questionnaire was used to provide a measure of emotional distress in the week 
preceding testing. To determine if these variables were significantly related to the 
117 
 
CogState composite score, or time since diagnosis, Pearson’s product-moment 
correlations were calculated and are presented in Table 11.  
Table 11 
Correlations between IQ, Emotional Distress, CogState Overall Performance and 
Time Since Diagnosis 
 Time since 
diagnosis 
(months) 
CogState 
composite z-
score 
IQ z-score PI-ED total 
score 
Time since diagnosis  1 .32 -.06 .28 
CogState composite z-
score 
- 1 .43** .12 
IQ z-score - - 1 -.26 
PI-ED total score - - - 1 
Note. PI-ED = Paediatric Inventory of Emotional Distress 
**p<.01 (two-tailed) 
 
 This analysis shows that there is a medium but non-significant relationship 
between time since diagnosis and the CogState composite score although it is in the 
opposite direction to expected i.e. as time since diagnosis becomes longer overall 
performance on the battery improves. However, there is also a significant medium to 
large relationship between estimated IQ and the CogState composite score and a 
medium but non-significant relationship between time since diagnosis and PI-ED 
total score. Therefore a partial correlation controlling for the effect of IQ and 
emotional distress was conducted. Controlling for these relationships the relationship 
between time since diagnosis and performance on the CogState composite score did 
not reach significance at the α=.05 level r =.32, p = .06, 95% CI [.01, .57] although 
the confidence interval is wide indicating this is not a robust finding. Based on this 
analysis the hypothesis that time since diagnosis will be negatively correlated with 
overall performance on the CogState battery is not supported.  
 In addition to considering overall performance on the CogState battery this 
analysis also shows that in this sample there is no significant relationship between 
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time since diagnosis and IQ, r=-.06, p=.71, 95% CI [-.34, .21] in contrast to the 
current literature. This result remains the same when controlling for the effect of 
emotional distress at the time of testing, r=.01, p=.96, 95% CI [-.27, .33]. This will 
be discussed further in the next chapter.  
 
3.6 Summary of the results 
 In summary, in relation to the first research question regarding the construct 
validity of the CogState battery, based on convergent validity with the standard 
measures used in this study only the Identification task is robustly supported as a 
measure of visual attention. There is partial support for it as a measure of vigilance. 
Partial support is given to the CPAL task as a measure of visual learning, and the 
One-Back task as a measure of working memory. The GMLT in the under 10 year 
old battery is partially supported as a measure of executive functioning although with 
caution given the very small sample size. The results of this study do not provide 
evidence in support of the validity of the Detection task as a measure of psychomotor 
functioning or processing speed, the One Card Learning task as a measure of visual 
learning and memory or the GMLT in the 10-16 year old battery as a measure of 
executive function based on convergent validity with the specific measures used to 
provide a standard measure of each construct. These results are in contrast to the 
current adult construct validity literature on CogState and possible contributing 
factors will be considered further in the next chapter  
 In relation to the second research question regarding overall performance on 
the Cogstate battery decreasing as time since diagnosis increases the results of this 
study do not support this hypothesis. In addition no relationship was found between 
IQ and time since diagnosis.   
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The possible reasons for these results and their clinical and theoretical 
implications are discussed in the next chapter. 
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4 Discussion 
4.1 Chapter Overview 
 This chapter provides an overview of the results of the study and places them 
in the context both of the previous literature on the CogState battery but also wider 
clinical factors. The strengths and weakness of the methodology used are described 
and the potential impact of this on the outcomes of the study are considered. 
Following this the implications of this study both in clinical and theoretical contexts 
are discussed and recommendations for future research given. The chapter ends with 
a brief conclusion.  
 
4.2 Evaluation of Research Hypotheses 
 In this section each research hypothesis will be considered in turn and the 
results of this study discussed in relation to the existing literature.  
4.2.1 Research question 1: Does CogState demonstrate adequate construct 
validity in a population of children who have survived a brain tumour or 
leukaemia when compared to a standard neuropsychological battery? 
4.2.1.1 Factors affecting the interpretation of all hypotheses. 
 Before considering the hypothesis in turn the factors which impact in general 
on the interpretation of the results will be discussed.  
4.2.1.1.1 Computerised verses standard assessment measures  
Firstly the impact of computerised assessment verses standard measures should 
be considered. Whilst the tasks chosen in each cognitive domain aim to measure the 
same cognitive construct it may be that the way children approach these tasks when 
administered on a computer or by a person could be different, meaning that it is the 
methodology, or form of delivery of the tests, rather than the cognitive skill per se 
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that is contributing more to the variance in scores. There is limited literature on this 
topic to inform what these differences might be as most validation studies of 
computerised tests do not discuss the effects of the mode of presentation specifically. 
Early reviews of the use of computerised measures commented that the extraneous 
factors associated with computerised assessment when compared to “pen and paper” 
assessment should be identified and studied to determine if they have disruptive 
effects on outcome (Schatz & Browndyke, 2002) however few studies have 
explicitly done this. Luciana and Nelson (Luciana & Nelson, 2002) looked at the 
CANTAB computerised assessment battery in young children aged 4-12 years. They 
found that for the four year old group in their sample the computerised 
administration of particularly complex strategy based tasks appeared to impair the 
children’s performance, which improved when a 3D model of the task was presented 
in addition to the computer based stimuli. However no difficulties were noted in the 
rest of the sample indicating that this may only affect very young children. In adults, 
whilst several standard neuropsychological measures have been adapted into 
computerised versions with comparable psychometric properties there are some 
notable exceptions including the Wisconsin Card Sort Task where equivalence 
between the computer and standard versions has not been shown (Fortuny & Heaton, 
1996). Lalonde and colleagues (Lalonde, Henry, Drouin-Germain, Nolin, & 
Beauchamp, 2013) studied a virtual reality version of the Stroop test in adolescents 
and compared their performance to the version of the Stroop Test in the D-KEFS 
battery and to the BRIEF finding medium to large correlations for both but larger for 
the BRIEF. Given the equivalence of the test stimuli the fact that this correlation was 
lower than that of the BRIEF measure with the virtual reality Stroop task suggests 
the mode of task delivery did have a significant effect on the outcome.  
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In summary the specific impact of the computerised modality of testing on 
performance is surprisingly not well understood. It seems likely, however, based on 
the current limited literature that this difference in the surface characteristics of the 
tests could have an impact on the strength of the relationship between performance 
on the tests that may or may not be related to the cognitive construct they are 
designed to assess.  
4.2.1.1.2 Child verses adult assessment  
Secondly when considering comparisons between this study and previous 
CogState construct validity studies (Cysique et al., 2006; Maruff et al., 2009; 
Pietrzak et al., 2009; Yoshida et al., 2011) the most striking difference is that these 
studies were conducted with adults rather than children. The changes to the tasks in 
the CogState paediatric battery compared to the adult battery are fairly minimal, 
consisting mainly of more user friendly card stimuli for the youngest age group, two 
fewer target cards in the OCL task for all age groups and the maze being visible once 
found in the GMLT for the youngest age group. There were also other subtle changes 
in the appearance of the tasks (e.g. a grey background instead of a green background, 
size of the cards slightly enlarged) due to an updated version of the battery being 
used in this study compared to that used in previous publications. However, beyond 
these cosmetic changes in the appearance of the battery it is possible that 
developmental changes in the acquisition of cognitive skills will differentially affect 
performance on computer based tasks verses standard neuropsychological measures, 
and the specific cognitive skills that the children use when performing the tasks 
compared to adults. As discussed above there is some evidence that very young 
children find computerised 2D representations of complex strategy formation tasks 
more difficult than the 3D standard version, although this did not seem to affect the 
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children in the age range covered by this study and no such stimuli are used in the 
CogState tasks. However the literature in this area is very limited. It could be 
hypothesised based on the ubiquity of computers in everyday life that has developed 
over the last 20 years that children may be more familiar with using computers and 
engaging with digital stimuli than many adults are, however there is no research 
within the cognitive assessment literature to support this claim and consider its 
implications for computerised testing.  
 When considering children’s approach to neuropsychological measures in 
general when compared to adults it is important to remember that children are not 
just very young adults and that brain-behaviour relationships seen on a given test in 
adult sample may not apply in the same way to children (Baron, 2004). For example 
the Trail Making Test is described as measuring attentional control, inhibitory 
control and cognitive flexibility (Baron, 2004; Lezak et al., 2004) however in 
children aged 7-8 years where speed of response is still at an early developmental 
stage this ability may have a larger influence on performance than in older children 
or adults (Kelly, 2000). These factors may be further complicated by the 
developmental impact of early brain insults and subsequent potential for 
reorganisation of functioning (Warner-Rogers, 2013) meaning that the primary 
cognitive abilities affecting a child’s performance on a given task are not always 
necessarily clear. 
4.2.1.1.3 Effect of the clinical presentation in children treated for cancer  
Thirdly no previous studies have assessed the CogState battery in children who 
have been treated for CNS tumours or leukaemia, therefore the potential for factors 
associated with this clinical population to differentially affect performance on 
computerised verses standard measures should be considered. Previous adult 
124 
 
construct validity research has used control, schizophrenia, AIDS dementia complex, 
and mild TBI samples. Two studies (Pietrzak et al., 2009; Yoshida et al., 2011) have 
reported correlations for both their control sample and sample of patients diagnosed 
with schizophrenia separately to allow comparison of construct validity in the two 
groups. These studies show generally comparable patterns of relationship strength 
with the correlations mostly higher in the patient groups suggesting that for these 
clinical populations other effects of their clinical presentation did not differentially 
influence the computerised or standard assessment. For children treated for cancer 
the potential extraneous clinical characteristics which could differentially affect their 
performance on the different assessments include sensory difficulties and motor 
impairments (Armstrong et al., 2009). Although difficulties severe enough to prevent 
testing were an exclusion criterion for the study more subtle difficulties could have 
been present which could have influenced the study findings. Examples of this which 
are specific to particular tests are discussed below with the relevant hypothesis. 
4.2.1.1.4 Use of single measures in each cognitive area 
Fourthly this study has used single tests or subtests in each cognitive area, except 
executive function, to measure performance. The reasons for this are discussed in 
section 2.1 and 4.4.4.1 however the broad impact of this on the interpretation of the 
results will be considered here. Best practice in clinical and research settings would 
be to include multiple measures of each construct being tested (Baron, 2004; Kelly, 
2000). This increases the reliability of the results by reducing the impact of 
extraneous variables such as a lapse in concentration on one test. It also allows for 
further consideration of method variance (i.e. the method or form of measurement) 
compared to trait or construct variance by allowing for comparison between different 
standard measures as well as between the standard measures and the computer 
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measures. Use of a composite score based on more than one measure would also 
have allowed different facets of each cognitive domain to be included providing a 
more comprehensive measure of the construct. Both reliability factors and method 
variance may have contributed to the wide confidence intervals seen for each 
correlation co-efficient through increasing the standard error of measurement. Given 
these wide confidence intervals the presence or lack of correlation seen between 
specific measures in this study should be interpreted with a degree of caution. 
 Factors specific to each hypothesis will now be discussed including reference 
to previous research on that task.  
 
4.2.1.2 Hypothesis 1: The Detection task of the Cogstate battery measures 
psychomotor function and processing speed and will be positively 
correlated with performance on the Grooved Peg Board task and the 
WISC-IV Symbol Search subtest. 
This hypothesis was not firmly supported based on the data in this study with 
moderate correlations found between these subtests in the expected direction which 
were non-significant when correction for multiple comparisons was applied and had 
broad confidence intervals containing zero. 
 The GPB task was chosen as a measure of psychomotor function and has 
been used to assess this construct in previous larger studies of the CogState battery in 
an adult population (Cysique et al., 2006; Maruff et al., 2009). In these studies a 
stronger relationship was found between the GPB dominant hand variable and DET 
(r=.57-.81) which has not been replicated by these results (rs=.33). However another 
adult study using an alternative measure of psychomotor processing, the Token 
Motor task, with similar dexterity requirements to the GPB (Yoshida et al., 2011), 
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failed to find any significant correlation with the DET task. They suggest this may be 
due to the increased fine motor control and dexterity requirements of the Token 
Motor task when compared to the response required in the DET task. This may also 
have played a role in this study as the GPB requires participants to pick up and 
manipulate small pegs in contrast to the simple button presses which form the 
response modality of the DET task. There is some evidence that around a quarter of 
children treated for ALL display impaired motor and dexterity performance (De Luca 
et al., 2013) which may have differentially affected their performance on the GPB 
compared to the DET task. This hypothesis is supported by the fact that the mean 
performance of the whole sample on the GPB task was greater than 1 SD below the 
normative mean (z=-1.39) with 18 participants (49%) scoring in this impaired range 
whereas on the DET task mean performance was z=0.26 and only three participants 
(8%) scored lower than 1 SD below the normative mean. Therefore the lower 
correlation between the two tasks in this study may reflect an increased impact of the 
dexterity aspects of the GPB relative to the psychomotor processing aspects than in 
previous adult samples.  
The Symbol Search task was used as a measure of processing speed to assess 
this aspect of the DET task, as it has much lower psychomotor requirements than the 
GPB, although it does still require fine motor skills in order to manipulate the pencil. 
This specific task has not been used before in studies of the construct validity of 
CogState however the small to medium correlation found in this study (r=.28) is 
lower than would be predicted based on previous analyses of the DET task as a 
measure of processing speed. In their large study of adults diagnosed with 
schizophrenia Pietrzak et al. (2009) used the TMT-A, a coding task and a category 
fluency task as measures of processing speed to compare to the DET task finding 
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large correlations for all three (r=.56-.79). Although these three tasks place more 
demand on different cognitive constructs in addition to processing speed when 
compared to Symbol Search (e.g. TMT-A requires visuo-spatial attention, coding 
requires increased working memory and fine motor control and category fluency 
requires cognitive flexibility) it is unclear why these differences should increase 
rather than decrease the relationship to the DET task, which is a simple reaction time 
task. However, given the impairments seen on the GPB in this sample it could be that 
even the reduced psychomotor requirements of the SS test were still significantly 
impacting on the ability of this test to provide a relatively pure measure processing 
speed in this population, when compared to the simple reaction time results on the 
CogState DET task.   
 
4.2.1.3 Hypothesis 2: The Identification task of the Cogstate battery measures 
visual attention and vigilance and will be positively correlated with 
performance on the Map Mission and Score! subtests of the TEA-Ch. 
 This hypothesis was supported for the visual attention aspect of the IDN with 
a large relationship to the Map Mission subtest found (r=.52) and partially supported 
for the vigilance aspect with a moderate but non-significant correlation (r=.32) 
found.  
 Previous studies of the construct validity of the IDN task have focused either 
on its visual attention aspect (Cysique et al., 2006; Maruff et al., 2009) or on its 
vigilance or sustained attention aspect (Pietrzak et al., 2009) but none have 
considered both aspects simultaneously. Those studies which have looked at visual 
attention have found large positive correlations (.60 -.78) with tasks such as TMT-A 
and the Symbol Digit Modalities Test (SDMT; (Smith, 1982)) which assess complex 
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visual attention and scanning, and are affected by processing speed given the timed 
nature of the tasks. These skills are similar to those required by the Map Mission 
subtest which also requires selective attention in order to focus on the target symbol 
amid the detailed distracting background and is a timed test. The present result fits 
well with this previous research further supporting the importance of visual attention 
to performance on the IDN task.  
 The vigilance aspect of the IDN task has only be considered in one study 
(Pietrzak et al., 2009) which correlated it with a visual continuous performance task 
(CPT) finding a large relationship (r=.57). The Score! subtest used in this study does 
not show such a strong relationship which may, in part, reflect the different modality 
of the test with the IDN and CPT requiring visual sustained attention and Score! 
requiring auditory sustained attention. Recent research suggests that poor 
performance on attention tests in the auditory modality may be due to the effects of 
boredom whereas for tests in the visual modality distractibility may have a bigger 
effect (Berry, Li, Lin, & Lustig, 2014) indicating that different processes underpin 
successful performance in the different modalities. In addition speed of presentation 
has been shown to affect performance (Thompson, Opton, & Cohen, 1963) and this 
varied across the two tasks, with the Score! task being presented at a predetermined 
rate and the items in the IDN task presented as fast as the participant responded 
(indeed speed of response is the primary outcome variable so it encourages quick 
responding). Given these differences it may have been preferable to use a vigilance 
and sustained attention task in the visual modality such as Connor’s Continuous 
Performance task (Conners, 1992) as the comparator task in this study to minimise 
the effect of modality and outcome variable on the result, however this task was 
unavailable to the researcher.  
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4.2.1.4 Hypothesis 3: The One-Card Learning Task of the CogState battery 
measures visual learning and memory and will be positively correlated 
with performance on the CMS Dot location subtest. 
 This hypothesis was not supported by the data as only a small to medium 
non-significant correlation (rs=.19) was found between the two tasks. Whilst the Dot 
location subtest has not been studied before in relation to the OCL task this result is 
contrary to the current literature on the version of this task included in the adult 
battery which has been shown to have a large correlation with tasks of visual 
memory. Pietrzak and colleagues (2009) compared performance on the OCL task to 
the Brief Visuospatial Memory Test –Revised (Benedict, Schretlen, Groninger, 
Dobraski, & Shpritz, 1996) a task which requires participants to learn geometric 
designs and their location on the page over three learning trials making it similar in 
content to the Dot Location subtest. They found large correlations in both controls 
(r=.63) and people diagnosed with schizophrenia (r=.76). Using the same test Maruff 
et al. (2009) also found a large correlation in their sample of adult controls (r=.83), 
with significant correlations also being shown in their sample with the TMT-B, 
Symbol-Digit Modalities Test, Spatial Span and Rey Complex Figure Test-Delayed 
Recall.  
 One possible explanation for the lack of correlation in this study could be a 
lack of sensitivity in the Dot Location task. It has been criticised for floor effects in 
young children as an average scale score can be achieved by chance (Baron, 2004) 
and if such effects had occurred in the data it would lead to range restriction and 
reduce the ability to find a significant correlation (Goodwin & Leech, 2006). 
Inspection of the data shows that whilst mean performance on the test was close to 
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the normative mean (z=0.03) a wide range of scores were achieved (min: z=-2.0, 
max: z=1.67) and there is an acceptable standard deviation (SD=0.77) meaning the 
distribution of the scores was not significantly different from the normal distribution. 
This is not consistent with significant floor effects. It is unclear therefore why the 
relationship between these variables is so much smaller than analogous tasks in the 
previous adult literature.  
 
4.2.1.5 Hypothesis 4: The Continuous Paired Associate Learning Task of the 
CogState battery measures visual learning and memory and will be 
positively correlated with performance on the CMS Dot location subtest. 
 This hypothesis was partially supported with a medium correlation (r=.33) 
found in the expected direction, although non-significant when the correction for 
multiple comparisons was applied.  
 The CPAL task of the CogState battery is a newer subtest which has been 
studied relatively less. One study has compared the Japanese version of this task to a 
digit sequencing task (Yoshida et al., 2011) classifying it as a measure of working 
memory. In this study no significant correlation was found for controls (n=40, r=.19) 
or for adults diagnosed with schizophrenia (n=40, r=.28) however for the total 
sample including both groups the correlation did reach significance (n=80, r=.32). 
This correlation is comparable to that observed in this study (rs=-.33) although in this 
study it was investigated as a measure of visual memory and learning. This 
highlights the overlap between cognitive constructs and the skills required by any 
assessment measure, which are very unlikely to tap into only one narrowly defined 
aspect of cognitive functioning. Whilst a digit sequencing task does not include an 
element of learning over time as new number sequences are presented on each trial, 
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the Dot Location subtest does include an element of working memory in addition to 
learning as the participant must hold the locations of the dots in mind whilst 
manipulating the response chips into the correct positions on each trial. Therefore the 
current evidence tentatively suggests that the CPAL task involves visual working 
memory (perhaps to enable the participant to hold in mind where they have 
previously searched whilst looking for the correct location) in addition to the more 
overt construct of learning over time, both of which will be captured in the 
“accuracy” outcome variable.  
 
4.2.1.6 Hypothesis 5: The One-Back Task of the CogState battery measures 
working memory and will be positively correlated with performance on the 
WISC-IV Digit Span subtest.  
 This hypothesis was partially supported. A non-significant small to medium 
correlation (r=.23) was found for the total Digit Span scaled score. When considering 
the more specific LDSB measure of working memory a medium (but still non-
significant) correlation (r=.37) was found although the confidence intervals around 
this value were wide.   
 The construct validity of the OBK task has been studied in previous adult 
research relative to a variety of working memory tasks, although Digit Span has not 
been used before.  Maruff et al. (2009) found the strongest associations were between 
the OBK tasks and a spatial span test (taken from the WMS-III; Wechsler) and the 
SDMT (r=.80-.81) although the visual and auditory versions of the test are not 
distinguished in this report. Cysique et al. (2006) also used the SDMT with the 
results separated by modality finding significant medium to large correlations 
between both the visual modality (r=.43) and auditory modality (r=.40) in their adult 
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sample of patients with HIV.  Pietrzak et al. (2009) also used the spatial span test and 
a letter-number span test in their study. They found large correlations for the letter-
number span test in both controls (r=.61) and people diagnosed with schizophrenia 
(r=.74) and medium to large correlations for the spatial span test (r=.43 for controls 
and r=.56 for patients). In contrast Yoshida et al. (2011) did not find a significant 
correlation in their study using a digit sequencing task as the standard measure of 
working memory (total sample r=.18). They claim the difference in modalities of the 
tests (OBK is visual and the digit sequencing is auditory) could be the reason for this 
lack of relationship however is not consistent with the other studies quoted above 
where both visual and auditory tasks have been used and comparable or even larger 
correlations found between OBK and the auditory tasks. Therefore whilst the 
different modality of the OBK and Digit Span tests might have had some impact on 
the strength of the relationship between performances on these tests it is unlikely to 
be the only reason for the weaker relationship found in this study.   
 
4.2.1.7 Hypothesis 6: The Groton Maze Learning Task of the CogState battery 
measures executive function, including cognitive flexibility and will be 
positively correlated with performance on TMT-B and the BRIEF GEC. 
 The analysis of this hypothesis was limited by the lack of current acceptable 
normative data for this task in children covering the full age range used in this study 
and the different versions of the task used for different age groups. However when 
the data was analysed separated by age group the results suggested that for the 8-9 
year old group (n=8), for whom the path through the maze remained visible as they 
completed the task, a strong relationship was present with both TMT-B (rs=-.86) and 
BRIEF GEC (r=-.61) although the second of these is a less reliable relationship as 
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the 95% confidence intervals included zero. For the older group (n=29), for whom 
the task was the same except the path did not remain visible during the task, no 
significant relationships were found for either the TMT-B (rs=.24) or the BRIEF 
GEC (r=.12).  
 The reasons for this differential finding for the two versions of the task are 
not clear. Firstly it must be considered that the younger age group is very small, 
increasing the chances of finding a significant correlation by chance. However this is 
taken into account with the significance testing of the correlation and the relationship 
between the GMLT and TMT-B remains highly significant (p=.007). Therefore 
whilst this result should be treated with caution given the sample size, it does 
tentatively indicate that the different task requirements of the two versions of the 
GMLT may influence the constructs which the task primarily measures.  
  The 10-16 year old version of the task appears to have a much higher 
working memory load than the version for younger children, as they must remember 
each step in the pathway individually without ever seeing the shape of the path as a 
whole. However, this is not supported by previous analysis of the constructs 
measured by the various outcome variables of the GMLT in adults, which did not 
find a significant correlation between GMLT-Total Errors and the OBK task (r=.04) 
thought to measure working memory (Pietrzak et al., 2008). However, in this study 
whilst the correlation between the GMLT and OBK was non-significant and very 
small, r=.004, p=.49, the relationship with LDSB, the standard measure of working 
memory, was significant, r=-.47, p=0.008 indicating a relationship with a large effect 
size between the two variables. This result suggests that working memory (as 
measured by LDSB) does have an effect on performance on the version of the 
GMLT administered to 10-16 year olds, accounting for 22% of the variance in 
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performance on this task. It is of note that the OBK task does not display the same 
relationship, suggesting that the aspect of cognitive functioning tapped into by the 
GMLT and LDSB is not shared by the OBK task, as might have been expected if all 
three tasks are measuring an aspect of working memory. Relationships between 
GMLT Total Errors and measures of working memory in the younger age group are 
not significant however this is hard to interpret given the very small sample size. 
These results tentatively suggest that the different task requirements in the versions 
of the GMLT given to 8-9 year olds and 10-16 year olds may mean that the task 
relies less or more strongly on working memory dependent on presentation. 
Previously published studies of this discrepancy in administration are not available, 
however, previous studies of the GMLT in children (aged between 7-9 years, but 
completing the version of the GMLT given to 10-16 year olds in this study) has 
suggested that by using the more specific outcome measure of Rule Break Errors, the 
effects of spatial memory and executive functioning can be distinguished (Thomas et 
al., 2011). When using this more specific variable the relationships with LDSB did 
reduce in strength (r=-.29) suggesting it may be less impacted by working memory 
however, the correlations with TMT-B and BRIEF GEC remained small and non-
significant (r=.19 and .14 respectively). In summary the discrepancy between the 
strong large correlations seen for the 8-9 year old and the small to medium seen for 
the 10-16 year olds is difficult to explain. It may relate to a lack of reliability in the 
8-9 year old data given the small sample size or the differential impact of working 
memory on performance. However the impact of working memory ability alone does 
not explain the small relationships seen in the older age group as when its impact is 
reduced the correlation does not increase.  
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 In comparison to the more reliable 10-16 year old data, previous validity 
studies in adults have found medium to large relationships between the GMLT and 
other measures of executive function. Peitrzak et al. (2009) studied the relationship 
between the Total Errors variable of the GMLT and the Neuropsychological 
Assessment Battery Mazes task (Stern & White, 2003) finding a large correlation in 
both their control and patient samples (both r=.56). They report this as evidence for 
the GMLT Total Error variable as a measure of reasoning and problem solving, 
which are both aspects of executive function. These tasks are, at a face validity level, 
more similar to each other in form which may account in part for larger relationship 
found than in the older age group in this study. Yoshida et al. (2011) also included 
the GMLT in their adult validation study of the Japanese version of CogState 
comparing it to the Tower of London Task, again describing both as measures of 
reasoning and problem solving. They found a significant but small to medium 
relationship between these variables for their total sample only (r=.25).  
The findings of this study are more in line with this later research, and may 
similarly be impacted by the different surface characteristics of the comparator task 
and measure used. There is no research on the relationship between the GMLT and 
informant report measures such as the BRIEF. Previous research looking at the 
relationship between the BRIEF and observed performance based measure of 
executive function have found small to medium effect sizes for the relationship 
(Mahone et al., 2002; Mangeot, Armstrong, Colvin, Yeates, & Taylor, 2002) 
indicating that these measures do assess different aspects of executive function. In 
this study the relationship between the TMT-B and the BRIEF GEC was large 
(r=.51) which exceeds that found in other similar studies but supports these two very 
different modalities of measurement as tapping into related constructs. However, the 
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increased variation in the data due to the mode of measurement, not just of computer 
to non-computer tasks, but also of performance to informant report measures may 
account for the lower correlations seen in this study when considering the more 
reliable 10-16 year old group.  
4.2.1.8 Comparison with other screening measures previously evaluated in a 
paediatric oncology population. 
 Of the screening measures discussed in section 1.9 three addressed issues of 
construct validity through convergent validity with other measures, all of which 
found correlations of the order found in this study. Conklin et al. (2013) studying the 
Impact, computerized battery assessed only the concurrent validity of the verbal, 
visual and working memory tasks in their battery (the processing speed, psychomotor 
speed and divided attention tasks were not addressed) with other computerised 
experimental tasks of the same constructs. They found only small to medium 
correlations (r=.25-.30) for the verbal and visual tasks only with no relationship 
found for the working memory tasks. Given that both their experimental and 
comparator tasks were in a computerised format with much more similar surface 
characteristics than the tasks used in this study it is notable that they did not find 
stronger relationships. The other two papers were reporting on informant report 
measures of single constructs only. Howarth et al. (2013) found small to medium 
correlations between the BRIEF working memory scale and digit span forwards and 
backwards and self-ordered search tasks (r=.21-.24).  Patel et al. (2007) found small 
to medium correlations between the social problems subscale (r=.31) and the 
attention problems subscale (r=.22) of the CBCL and their classification of children 
as have attention impairment based on six standard measures of attention. Therefore, 
whilst the correlations found in this study are not as high as previous adult construct 
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validity studies of the CogState battery they are comparable to those found in studies 
of other measures in this paediatric oncology population. This may suggest that 
factors associated with this clinical population, not least the smaller sample sizes 
achieved in each of these studies when compared to the adult literature, may impact 
upon the correlations achieved.  
 
4.2.2 Research Question 2:  Given the research showing intellectual 
performance declines over time since diagnosis (e.g. (Spiegler et al., 
2004)) is there a relationship between time since diagnosis and 
performance on the CogState battery? 
 This research question gave rise to one hypothesis, considered below. In 
addition to the hypothesis itself the result regarding the relationship between time 
since diagnosis and IQ will also be considered in this section.  
4.2.2.1 Hypothesis 7: Time since diagnosis will be negatively correlated with 
overall performance on the CogState battery. 
 This hypothesis was not supported with the data showing a trend towards a 
medium relationship in the opposite direction to that predicted, although considerable 
variability in the data means that the confidence intervals are wide and cross zero 
indicating there may be no relationship at all. In spite of this potential lack of 
reliability in the data it is interesting that there is a trend towards participants who are 
further from their diagnosis and therefore treatment performing better on the battery, 
in contrast to the current literature. This could suggest that the CogState battery is not 
sensitive to a decrement in performance over time, or that within this mixed 
diagnosis and treatment sample a decrement over time in performance in the specific 
areas measured by the DET, IDN, OCL and OBK tasks, is not present, and instead 
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performance actually improves. In support of the second of these alternatives is the 
fact that there is also no significant relationship between time since diagnosis and IQ 
as measured by the WASI in this sample. However, mean performance in the sample 
on both the CogState composite variable and the IQ variable is not significantly 
different from the normative mean in spite of significant impairments in several of 
the standard tests (Grooved Peg Board, Map Mission, Score!, Digit Span, TMT-B, 
BRIEF GEC) suggesting that these variables are not capturing the clinical deficits 
seen in the sample, which may be the aspect of performance that decreases over time. 
The clinical characteristics of the sample in this study should also be considered 
when comparing these results to the current literature. Spielger et al. (2004), Ris et 
al. (2001, 2013), Mulhern et al. (2001) and Krull et al. (2013) all of whom found 
significant decreased in IQ over time all studied samples of children who had 
received cranial radiation therapy. In this sample only two children had received 
radiotherapy with the majority of the sample being treated with one or more of 
chemotherapy (including intrathecal chemotherapy), corticosteroids and surgery. A 
more similar clinical sample was studied by Copeland et al. (1996) whose 
longitudinal study sample did not include any children who had received CRT, 
instead being treated with chemotherapy that was either intrathecal (ITC) or 
intravenous. In this study in the first three years post treatment mean scores on IQ 
measures, academic achievement, language, memory, executive function and 
“freedom from distractibility” were all within the normal range with no significant 
declines over time and significant improvements in performance IQ,  “freedom from 
distractibility” and fine motor skills. Perceptual motor skills declined in the group 
who had received ITC chemotherapy but not those who hadn’t. In the subset of 
children who were followed up between 5 and 11 years after their diagnosis, most 
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similar in the course of their recovery to this sample, significant decline in 
performance was only seen for executive function skills with performance IQ and 
tactile spatial skills improving and all other areas remaining constant. The results of 
this study fit well with this pattern suggesting that in the absence of CRT significant 
declines in cognitive functioning are not found to be widespread. However further 
longitudinal research following children who have received less aggressive 
treatments such as ITC over time would be needed to provide a clearer picture of 
how deficits in cognitive functioning develop or remit.  
 
4.3 Additional Discussion of Cognitive Impairment in the Sample 
 As mentioned above, in characterising the clinical performance of the sample 
it was noted that the sample as a whole did not show significant deficits in 
performance on the WASI measure of estimated IQ, or any of the CogState tasks, 
however significant deficits were found on the Grooved Peg Board, Map Mission, 
Score!, Digit Span, TMT-B and BRIEF GEC tasks indicating difficulty in the areas 
of psychomotor processing, visual attention, sustained attention, working memory 
and executive functioning respectively. Whilst an analysis of the criterion validity of 
the CogState battery is beyond the scope of this project these results do tentatively 
suggest that it may not be sensitive to the areas of impairment indicated by the 
standard measures. However other possibilities should be considered, including the 
current normative data available for the CogState battery overestimating the 
performance of the children in this sample, or the standard assessment measures 
being differentially affected by other clinical variables in the sample including fine 
motor ability and fatigue. Further research using a matched control sample to 
examine the relative performance of children treated for cancer and typically 
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developing children on both batteries is needed to form more reliable conclusions in 
this area, which could also include consideration of the CPAL and GMLT tasks of 
the CogState battery excluded from this analysis.  
 Apart from the sensitivity or not of the CogState battery it is of note that the 
mean IQ in the sample was not significantly different from normal, even in the face 
of more specific neuropsychological impairments (effect sizes for the impairments 
were all medium to large). There are two factors to consider here, the 
representativeness of the estimated IQ scores compared to more comprehensive 
assessments of IQ and the WASI in particular, and the frequency of this pattern of 
results in the literature. Firstly the measure of IQ used in this study is a short form 
which can provide an estimate of total IQ which correlates strongly with full scale IQ 
scores based on comprehensive IQ batteries (r=.81 with WISC-III) but which does 
not include assessment of all of the areas of cognitive functioning that go into such 
measures, such as a measure of working memory or processing speed. Therefore 
although the WASI can provide a reasonably reliable estimate of full scale IQ it will 
not necessarily reflect broader areas of deficit. It should also be noted that the WASI 
was published 15 years ago and the normative data is therefore somewhat out of date. 
As a result of this scores may have become inflated due to the Flynn effect (Flynn, 
1984, 1987a) which may be masking deficits in overall intellectual functioning that 
would be detected on more up to date measures.  
 However given these limitations, the pattern of overall IQ scores being within 
the normal range but more specific deficits being present is not that uncommon in the 
literature, especially in children who have not been treated with CRT. For example 
Anderson et al. (1997) reported on their sample of children treated with or without 
CRT in addition to chemotherapy finding that subtle deficits in neurocognitive 
141 
 
functioning in areas such as executive function were still present in groups where no 
overall intellectual deficit was found. Vaquero et al. (2008) found no significant 
difference in overall IQ in their Astrocytoma patient group treated with surgery alone 
compared to controls, however, there were significant deficits on tasks of working 
memory and executive functioning. Waber at al. (2013) report on children treated 
only with corticosteroids finding significant impairments on tasks of visuospatial 
construction and memory when the overall IQ measure was in the normal range. 
Within this context the results of this study fit well given the very low levels of 
radiotherapy received in the sample and further highlight the need for any screening 
measure to be broad enough to cover all areas of neurocognitive functioning which 
may have been affected by treatment, even when overall intellectual functioning 
appears to be normal.  
 
4.4 Critique of Methodology 
 This section provides a critique of the methodology used in the current study 
and considers methodological strengths and weaknesses of the research and possible 
impacts on the findings of the study. 
4.4.1 Design and analysis.  
 The study used a cross sectional correlation design to investigate the 
convergent construct validity between the CogState tasks and selected standard 
neuropsychological measures. This is a widely used design for research of this type 
which facilitates examination of both the significance of the relationships between 
variables and also the effect size of the relationship in the form of the correlation 
coefficient, providing more information about its clinical significance. Specific a 
priori hypotheses were developed about which assessment measures would be 
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significantly correlated based on previous research into the cognitive construct they 
were designed to test. This was done in order to focus the analyses and reduce the 
risk of type 1 errors associated with the large numbers of correlations conducted in a 
full correlation matrix. This method has been employed in several previous studies of 
the CogState battery (Cysique et al., 2006; Pietrzak et al., 2009; Yoshida et al., 2011) 
and other neuropsychological measures (e.g. (Conklin et al., 2013). However a 
weakness of this approach was that only convergent and not discriminant validity 
was explored. Using both of these methods is described as best practice in this area 
(Campbell & Fiske, 1959) and would provide a more robust understanding of the 
specificity of the constructs measured by the CogState tasks and a more accurate 
reflection of the fact that no neuropsychological measure measures only one precise 
cognitive construct (Maruff et al., 2009). This method was not chosen as the sample 
size which would be needed to conduct this analysis including appropriate 
adjustments for multiple comparisons exceeded that which was feasible to collect 
during the period of the study.  
Whilst the focused analysis and correction for multiple comparison mean that 
the chance of type 1 error in the results has been minimised, the correction applied to 
the α level in this study, using the Holm method, although less conservative than the 
Bonferonni method, is still quite conservative and may have led to the disregarding 
of theoretically important correlations between the variables (type 2 error). To 
counteract this correlation coefficients and p-values have been reported in full in the 
results section to illustrate the strength of relationships which did not meet the strict 
criterion set for significance and confidence intervals were calculated to provide 
further information on how reliable these estimates of relationship are. In addition to 
the already relatively strict correction in the plan of analysis this was further reduced 
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due to the unanticipated need to split the GMLT data into two age groups. This may 
have reduced the power of the study to detect the anticipated effects, however a 
sensitivity analysis with the obtained sample size of 37 and α=.05 indicates the study 
was able to detect effect sizes at the predicted level based on previous research (.50) 
with a power of .90, higher than the .80 aimed for. This was due to the study 
recruiting 37 participants rather than the 32 required by the sample size calculation.   
 For the second research question concerning the relationship between time 
since diagnosis and performance on the CogState battery a correlation design was 
also used. The advantages of this approach included the ability to collect this data 
within the same research design as utilised for the first research question and the 
ability to control for the effects of potentially confounding variables using partial 
correlation. Weaknesses of this design are that it does not provide information about 
the time-course of the development of difficulties in an individual, only providing a 
cross sectional snapshot across individuals in the study group. Given the 
heterogeneity in diagnosis and treatment within this group (due to both pragmatic 
recruitment reasons and to improve the ability to generalise the results to research 
question 1) significant relationships between time since diagnosis and overall 
cognitive ability in particular individuals who received particular treatments may 
have been masked. A longitudinal research design which followed a more well 
defined and homogenous group of patients would be a more powerful way to 
approach this research question, however, such designs are pragmatically challenging 
and beyond the scope of this study and therefore were not possible. In the absence of 
being able to use a longitudinal design the partial correlation used was appropriate.  
A further weakness in the data when addressing this question was that at the time of 
analysis suitable normative data were not available for the CPAL or GMLT from the 
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CogState battery meaning that z-scores could not be calculated and they could not 
contribute to the composite z-score of performance on the battery as a whole. This 
meant that this composite score did not include a measure of executive functioning, 
one of the aspects of cognitive functions which may be more likely to show 
deterioration over time compared to peers due to the later developmental trajectory 
for the development in this area. This may have contributed to the finding for this 
hypothesis as discussed above in section 4.2.2.1. 
 
4.4.2 Procedure. 
 Assessment sessions took place in participant’s homes. This was a strength of 
the procedure in that it limited the burden on families who already have numerous 
hospital visits to attend, and also meant that the children were in a familiar setting 
which may have lessened their test taking anxiety. However testing in this setting did 
limit the control which the researcher could exert over the environment leading to 
some distractions being present (such as dogs barking, people walking through the 
room) during some testing sessions. These distractions may have affected the 
participant’s performance on particular subtests thereby increasing the error variance 
in the data and one data point on the OCL task was excluded for this reason. 
Research in adults with mild TBI has shown that distraction can have a significant 
negative effect on task performance relative to controls (Schnabel & Kydd, 2012) 
suggesting it may have impacted this sample given their similar neuropsychological 
weaknesses. However no major difficulties were noted during the sessions (with the 
exception mentioned above) with most taking place in quiet rooms, so it is therefore 
unlikely the effect on the data was large or systematic.  
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 The CogState battery was completed once by participants in this study. It is 
recommended by the Test publishers that ideally when children complete the battery 
for the first time they complete a practice session prior to the testing session. This is 
to familiarise them to the controls and negate the practice effects which are seen 
from the first to second completion but not thereafter. However given that this study 
was not interested in change in performance on the battery over time it was advised 
that this practice session could be omitted without significant detriment to the 
validity of the assessment (A. Schembri, personal communication, October 6, 2013). 
To maintain the ability for the entire research battery to be completed in one testing 
session that did not place an undue burden of fatigue on the participant this approach 
was adopted. The administration of the battery in this study involved the researcher 
sitting with the child and going through the instructions with them prior to each 
subtest to support their understanding of the task, with additional support provided in 
the first few trials if there appeared to be any misunderstanding. Practice trials were 
included in the CPAL and GMLT tasks where the task rules were more complex. If 
difficulties in understanding the battery had been a factor in this study it would be 
expected that overall scores would show lower performance relative to the normative 
data. As there were no significant differences on any of the scales this was unlikely 
to have been a factor.   
All participants completed the tests in a standard order with the CogState 
battery first and the standard battery second. This format was chosen to facilitate 
assessment of the acceptability of the CogState battery (see Appendix L) without 
interference from the other tests. Within the batteries the tasks and subtests were also 
presented in a standard order as described in the Method chapter. This was due to the 
fact that the CogState task order should not be counterbalanced as there may be 
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proactive interference between similar stimuli in the OCL and OBK tasks (B. Harel, 
personal communication, March 6, 2013). In order to standardise presentation across 
the two batteries the standard battery of tasks was also presented in a fixed order. Set 
order of subtest presentation is standard practice in most neuropsychological 
assessment measures (e,g (Wechsler, 2003)), however, the potential order effects 
which may have resulted from this should be considered. It is commonly understood 
that fatigue towards the end of long testing sessions can impair the child’s motivation 
affecting performance (Baron, 2004) although the literature on the effects of fatigue 
is mixed, with some studies finding it leads to significant decrease in performance 
(Krupp & Elkins, 2000) and others finding no significant effect, even in clinical 
groups more susceptible to the effects of fatigue (Johnson, Lange, DeLuca, Korn, & 
Natelson, 1997). If fatigue did effect performance in this study it may have 
differentially affected those tasks completed at the end of the session which included 
the Digit Span subtest and the Trail Making Test. These two tests showed some of 
the greatest levels of deficit in performance relative to normative samples and it 
cannot be discounted that fatigue may have contributed to this. However, the strong 
correlation between the BRIEF scores, completed by the parent, and TMT 
performance does indicate that the levels of deficit seen in this area on both 
assessments are in large part due to executive function difficulties. To lessen the 
chances of a significant effect of fatigue a rest break was offered to all participants 
prior to starting the standard battery of tests (and accepted by the majority) with 
additional breaks available on request or if felt necessary by the researcher to 
maintain motivation and arousal levels.   
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4.4.3 Sample. 
 The sample achieved is a strength of the study. Although this size of sample 
is relatively small in comparison to those reported in the adult validity studies of 
CogState it is comparable to others in this difficult to recruit clinical group. The 
sample size exceeded that required by the power calculation meaning that the study 
was not underpowered for the analyses planned. There was minimal missing data 
meaning the majority of analyses were conducted with full power. The recruitment 
rate was very high in the two clinical services where the entire eligible clinical 
population was approached (75% at NNUH and 75% at QEHKL). Recruitment rate 
is harder to interpret in the third service (Addenbrooke’s, 19%) as recruitment was 
limited to those who had responded by the time the sample size was achieved.  
 The sample was well balanced by gender with wide age at testing and age at 
diagnosis ranges. The wide range of times since diagnosis meant that range 
restriction in this variable was not an issue in relation to the second research 
question. This variability in the sample also increases the generalisability of the 
results to a clinical outpatient setting. Recruitment was not stratified by diagnosis. 
This was done for pragmatic reasons of facilitating the largest possible sample in the 
time available for the study. The mix of diagnoses in the sample is weighted towards 
leukaemia, with fewer brain tumour patients than might be expected. Several factors 
could have influenced this. Firstly patients with motor or sensory impairments severe 
enough to prevent testing were excluded from the study. This will have differentially 
excluded patients treated for brain tumours where these difficulties are more 
common (Armstrong, 2010; Ward, DeSantis, Robbins, Kohler, & Jemal, 2014). 
Secondly recruitment was conducted first at the two POSCUs in the region due to the 
order in which regulatory approvals were achieved. These centres see relatively 
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fewer brain tumour patients than the PTC where recruitment was limited partly by 
the remaining space in the sample. Thirdly, at the PTC a newly commissioned 
service specifically aimed at brain tumour survivors opened just prior to the 
recruitment period. This meant that several potentially eligible participants had either 
recently received a neuropsychological evaluation or where due to do so soon 
making it clinically inappropriate to include them in the study.  
 It is also interesting that the mix of treatments received by the study sample 
included very limited amounts of radiotherapy. This may reflect the clinical picture 
in the UK where radiotherapy is largely a treatment of last resort for the treatment of 
ALL, replaced by ITC (Pui & Evans, 2006). In the case of BT, radiotherapy is a 
more integral part of many treatment regimens. Dose related effects of radiotherapy 
on cognitive outcomes have been frequently shown (e.g. Armstrong, 2010; Spiegler 
et al., 2004) leading to protocols which aim to postpone radiotherapy for the 
youngest patients (e.g. Batra et al., 2014) however, some evidence relating to newer 
conformal radiotherapy protocols suggests no detrimental effects. Merchant et al. 
(2004) report no effect on IQ, academic performance, memory or learning up to four 
years after treatment influencing other treatment protocols to include radiotherapy. 
However it remains the case that in this sample only 2 participants, one treated for 
ALL and one for BT, received this treatment.  
 However, given the study questions and methodology the mix of diagnoses 
and treatments achieved is not of great detriment to the conclusions which can be 
drawn. There was no range restriction in performance on any of the measures 
suggesting that a suitable range in presentations in order to be able to detect the 
relevant correlations was present. Each participant served as their own control in 
respect to the first research question meaning that the variability in the sample would 
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not have affected the results here. It may have been more detrimental to the analysis 
of the second research question as discussed above.  
  
4.4.4 Measures. 
 The choice of measures used in this study is central to the findings of the 
study. The matching of the CogState and standard tasks, factors affecting the use of 
subtests more generally and particular issues will be discussed below.  
4.4.4.1 Matching of CogState and standard tasks 
 Given the decision to focus the analyses in the current study on to the 
relationships between the CogState tasks and specific standard measures covering the 
same cognitive construct the matching of those measures is an important element of 
the methodology which could have had a large impact on the results found. Standard 
measures were chosen based on several factors described in the Method chapter 
including established psychometric properties in the relevant cognitive area, prior use 
in adult construct validity research of the CogState tasks, clinical usage and 
availability to the researcher. Of these, established psychometric properties in the 
area of construct validity is most important from a theoretical standpoint, given these 
measures were being used as an established measure of the construct against which 
the CogState tasks were evaluated. All of the tasks used do report evidence of 
validity in the given area as described in the Method chapter, however the 
applicability of this evidence to this particular sample of children is perhaps 
questionable given that none of these measures (except the Dot Location subtests of 
the CMS which has been studied in children with brain tumours) have been evaluated 
for construct validity in children treated for cancer, and several of the normative data 
samples (e.g. for the Trail Making Test, the Dot Location subtest and the Grooved 
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Peg Board) used were collected in different countries. However this is a recognised 
limitation of the psychometric and normative data available for the majority of 
neuropsychological measures available for children (Baron, 2004) and is unavoidable 
given how widespread a problem it is. Several of the measures (e.g. Symbol Search, 
Digit Span, Trail Making Test, Map Mission and Grooved Peg Board) have been 
used in samples of children with traumatic brain injuries and other 
neurodevelopmental disorders such as ADHD providing some construct validity in 
similar populations.  
 The specificity of the tasks is considered in further detail below. It should be 
acknowledged that given the fact that no neuropsychological assessment measure can 
provide a pure measure of one neurocognitive construct, had different standard tasks 
been chosen to match the CogState tasks different correlations might have been 
found. Using more than one task in each area and creating a composite score for that 
construct might have helped to counteract these difficulties and may have improved 
the reliability of the results.   
4.4.4.2 Use of subtests.  
 In the standard battery subtests from larger assessment measures were used to 
address five of the hypotheses. These were the Symbol Search measure from the 
Processing Speed index of the WISC-IV; the Digit Span subtest from the Working 
Memory index of the WISC-IV; the Map Mission subtest from the Selective/Focused 
attention factor of the TEA-Ch; the Score! subtest from the Sustained Attention 
factor of the TEA-Ch and the Dot Location subtest from the Visual Immediate index 
of the Children’s Memory Scale. It was decided to use subtests rather than full index 
scores in these areas for the pragmatic reason of reducing the length of the testing 
session, thereby reducing the burden on participants and limiting the effects of 
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fatigue on the results. Using full index scores would have necessitated two research 
visits which would have resulted in the CogState battery and the standard battery 
being completed on different days. This would have led to an increase in error 
variance in the data by increasing the variability in the environmental variables 
affecting test performance.  
The use of subtests as stand alone measures of cognitive constructs is not ideal 
and may reduce the reliability of the results. Subtests alone should only be used if 
they display adequate reliability properties (Campbell, Brown, Cavanagh, Vess, & 
Segall, 2008), which most of these tests do, however the reliability of Map Mission 
subtest and Score! subtests and the TMT is lower than the other measures being in 
the ‘adequate’ range. The decreased reliability associated with using subtest 
measures alone may account for the large confidence intervals seen in the data and 
therefore may have decreased the robustness of the results. However, for the reasons 
described above it was thought to be the best compromise in terms of breadth and 
brevity of the standard battery.  
4.4.4.3 Normative data. 
 There were difficulties relating to the available normative data for several of 
the measures included in this study.  
In the CogState battery the normative data available for the CPAL and GMLT 
tasks contained very low numbers in several of the age bands covered by this study 
therefore it was deemed unsuitable to use this data to calculate age standardised z-
scores. This meant that raw data were used for these two subtests. For the CPAL 
task, where the same task was completed by all ages, this did not pose significant 
problems. However it is of note that the two lowest scores, which constituted outliers 
to the data set, were achieved by the two youngest participants in the study. This 
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highlights the importance of normative data, where these performances could have 
been put into the context of their peers. For the GMLT the lack of suitable normative 
data was more problematic as different versions of the task were completed by 
different age ranges meaning that the data had to be analysed separately. The 
implications of this have been discussed above but overall served to reduce the 
sample size in each age group and therefore reduce the reliability of the results.  
The normative data for the TEA-Ch covers the age range 6-15:11 years despite 
several reviews of the test and the manual itself in parts describing the age range as 
6-16 years. This restriction in the age range meant that the four 16 year old 
participants had their data on the Map Mission and Score! subtests standardized 
using the data from the 15-15:11 age group. No other suitable, widely clinically used 
attention measure which includes a measure of sustained attention is available for 
this age range. Using data from a younger comparison sample may have resulted in 
these participants receiving inflated standard scores, however the impact of this is 
likely to have been minimal given the developmental trajectory of these attention 
skills having stabilised by this age range. Within this data set two of the four affected 
participants scored ≥1SD below the mean on the Map Mission subtest and one on the 
Score! subtest (there was missing data for the other participant) suggesting that 
inflation of abilities did not significantly affect the data.   
 For the two measures included in the standard battery which were not part of 
larger assessments, the Grooved Peg Board and the TMT-B, the normative data is 
more fragmented as it was collected from a variety of different studies in different 
age groups. This may have increased error variation in the results due to different 
administration practices. Both measures are scored based on time to completion and 
include the need for the researcher to correct mistakes during this time meaning that 
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they may be vulnerable to different administration practices. However, both were 
administered in this study according to established administration guidelines to 
minimise the effect of this.  
4.4.4.4 Specificity of measures and impact of surface variables. 
 No neuropsychological measure exclusively taps into one cognitive construct 
(Lezak et al., 2004), both because cognitive constructs do not exist in isolation and 
because assessment tasks are complex. At a baseline all measures require enough 
concentration to be able to attend to and complete the task. In addition, timed tasks 
will be affected by processing speed and any task requiring a motor response will be 
affected by psychomotor processing. Relative differences in the additional 
requirements of the CogState tasks and the standard battery tests may account for 
some of the variability in the relationships between them, separate from the construct 
of interest. For instance the Grooved Peg Board task was used as a measure of 
psychomotor processing, however it involves a much higher level of dexterity than 
that required by the Detection task. The Digit Span task was used as a measure of 
working memory however the total score is made up of both the forwards and 
backwards conditions meaning it is actually a measure of both immediate memory 
and working memory. To try to separate these processes out the Longest Digit Span 
Backwards variable was also used in the analysis but this measure also requires 
sequencing skills, auditory processing and attention to complete successfully 
(Wechsler, 2003). Of these skills, perhaps only attention is also required by the OBK 
task of the CogState battery.   
 Whilst these factors need to be taken into account when interpreting the 
strength of the relationships seen in this study the same would have been true 
regardless of the standard measures chosen given the different nature of completing 
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computerised and standard measures. Given this the size of the relationship seen 
between several of the variables is consistent with them tapping in to similar 
cognitive constructs. What the analysis in this study does not address is which other 
constructs they are also measuring, which could be addressed using discriminant 
validity methods.  
 
4.5 Implications of the Study 
4.5.1 Clinical implications. 
 The results of this study would not seem to fully support the use of the 
CogState battery clinically with a paediatric oncology population without further 
research (see below, section 4.6). However there are several clinical implications of 
the potential for this in the future and clinical implications arising from the 
characterising of this clinical sample more generally and the analysis of change in 
cognitive ability over time since diagnosis.  
 Computerised cognitive testing, once well validated, has many implications 
that need to be considered prior to use in clinical settings. There are considerable 
benefits to the speed with which children can complete the screening battery with 
little intervention required by the examiner opening the possibility for several 
children to be screened simultaneously. As the scoring system is automated both the 
time taken to score and the potential for errors in the scoring are reduced. However 
there are limitations. With the limited interaction between examiner and child there is 
less opportunity for observation of behavioural information often critical to the 
interpretation of results. Whilst the computer allows for a very standardised 
presentation of stimuli, the inflexibility of this means that the examiner is not able to 
“test the limits” of the child’s ability in the same way that they might to obtain extra 
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qualitative information in a standard assessment (Schatz & Browndyke, 2002). As a 
result of these limitations, in the context of neuropsychological evaluation of 
children who have been treated for cancer, it is most clinically appropriate that 
computerised assessments such as the CogState battery, if further construct and 
criterion validity and appropriate sensitivity and specificity are established, are used 
for screening purposes only followed by full conventional assessment for those found 
to be impaired in any areas. However this screening function, if established, would 
still have significant positive impacts on the ability of services to meet the NICE and 
SIGN guidance that all at risk children should be assessed.  
A relationship between time since diagnosis and performance on either the 
CogState battery or the IQ summary score was not established in this study. This is 
largely consistent with studies where children had not received CRT and inconsistent 
with studies where they had. This provides further support to the already established 
principle that CRT is particularly damaging to young children and has long term 
developmental consequences, and supports the more hopeful position that limiting 
the use of this treatment mitigates these effects to a large extent. However caution 
should be exercised in drawing any firm conclusions from this cross sectional 
analysis and further longitudinal research is required.  
The pattern of impairment seen in this study on the standard measures has 
clinical implications for the breath of the assessments needed to detect areas of 
difficulty. Whilst overall IQ may be in the normal range, significant impairments can 
be present in specific cognitive areas. Any screening measure for use clinically 
should therefore cover all of these areas if it is to be useful in this population.   
The level of impairment seen in the sample also has clinical implications. By 
definition all of the children in the sample had not received a neuropsychological 
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evaluation in the last year and the vast majority of the sample had never been 
assessed, up to several years after their treatment. This suggests that there may be 
significant levels of neurocognitive and psychomotor impairment which go 
unrecognised and therefore unaddressed in this population of children which, 
although relatively subtle, could have implications for their education, quality of life, 
social functioning and future prospects (Ness et al., 2008). This reinforces the level 
of need for all children at risk to have some form of assessment so that those 
experiencing difficulties can be identified and followed up.  
 
4.5.2 Theoretical implications. 
 The areas of impairment seen in this study, in psychomotor skills, visual 
attention, sustained attention, working memory and executive functioning, fit in well 
with the previous literature on areas of cognition most often affected. Given the 
majority of the sample were not treated with radiotherapy and yet significant 
impairment was found compared to test normative data, these results also support the 
growing literature on the detrimental effects of chemotherapy treatment alone, 
without concurrent radiotherapy. The effects of chemotherapy treatment in the 
absence of radiotherapy are becoming more prominent, both clinically and in the 
literature, given the reduction in the use of radiotherapy as a first line treatment. 
Given that the impact of intrathecal chemotherapy is not limited to specific areas of 
the brain and rather is thought to negatively impact on the development of NAWM 
and the integrity of existing white matter (Reddick et al., 2006) the negative impact 
of chemotherapy on the cognitive areas seen in this study provides some support to 
theories that they are underpinned, at least in part, by diffuse neural networks reliant 
on the integrity of white matter.   
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 The study also has theoretical implications regarding the importance of 
assessing construct validity of measures in specific populations and age groups. The 
adult version of the CogState battery has very good evidence of its construct validity 
in a wide range of populations. However, given the much reduced correlations found 
in this study, taking into account the limitations of the study, it is clear that it should 
not be assumed that construct validity remains stable across age ranges or clinical 
populations. Performance on measures of cognitive functions is only ever a proxy 
measure of the cognitive construct itself and may be affected by developmental and 
extraneous test factors. For example in this study significant levels of psychomotor 
impairment were seen, including fine motor skills and dexterity, on the GPB task. 
Fine motor skills are an integral part of any test requiring responses using a pen or 
pencil such as the SS and MM tasks, therefore ability in this area might account for a 
larger portion of the variance in performance on these tasks in this particular 
population than in other groups of children, diluting their ability to measure 
processing speed and visual attention respectively. These factors should be taken into 
account when evaluating new tests, and those with more established psychometric 
properties, in specific populations.  
  
4.6 Future Research  
 The initial results of this study warrant further investigation in future research 
on the CogState paediatric battery, as although they are less conclusive than in the 
adult studies they are on the whole comparable with other batteries evaluated for use 
in this population. As the normative data for the battery improves through increasing 
use it will become easier to investigate the battery as a whole. A larger study with the 
power to address both concurrent and discriminant validity would increase 
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understanding of the cognitive constructs that the tasks are actually tapping in to in 
this population. Criterion validity and predictive validity also need to be addressed 
given the questions raised by the tentative analysis in this study over the sensitivity 
of the battery in this population. It has been shown to be sensitive to deficits in other 
adult and child populations therefore further research should be able to determine if 
this results of this study are truly representative of outcomes in this clinical group or 
not.  
 Following establishment of criterion and construct validity, inclusion of the 
battery in longitudinal studies alongside more traditional measures would be useful 
in establishing its sensitivity to change over time. This is particularly relevant due to 
the psychometric properties of the CogState battery meaning that it is suited to 
tracking change over much more flexible time courses than traditional measures.  
 More broadly, future research in this area needs to focus on translating the 
large body of literature describing the neurocognitive deficits seen in specific groups 
into practical and clinical outcomes for children attending paediatric oncology 
clinics. Of primary importance in achieving this outcome will be the further 
development and use of psychometrically sound neurocognitive screening tools, such 
as the CogState battery investigated in this study, in order to facilitate the assessment 
of every child at risk of neurocognitive impairment. Given the level of previously 
unknown cognitive impairment seen in the participants in this study, such screening 
protocols, if adopted clinically, would be likely to identify large numbers of children 
who have cognitive difficulties following their treatment and would benefit from 
support and treatment. Further research focused on what this support and treatment 
should be is also needed to clarify the effectiveness of both pharmacological and 
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cognitive rehabilitation based approaches, and to continue developing new 
interventions which may be of benefit to these children as they develop.  
 Such large scale screening approaches would also facilitate further progress 
in understanding the risk factors for poor neurocognitive outcome, including more 
recent research into genetic risk factors, and the characteristics of children who 
respond or fail to respond to various interventions. Furthermore, it would make the 
further longitudinal research needed to understand in more detail the time course of 
neurocognitive outcomes following particular treatment regimens increasingly 
feasible to complete.  
 To accomplish these aims the artificial boundary between research and 
clinical work will need to be removed so that all clinical work in the area of 
neurocognitive follow up is able to contribute to the research literature and all 
research includes neurocognitive measures which are embedded into clinical 
practice. Only by working in this way can sufficient children be studied to gather 
generalizable and robust data, and can that data be clinically useful, both as it is 
collected and beyond. Collaborations working towards this aim do exist around the 
world, but continued efforts towards increasing their coverage, especially in the UK, 
are always needed.     
 
4.7 Conclusion 
Whilst the CogState paediatric battery remains a promising tool as a 
screening measure in a paediatric oncology population, particularly relative to the 
other screening tools described in the current literature, the results of this study 
would not appear to provide strong and robust support for its construct validity. This 
may in part be due to methodological limitations of the current study and further 
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studies are needed in larger samples, using a wider variety of standard measures, to 
more firmly establish its construct validity, both concurrent and divergent. There is 
also a need to investigate the criterion validity of the battery further to establish that 
it is sensitive enough to detect the cognitive deficits seen in this clinical population. 
Once these factors have been established it may prove to be a useful screening tool in 
clinical practice and a quick and reliable measure for use in multisite research.  
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Appendix A 
Invitation Letter and Consent to Contact Form 
 
 
 
Dear Parent 
We would like to invite you and your child to take part in a research study. This 
study is investigating a new way of assessing thinking and memory in children who 
have been treated for brain tumours or leukaemia. Previous research has found that 
children can often experience difficulties with parts of their thinking and memory 
after being treated for cancer. It is recommended that their thinking and memory is 
assessed as part of their long term follow up so that any problems can be identified 
early. This research aims to assess how good a short computerized measure is at 
doing this and to see if it can be easily used by patients and the service.  
Enclosed with this letter is an information sheet giving further details about the study 
and the contact details of the researchers if you would like to ask any questions. 
If you would like to find out more about the study and the possibility of you and your 
child taking part please complete the form at the bottom of this letter giving you 
consent to be contacted by the research team and return it to the person who gave 
you the letter.  
Best wishes 
Liz Prince 
Trainee Clinical Psychologist 
 
I am interested in finding out more about the study: Evaluation of a new cognitive 
assessment measure in children who have had cancer 
Please contact me on the following details: 
Name of child: _____________________________ 
Name of parent: ____________________________ 
Address: ___________________________________________________________ 
Telephone number: __________________________________ 
Email address: _______________________________ 
Please put a tick next to your preferred method of communication   
  Faculty of Medicine and Health Sciences 
School of Medicine 
Department of Psychological Sciences 
University of East Anglia 
Norwich Research Park 
Norwich NR4 7TJ 
United Kingdom 
Email:e.prince@uea.ac.uk 
Web: www.uea.ac.uk 
 
198 
 
Appendix B 
Parent Participant Information Sheet 
 
 
 
 
 
Information about the Research 
 
Study Title: Evaluation of a new cognitive assessment measure in children 
who have had cancer 
 
We would like to invite you and your child to take part in our research study. Before 
you decide if you and your child should take part we would like you to understand 
why the research is being done and what it would involve for you and your child. 
You will have the opportunity to go through the information sheet with one of the 
researchers and they will answer any questions you have. Talk to others about the 
study if you wish.  
 
Part 1 tells you the purpose of this study and what will happen to you and your child 
if they take part.  
 
Part 2 gives you more detailed information about the conduct of the study.  
 
Ask us if there is anything that is not clear. 
 
Part 1 
 
What is the purpose of the study? 
Children who have received treatment for cancer, particularly brain tumours or 
leukaemia, can experience difficulties in their thinking and memory in the months 
and years after their treatment. This can affect their performance at school as well 
as other areas of their lives. It is recommended that all children who are at risk of 
experiencing these problems receive an assessment of their thinking and memory 
as part of their long term follow up following cancer treatment. However not all 
children are currently receiving these assessments. Part of the reason for this may 
be that the assessments currently used take a very long time and are expensive to 
complete.  
 
This study is investigating if a new, brief computerised assessment called CogState 
could be used with children with cancer. To do this we need to find out if CogState 
  Faculty of Medicine and Health Sciences 
School of Medicine 
Department of Psychological Sciences 
University of East Anglia 
Norwich Research Park 
Norwich NR4 7TJ 
United Kingdom 
 
Email:e.prince@uea.ac.uk 
 
Web: www.uea.ac.uk  
199 
 
measures the same things as the tests which are currently used and if it is as 
sensitive as the old tests in picking up and problems the child may have in their 
thinking and memory. We also want to know if children with cancer are happy to 
complete CogState and if it can be used easily within the oncology service.  
 
This study is being conducted in part fulfilment of a Doctorate in Clinical Psychology 
at the University of East Anglia (UEA). The data will also be used in a separate 
project by another trainee clinical psychologist in part fulfilment of a Doctorate in 
Clinical Psychology at the University of East Anglia (UEA)  
 
 
Why have my child and I been invited to take part?  
Your child has been invited to take part because they have been treated for a brain 
tumour or leukaemia and are currently being followed up by the paediatric oncology 
team. You have been invited as your child’s parent to complete some questionnaires 
about your child. We are aiming to recruit 35 children and their parents to the study 
in total. This means that not everyone who shows an interest in taking part in the 
study may be able to take part.  
 
Do my child and I have to take part? 
It is up to you to decide if you and your child should join the study. We will describe 
the study and go through this information sheet. If you agree to you both taking part, 
we will then ask you to sign a consent form. We will also ask your child to sign a 
form saying they are happy to take part in the study. You are free to withdraw your 
child at any time, without giving a reason. This would not affect the standard of care 
your child receives. 
 
What will happen to me and my child if we take part? 
If your child takes part in the study there will be no changes in their medical care.   
 
A researcher will arrange to meet with you and your child for one visit that will last 
approximately 1 ½ hours with a break half way through. This visit can take place at a 
time and location which is convenient for you. This may be at your home, the 
hospital or a different location. During this visit the researcher will answer any 
questions you may have about the study and confirm that both you and your child 
are still happy to take part. The researcher will then complete a number of different 
cognitive assessments with your child. Some of these will be on a laptop computer 
and some will be pencil and paper tests. Your child will also be asked to complete 
two short questionnaires. Whilst these assessments are taking place you will be 
asked to complete three short questionnaires about your child.  
 
Following this visit, with your consent, we will send a brief report of your child’s 
results on the standard tests to the clinical team looking after your child’s cancer 
treatment and follow up. You may be contacted by the team following this if they 
think the assessments indicate that your child may benefit from further testing or 
follow up.  
 
We may wish to clarify information about your child’s diagnosis and medical 
treatment by looking at their medical notes or speaking to their doctor.  
 
What are the possible disadvantages/risks of taking part? 
It is unlikely that there are any risks to child as a result of taking part in this study as 
no changes are being made to their medical care. Some children may find 
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completing the assessment measures tiring or distressing. If this should happen the 
assessment will be stopped and appropriate support for you and your child provided. 
You may be encouraged to contact your child’s clinical team for further support if 
necessary. Your child will be able to take breaks during the assessment if they need 
to. The assessment can be stopped at any time if your child does not want to 
continue.  
 
 
What are the possible benefits of taking part? 
 
Your child may be helping to make assessments of thinking and memory more 
easily available to other children who have been treated for brain tumours or 
leukaemia.   
 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. The detailed information on this is 
given in Part 2. 
 
Will my child’s taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be 
handled in confidence. The details are included in Part 2. 
 
 
If the information in Part 1 has interested you and you are considering 
participation, please read the additional information in Part 2 before making 
any decision. 
 
Part 2 
 
What will happen if I don’t want my child to carry on with the study? 
If you don’t want your child to continue with the study at any point you can withdraw 
your consent and the assessment will be stopped. Any information that identifies 
you or your child will be destroyed. Anonymous data collected up to that point may 
be retained. 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions. They can be contacted 
by email at e.prince@uea.ac.uk. If you remain unhappy and wish to complain 
formally, you can do this via the NHS Complaints Procedure. Details can be 
obtained from PALS (01603289036) 
 
In the event that something does go wrong and you are harmed during the research 
and this is due to someone‘s negligence then you may have grounds for a legal 
action for compensation against the University of East Anglia but you may have to 
pay your legal costs. The normal National Health Service complaints mechanisms 
will still be available to you (if appropriate). 
 
Will our taking part in the study be kept confidential? 
All information which is collected about your child during the course of the research 
will be kept strictly confidential and stored in line with Caldicott principles, the Data 
Protection Act and the regulations of the UEA.  
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Data collected electronically will be kept on a password protected laptop and 
encrypted memory stick only. Information held on paper will be kept in a locked filing 
cabinet. The assessment results will be coded with a participant identification 
number and stored separately from any identifiable information. Data will only be 
accessible to members of the research team. Data will be kept for at least 5 years 
as per UEA regulations and then securely disposed of.   
 
The data collected from your child will be collated with the data from other 
participants and written up in a way that means no individual participant is 
identifiable.  
 
Will anyone be told that my child and I are taking part in the study? 
We will inform the paediatric oncology service currently responsible for your child’s 
cancer treatment and follow up that you and your child are taking part in this study.  
 
If you consent we will also send them a brief report on your child’s results on the 
standard assessment measures at the end of the study.  
 
What will happen to the results of the research study? 
The results of the study will be written up and submitted as two thesis assignments 
and two service research projects to the UEA in part fulfilment of the Doctorate in 
Clinical Psychology.  
We will also seek to publish the results in relevant scientific journals.  
You may request a brief report of the results of the study.  
  
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has been reviewed 
and given favourable opinion by Yorkshire & The Humber – Sheffield Research 
Ethics Committee. 
 
Further information and contact details 
 
For further information please contact:  
 
Liz Prince 
Trainee Clinical Psychologist 
Norwich Medical School 
University of East Anglia  
Norwich Research Park 
Norwich 
Norfolk 
NR4 7JT 
Email: e.prince@uea.ac.uk.  
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Appendix C 
16 Year Old Participant Information Sheet 
 
 
 
 
 
Information about the Research 
 
Study Title: Evaluation of a new cognitive assessment measure in children 
who have had cancer 
 
We are asking if you would join in a research project to find the answer to the 
question of whether a new assessment is good at measuring the thinking and 
memory of children who have had cancer.  
 
Before you decide if you want to join in, it‘s important to understand why the 
research is being done and what it will involve for you. So please consider this 
leaflet carefully. Talk to your family, friends, doctor or nurse if you want to. We will 
also ask you parent if they are happy to take part in the parts of the study which 
involve them.  
 
Part 1 tells you the purpose of this study and what will happen if you take part.  
 
Part 2 gives you more detailed information about how the study is being run.  
 
Part 1 
 
Why are we doing this research? 
Children who have had certain types of cancer can sometimes have some problems 
with their thinking or memory after their treatment. There are ways to find out what 
these problems are by a clinical psychologist asking the child to complete a lot of 
different tests and puzzles. This takes a long time and is not currently done with 
everyone. We want to find out if a new short assessment on a computer is able to 
find this information in a quicker and easier way. To do this we need to compare it to 
the tests and puzzles used at the moment to see if it is as good as them.  
 
The person doing this research and another trainee will also use the results to write 
two reports for a course they are doing in Clinical Psychology. 
  Faculty of Medicine and Health Sciences 
School of Medicine 
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Norwich NR4 7TJ 
United Kingdom 
 
Email:e.prince@uea.ac.uk 
 
Web: www.uea.ac.uk  
203 
 
 
What is the assessment that is being tested? 
The assessment is called CogState and is a group of games and puzzles on a 
computer often using playing cards. It has been used before with lots of other adults 
and children but not yet with children with cancer.  
 
Why have I been invited to take part? 
You have been invited to take part because you have been treated for a brain 
tumour or leukaemia and are currently being followed up by the paediatric oncology 
team. We are aiming to recruit 35 children to the study in total. This means that if 
more than 35 children reply saying they would like to take part not everyone will be 
able to be involved in this study.  
 
Do I have to take part? 
No. It is up to you. We will ask you for your consent and then ask if you would sign a 
form. We will also ask your parents to give their agreement to you taking part and 
their consent to complete the parts of the project which involve them. We will give 
you a copy of this information sheet and your signed form to keep. You are free to 
stop taking part at any time during the research without giving a reason. If you 
decide to stop, this will not affect the care you receive. 
 
What will happen to me if I take part? 
If you take part in the study there will be no changes in your medical care.   
 
The person doing the research will arrange to come and see you and your parents 
at a place and time you are happy with. This visit will take about 1 ½ hours with a 
break in the middle. During this visit the person doing the research will answer any 
questions you or your parents may have about the study and will ask you to sign a 
form to say you are happy to take part. Then you will complete a number of different 
tasks, puzzles and questionnaires with the person doing the research. Some will be 
on a computer and some will be on paper. While you are doing this you parent will 
fill in a few questionnaires about you.   
 
After this visit, with your permission, we will send a brief report of how you did on the 
standard tests and puzzles used in the research to the team at the hospital who look 
after your cancer treatment. After seeing the report the team may think it would be 
helpful to find out some more information on how you are doing and they may 
contact you and your parents to discuss this.  
As part of the research we might also want to check with your doctor or your medical 
notes some details about your illness and the treatment you have had. 
 
Is there anything to be worried about if I take part? 
It is very unlikely taking part in the study will harm you in any way. Some children 
might find completing the tests and puzzles a bit boring, tiring or upsetting. If you 
feel upset you can talk about this with the person doing the tests with you and they 
will tell you where you can get further help if you need it. You will be able to take a 
break at any point and you can ask for the session to stop completely if you want to.  
 
What are the possible benefits of taking part? 
 
You may be helping us to make these assessments of thinking and memory more 
easily available to other children like you who have been treated for cancer.  
204 
 
 
Contact details 
If you would like more information about the study you can contact the research 
team by emailing e.prince@uea.ac.uk. 
 
Thank you for reading so far – if you are still interested, please go to Part 2: 
 
Part 2 
 
What will happen if I don’t want to carry on with the study? 
If you don’t want to continue with the study at any point you can withdraw your 
consent and the assessment will be stopped. Any information that identifies you will 
be destroyed. Anonymous data collected up to that point may be retained. 
 
What if there is a problem or something goes wrong? 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions. They can be contacted 
by email at e.prince@uea.ac.uk If you remain unhappy and wish to complain 
formally, you can do this via the NHS Complaints Procedure. Details can be 
obtained from PALS (01603289036) 
 
In the event that something does go wrong and you are harmed during the research 
and this is due to someone‘s negligence then you may have grounds for a legal 
action for compensation against the University of East Anglia but you may have to 
pay your legal costs. The normal National Health Service complaints mechanisms 
will still be available to you (if appropriate). 
 
Will anyone else know I am doing this? 
We will keep your information in confidence. This means we will only tell those who 
have a need or right to know. With your consent we will tell the team at the hospital 
who look after your cancer care that you are taking part. We will store your test 
results separately from your name so that people not involved in the research 
cannot tell who you are. All the information we collect will be kept in locked 
cupboards or on computers with passwords. It will be kept for at least 5 years as this 
is the rules of the university and the NHS, and then securely disposed of.   
 
What will happen to the results of the research study? 
The results of the study will be written up and submitted as two thesis assignments 
and two service research projects to the UEA in part fulfilment of the Doctorate in 
Clinical Psychology.  
 
We will also seek to publish the results in relevant scientific journals. We will do this 
in a way that means it is not possible to tell who you are or results of you individual 
assessment.  
 
You may request a brief report of the results of the study.  
 
Who has reviewed the study? 
Before any research goes ahead it has to be checked by a Research Ethics 
Committee. They make sure that the research is fair. Your project has been checked 
by the Yorkshire & The Humber - Sheffield Research Ethics Committee.  
 
Thank you for reading this – please ask any questions if you need to  
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Appendix D 
11-15 Year Old Participant Information Sheet 
 
 
 
 
Information about the Research 
 
Study Title: Evaluation of a new cognitive assessment measure in children 
who have had cancer 
 
We are asking if you would join in a research project to find the answer to the 
question of whether a new assessment is good at measuring the thinking and 
memory of children who have had cancer.  
 
We will ask your parent to give permission for you to take part. We will also like you 
if you want to take part. Before you decide if you want to join in, it‘s important to 
understand why the research is being done and what it will involve for you. So 
please consider this leaflet carefully. Talk to your family, friends, doctor or nurse if 
you want to. 
 
Part 1 tells you the purpose of this study and what will happen if you take part.  
 
Part 2 gives you more detailed information about how the study is being run.  
 
Part 1 
 
Why are we doing this research? 
Children who have had certain types of cancer can sometimes have some problems 
with their thinking or memory after their treatment. There are ways to find out what 
these problems are by a clinical psychologist asking the child to complete a lot of 
different tests and puzzles. This takes a long time and is not currently done with 
everyone. We want to find out if a new short assessment on a computer is able to 
find this information in a quicker and easier way. To do this we need to compare it to 
the tests and puzzles used at the moment to see if it is as good as them.  
 
The person doing this research and another trainee will also use the results to write 
a report for a course they are doing in Clinical Psychology. 
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What is the assessment that is being tested? 
The assessment is called CogState and is a group of games and puzzles on a 
computer often using playing cards. It has been used before with lots of other adults 
and children but not yet with children with cancer.  
 
Why have I been invited to take part? 
You have been invited to take part because you have been treated for a brain 
tumour or leukaemia and are currently being followed up by the paediatric oncology 
team. We are aiming to recruit 35 children to the study in total. This means that if 
more than 35 children reply saying they would like to take part not everyone will be 
able to be involved in this study. However you might be able to be involved in other 
research in the future if you want to.    
 
Do I have to take part? 
No. It is up to you. We will ask you for your agreement and then ask if you would 
sign a form. We will also ask your parents to give their permission for you to take 
part. We will give you a copy of this information sheet and your signed form to keep. 
You are free to stop taking part at any time during the research without giving a 
reason. If you decide to stop, this will not affect the care you receive. 
 
What will happen to me if I take part? 
If you take part in the study there will be no changes in your medical care.   
 
The person doing the research will arrange to come and see you and your parents 
at a place and time you are happy with. This visit will take about 1 ½ hours with a 
break in the middle. During this visit the person doing the research will answer any 
questions you or your parents may have about the study and will ask you to sign a 
form to say you are happy to take part. Then you will complete a number of different 
tasks, puzzles and questionnaires with the person doing the research. Some will be 
on a computer and some will be on paper. While you are doing this you parent will 
fill in a few questionnaires about you. .  
 
After this visit, if your parents agree, we will send your team at the hospital a brief 
report on how you did on the standard tasks and puzzles. If they think they might 
need some more information they may talk to your parents about this. As part of the 
research we might also want to check with your doctor or your medical notes some 
details about your illness and the treatment you have had. 
 
Is there anything to be worried about if I take part? 
It is very unlikely taking part in the study will harm you in any way. Some children 
might find completing the tests and puzzles a bit boring, tiring or upsetting. If you 
feel upset you can talk about this with the person doing the tests with you and they 
will tell you where you can get further help if you need it. You will be able to take a 
break at any point and you can ask for the session to stop completely if you want to.  
 
What are the possible benefits of taking part? 
You may be helping us to make these assessments of thinking and memory more 
easily available to other children like you who have been treated for cancer.  
 
Contact details 
If you would like more information about the study you can contact the research 
team by emailing e.prince@uea.ac.uk.  
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Thank you for reading so far – if you are still interested, please go to Part 2: 
 
 
Part 2 
 
What if there is a problem or something goes wrong? 
If you are worried about any part of the study you should talk to your parents and the 
people doing the research first as they may be able to answer your question. If you 
are still worried and you would like to complain you can do so using the NHS 
complaints procedure. PALS will be able to help you and your parents to do this 
(01603289036).  
 
If something does go wrong and you are harmed in away because of the research 
team doing something wrong you may be able to claim for compensation from the 
University of East Anglia. Your parents will help you to do this.  
 
Will anyone else know I am doing this? 
We will keep your information in confidence. This means we will only tell those who 
have a need or right to know. With your parent’s permission we will tell the team at 
the hospital who look after your cancer care that you are taking part. We will store 
your test results separately from your name so that people not involved in the 
research cannot tell who you are. All the information we collect will be kept in locked 
cupboards or on computers with passwords.  
 
 
Who has reviewed the study? 
Before any research goes ahead it has to be checked by a Research Ethics 
Committee. They make sure that the research is fair. Your project has been checked 
by the Yorkshire & The Humber - Sheffield Research Ethics Committee.  
 
 
 
Thank you for reading this – please ask any questions if you need to. 
 
 
  
208 
 
Appendix E 
8-10 Year Old Participant Information Sheet 
 
 
 
 
 
Study Title: Testing a new test of thinking and memory in children who have 
had cancer 
 
We are asking if you would like to take part in a research project. We will ask your 
parents to give permission for you to take part. We will also ask you if you want to 
take part so this leaflet is to tell you what the research is about.  
 
What is research? Why is this project being done? 
Research is a way we try to find out the answers to questions.  
 
We want to see if we can test the thinking and memory of children who have been 
treated for cancer in a quick and easy way.  
 
Why have I been asked to take part? 
You have been asked because you have been treated for a brain tumour or a blood 
cancer at the hospital.  
 
Did anyone else check the study is ok to do? 
Before any research is allowed to happen, it has to be checked by a group of people 
called a Research Ethics Committee. They make sure that the research is fair. Your 
project has been checked by the Yorkshire & The Humber- Sheffield Research 
Ethics Committee 
 
Do I have to take part? 
No. You can say no to the study if you want to. Nothing bad will happen if you 
decide to say no.  
 
What will happen to me if I take part? 
Nothing that the doctors are doing to look after you will change.  
 
One person who is doing the research will come and visit you and your family. They 
will do some different games and puzzles with you. Your parents will need to answer 
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a few questions about you. This visit will take about 1 ½ hours with a break halfway 
through. You can ask for other breaks if you want them.  
 
If your parents say yes, we will share some information about the tests and puzzles 
you did with your doctors. They might want to talk to your parents a bit more about 
this.  
 
We might also ask your doctors for a bit more information about your illness and the 
treatment you have had.  
 
Might anything in the research upset me? 
It is very unlikely that anything will upset you. If you do get upset just talk to the 
person doing the research and they will stop the task.  
 
Will joining help me? 
You may be helping other children like you by making it easier to look at their 
thinking and memory in the future.  
 
What if something goes wrong during the project? 
If something goes wrong or you want to make a complaint you should talk to your 
parents and they will help you decide what to do next.  
 
Will anyone else know I am doing this? 
We will keep all your information private. We won’t tell anyone you are taking part if 
they do not need to know.  
 
What if I don’t want to do the research anymore? 
If at any time you don‘t want to do the research anymore, just tell your parents or the 
person doing the research. They will not be cross with you and will be able to stop 
you taking part.  
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Appendix F 
Parent Consent Form (8-15 Year Old Participants)  
 
 
 
 
Study Title: Evaluation of a new cognitive assessment measure in 
children who have had cancer 
 
Name of Researcher: Liz Prince  
 
Please initial the box: 
 
1. I confirm that I have read and understand the information sheet dated 10/6/2013 (version 
2) for the above study. I have had the opportunity to consider the information, ask questions 
and have had these answered satisfactorily.  
 
2. I understand that my child’s participation is voluntary and that they are free to withdraw at 
any time without giving any reason, without their medical care or legal rights being affected.  
 
3. I understand that relevant sections of their medical notes and data collected during the 
study, may be looked at by individuals from the research team where it is relevant to my 
taking part in this research. I give permission for these individuals to have access to their 
records.  
 
4. I agree to complete some questionnaires about my child as part of the study.  
 
5. I agree to my child’s paediatric oncology team being informed that my child is taking part 
in the above study. 
 
6. I agree to my child’s paediatric oncology team being sent a brief report of the results of the 
standard measures used in the study.  
 
7. I agree for my child to take part in the above study.  
 
_____________________  ___________   _______________ 
Name of Parent/Guardian    Date     Signature  
 
 
_____________________  ___________   _______________ 
Name of Person    Date     Signature  
taking consent  
 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept in medical notes  
Patient Identification Number for this trial:  
 
CONSENT FORM  
 
 Faculty of Medicine and Health Sciences 
School of Medicine 
Department of Psychological Sciences 
University of East Anglia 
Norwich Research Park 
Norwich NR4 7TJ 
United Kingdom 
 
Email:e.prince@uea.ac.uk 
 
Web: www.uea.ac.uk 
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Appendix G 
Parent Consent Form (16 Year Old Participants) 
 
 
 
 
Study Title: Evaluation of a new cognitive assessment measure in 
children who have had cancer 
 
 
 
Name of Researcher: Liz Prince  
 
Please initial the box: 
 
1. I confirm that I have read and understand the information sheet dated 10/6/2013 (version 
2) for the above study. I have had the opportunity to consider the information, ask questions 
and have had these answered satisfactorily.  
 
 
2. I agree to complete some questionnaires about my child as part of the study.  
 
 
3. I agree for my child to take part in the above study.  
 
 
 
 
_____________________  ___________   _______________ 
Name of Parent/Guardian    Date     Signature  
 
 
 
_____________________  ___________   _______________ 
Name of Person    Date     Signature  
taking consent  
 
 
 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept in medical notes 
 
 
  
Patient Identification Number for this trial:  
 
CONSENT FORM  
 
 Faculty of Medicine and Health Sciences 
School of Medicine 
Department of Psychological Sciences 
University of East Anglia 
Norwich Research Park 
Norwich NR4 7TJ 
United Kingdom 
 
Email:e.prince@uea.ac.uk 
 
Web: www.uea.ac.uk 
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Appendix H 
16 Year Old Participant Consent Form 
 
 
 
 
Study Title: Evaluation of a new cognitive assessment measure in 
children who have had cancer 
 
Name of Researcher: Liz Prince  
 
Please initial the box: 
 
1. I confirm that I have read and understand the information sheet dated 10/6/2013 (version 
2) for the above study. I have had the opportunity to consider the information, ask questions 
and have had these answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my medical care or legal rights being affected.  
 
3. I understand that relevant sections of my medical notes and data collected during the 
study may be looked at by individuals from the research team where it is relevant to my 
taking part in this research. I give permission for these individuals to have access to my 
records.  
 
4. I agree to my parent completing some questionnaires about me as part of the study.  
 
5. I agree to my paediatric oncology team being informed that I am taking part in the above 
study. 
 
6. I agree to my paediatric oncology team being sent a brief report of the standard measures 
used in the study.  
 
7. I agree to take part in the above study.  
 
 
_____________________  ___________   _______________ 
Name of Participant   Date     Signature  
 
____________________  ___________   _______________ 
Name of Person    Date     Signature  
taking consent  
 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept in medical notes  
Patient Identification Number for this trial:  
 
CONSENT FORM  
 
 Faculty of Medicine and Health Sciences 
School of Medicine 
Department of Psychological Sciences 
University of East Anglia 
Norwich Research Park 
Norwich NR4 7TJ 
United Kingdom 
 
Email:e.prince@uea.ac.uk 
 
Web: www.uea.ac.uk 
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Appendix I 
8-15 Year Old Participant Assent Form 
 
 
 
Project title: Testing a new test of thinking and memory in children who 
have had cancer 
 
Child (or if unable, parent on their behalf) /young person to circle all they agree with:  
 
Has somebody else explained this project to you?     Yes/No  
 
Do you understand what this project is about?     Yes/No  
 
Have you asked all the questions you want?     Yes/No  
 
Have you had your questions answered in a way you understand?  Yes/No  
 
Do you understand it’s OK to stop taking part at any time?    Yes/No  
 
Are you happy to take part?        Yes/No  
 
If any answers are ‘no’ or you don’t want to take part, don’t sign your name!  
 
If you do want to take part, you can write your name below  
 
Your name  ___________________________ 
 
Date   ___________________________ 
 
The person who explained this project to you needs to sign too:  
 
Print Name ____________________________ 
 
Sign   ____________________________ 
 
Date   _____________________________ 
 
Thank you for your help  
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Appendix J 
Demographics Questionnaire 
Patient Identification Number: ________   Date: ________ 
Age: ______years _____ months 
Gender:  MALE / FEMALE 
 
Parental Level of Education: (Circle as appropriate)  
GCSE / A Levels or equivalent / Undergraduate Degree / Post Graduate 
Degree 
 
Diagnosis: 
__________________________________________________________ 
Time since diagnosis: _______ years ______ months 
Treatment: 1________________________________________ 
       2 ________________________________________ 
       3 ________________________________________ 
Time since treatment 1: ________years _______ months 
Time since treatment 2: ________years _______ months 
Time since treatment 3: ________years _______ months 
Current maintenance treatment?  Yes ⁬  No ⁬ 
Details of maintenance treatment: 
_____________________________________________________________
_____________________________________________________________
_____________________________________________________________  
215 
 
Appendix K 
Acceptability Questionnaire 
 
 
Please can you answer these questions about the computer puzzles you 
have just done? Circle the answer you most agree with for each question.  
 
1. How hard were the puzzles?     
Easy  A bit hard  Very hard 
2. Did you enjoy the puzzles? 
Didn’t enjoy it all  Enjoyed it a little bit   Enjoyed it a lot 
3. Were the puzzles interesting? 
Not interesting at all  A little bit interesting Very interesting 
4. Did the puzzles take a long time? 
Not a very long time  Quite a long time  A very long time 
5. Did you feel tired after doing the puzzles? 
Not tired at all  A little bit tired  Very tired 
6. Did you feel upset after doing the puzzles? 
Not upset at all  A little bit upset  Very upset 
7. Would you be happy to do the puzzles again? 
 
No Yes 
 
8. Is there anything else you would like to say about the puzzles? For 
example, was there a puzzle you liked the best? Or a puzzle you really 
didn’t like? 
 
_____________________________________________________________
_____________________________________________________________
_____________________________________________________________
_____________________________________________________________
_____________________________________________________________ 
 
 
Thank you for completing these questions! 
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Appendix L 
Service Based Research Project: The Acceptability and Feasibility of a Brief 
Neurocognitive Screening Battery in a Paediatric Oncology Population  
(Appendix Identifiers have been changed to reflect the location of the Appendix 
in the Thesis) 
Abstract 
Background. Children treated for CNS tumours and leukaemia are at risk of 
neurocognitive late effects. It is recommended that they receive regular 
neuropsychological assessment to facilitate appropriate follow up. Brief screening 
batteries, such as CogState, could help services meet this recommendation. This 
study aimed to assess the acceptability and feasibility of the CogState battery in a 
paediatric oncology population.  
Method. Thirty-seven children completed the CogState battery and an acceptability 
questionnaire as part of a larger study into the construct validity of the battery. Time 
taken to complete and score the battery was recorded for comparison with a standard 
battery. Recruitment rate was recorded.  
Results. Mean completion and scoring time of the Cogstate battery was significantly 
shorter than the standard battery. Recruitment rates were high and comparable to 
previous studies. Results indicated the battery was acceptable to the vast majority of 
participants in the areas assessed, and 89% reported they would be happy to 
complete the assessment again.  
Conclusion. The CogState battery is acceptable to this population and can be 
completed and scored significantly faster than brief batteries of standard measures 
suggesting it is feasible for use by busy clinicians once the psychometric properties 
of the battery have been established.   
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Introduction 
Around 20,000 children are diagnosed with some form of cancer each year 
(Steen & Mirro, 2000) of which around half are leukaemias and central nervous 
system (CNS) tumours. Five year survival rates for these types of cancer have 
increased dramatically in recent years meaning that the late effects of the disease and 
treatment regimens are becoming more prominent. Around 50%- 60% of survivors of 
childhood cancer will experience neurocognitive late effects (Hewitt, Weiner, & 
Simone, 2003) with survivors of leukaemia and CNS tumours most at risk (Costa, 
2010). The primary areas of deficit identified are attention and concentration, 
processing speed, visual perceptual abilities, memory and executive function (Butler 
& Haser, 2006; Nathan et al., 2007; Peterson et al., 2008; Robinson et al., 2010). 
Several bodies including the Children’s Oncology Group (Nathan et al., 2007), the 
National Institute for Health and Clinical Excellence (NICE, 2005) recommend 
neuropsychological assessment as a routine part of long term follow up for children 
at risk of neurocognitive late effects. It is acknowledged that these recommendations 
are currently not being fully implemented (Nathan et al., 2007). There are several 
barriers to this including the time and therefore cost involved in a full 
neuropsychological assessment combined with limited resources in the form of clinic 
space and appropriately qualified staff. NICE acknowledges that “Both professionals 
and parents/carers have identified a significant lack in formal psychological input … 
which represents a significant area of unmet need” (NICE, 2005 p. 75). 
To address this problem, brief, easily administered valid and sensitive 
screening instruments are needed which cover the areas of neurocognitive function 
repeatedly demonstrated to be at risk in the literature. These instruments must be 
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acceptable to patients and their families and feasible for use within paediatric 
oncology services. It is reported that neuropsychological assessment can induce 
feelings of failure and frustration in some children (Baron, 2004) making it 
unpleasant for the child and influencing compliance and test performance. There is 
limited research literature on this topic however one study into the Paced Auditory 
Serial Addition Task (PASAT) in young adults has shown that it can induce negative 
mood in participants previously in positive or neutral mood states (Holdwick & 
Wingenfeld, 1999). It is therefore important to further understand the experience of 
completing a measure through acceptability analyses to fully understand any 
potential impact on both test performance and the child more widely.    
Several screening batteries or measures have been assessed in the literature 
for use with this population, including informant report measures (e.g. Lai et al., 
2011), batteries of standard neuropsychological measures (e.g. Krull et al., 2008) and 
computerized measures (Conklin et al., 2013). However, only one study (Pejnovic et 
al., 2012) specifically consider the acceptability and feasibility of their battery 
beyond stating their recruitment rate. Using a structured approach to feasibility 
assessment they focused on the brevity, simplicity, relevance, acceptability and value 
of their assessment battery made up of tests and subtests from standard 
neuropsychological measures. They assessed the battery in children newly diagnosed 
with cancer who would receive CNS-directed therapy as part of their treatment and 
in controls finding it to be brief (M= 49.4 minutes, SD =12.8), acceptable to patients 
and controls and to add significant information.  
CogState is a brief computerized neurocognitive battery which takes 
approximately 20 minutes to complete. It consists of a selection of simple 
standardised experimental psychology paradigms such as n-back tasks and forced 
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choice reaction time tasks modified to make them applicable and acceptable in 
clinical use (Pietrzak et al., 2009). The battery makes use of non-verbal and 
culturally neutral stimuli and has been shown to demonstrate virtually no practice 
effects in adults or children (Falleti, Maruff, Collie, & Darby, 2006; Mollica, Maruff, 
Collie, & Vance, 2005) allowing for repeated administration over shorter time 
periods than traditional neuropsychological assessments. Subtests are available 
which are described as assessing psychomotor function, processing speed, visual 
attention, vigilance and sustained attention, visual memory and learning, working 
memory and executive functioning. Its computerised administration allows for 
accurate collection of data and automated scoring. Construct validity and criterion 
validity have been established in large samples of healthy adults, adults with 
schizophrenia, mild traumatic brain injury and AIDs dementia (Maruff et al., 2009; 
Pietrzak et al., 2009). It has been used with children and in both samples of typically 
developing children (Thomas, Reeve, Fredrickson, & Maruff, 2011) and a variety of 
samples from paediatric populations (Bangirana et al., 2009; Boivin et al., 2010; 
Mayes, Snyder, Langlois, & Hunter, 2007; Mollica, Maruff, & Vance, 2004). 
Construct and criterion validity in children is still being established. Given these 
properties the CogState paediatric battery has the potential to be a useful screening 
tool in paediatric oncology population at risk of neurocognitive late effects. In order 
for it to successfully incorporated into clinical services its construct and criterion 
validity, acceptability to services users and feasibility within the service context need 
to be assessed. This project aims to address the last two of these questions.  
Research Questions 
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1. To determine if assessment with the CogState brief neurocognitive battery is 
acceptable to children receiving Paediatric Oncology follow up following 
treatment for CNS tumours or leukaemia.  
2. To determine if assessment with the CogState brief neurocognitive battery is 
feasible for use in a Paediatric Oncology Outpatient setting.   
 
Method 
Design 
 The research questions were addressed as part of a larger cross-sectional 
correlation study focused on assessing the construct validity of the CogState battery 
in a paediatric oncology population. A questionnaire based design was used to 
address research question one with the participants of the larger study completing an 
acceptability questionnaire following completion of the CogState battery. Research 
question two was addressed in two ways. Firstly by recording the number of eligible 
patients approached to take part in the study who completed the battery. Secondly by 
recording the time taken to complete both the CogState battery and the standard 
battery to ascertain the brevity of the assessment compared to a brief battery of 
standard measures. The time taken to score both batteries for a sub-sample of five 
participants was also recorded. This was not recorded for the entire sample due 
feasibility difficulties in the larger study.  
Participants 
 Participants in the study were children aged between 8-16 years who had 
been treated for a CNS tumour or leukaemia at one of three hospitals in the region 
(n=37). All participants had stable disease as determined by their primary physician 
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which required being off active therapies for those treated for CNS tumours and at 
least in maintenance therapy for those treated for leukaemia. All participants had 
English as their primary language to ensure they understood all of the assessments. 
Exclusion criteria were pre-existing neurodevelopmental or genetic disorder; history 
of head injury; sensory or motor impairment severe enough to prevent testing or a 
neuropsychological evaluation including any of the study measures in the last year. 
Further details of the study sample are presented in Table 1.  
Table 1 
Demographic and clinical details of the sample 
Participant Characteristic Whole Sample (n=37) 
Gender n(%) 
    Male 
    Female 
 
16 (43) 
21 (57) 
Age at testing (years) 
    Mean 
    SD 
    Range 
 
12.7 
2.4 
8.5-16.9 
Age at diagnosis (years) 
    Mean 
    SD 
    Range 
 
5.5 
3.6 
0.5-15.6 
Time since diagnosis (years) 
    Mean 
    SD 
    Range 
 
7.1 
3.6 
0.25-13.25 
Diagnosis n(%) 
    Acute Lymphoblastic Leukaemia 
    Other Leukaemia 
    CNS Tumour 
 
27 (73) 
2 (5) 
8 (22) 
Treatment n(%)a 
    Surgery 
    Chemotherapy 
    Radiotherapy 
    Corticosteroids 
    Other 
 
7 (19) 
30 (81) 
2 (5) 
26 (70) 
3 (8) 
Maintenance treatment at time of testing 
n(%) 
    Yes 
    No 
 
4 (11) 
33 (89) 
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Parental Level of Education n(%) 
    None 
    GCSE/O Level 
    A-level or equivalent 
    Undergraduate 
    Post Graduate 
 
1 (3) 
12 (32) 
11 (30) 
11 (30) 
2 (5) 
WASI Two-subtest IQ (standard score)b 
    Mean 
    SD  
    Range 
 
101.50 
14.86 
78-135 
PI-ED total scorec 
    Mean 
    SD 
    Range 
 
12.05 
5.89 
3-28 
a Up to three treatments were recorded for each participant. 
b WASI = Weschler Abbreviated Scale of Intelligence; Standard scores have a mean 
100 and a standard deviation of 15  
cPI-ED = Pediatric Inventory of Emotional Distress; Clinical cut off is 10 for males 
and 11 for females 
 
Procedure 
 Ethical approval for the larger study was obtained from the Yorkshire & The 
Humber - Sheffield Research Ethics Committee (Appendix M). Local R&D approval 
was obtained from each clinical service (Appendices N-P) prior to recruitment 
beginning.  
Participants were recruited through three local paediatric oncology teams. 
Clinicians screened potential participants against the inclusion and exclusion criteria 
of the study. Those who were eligible  were initially approached by a member of the 
clinical team either during a routine clinic visit or by post with a follow up phone 
call, to provide initial information about the study (see Appendices A-E)  and obtain 
consent to be contacted by the researcher. Following this the researcher contacted the 
family and arranged the study visit. Details of the recruitment rate at the three 
clinical services are presented in Table 2. Service A and B were smaller local teams 
where the entire eligible clinical population was approached. Service C was a larger 
regional centre covering a wide geographical region. Recruitment from this centre 
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was limited by the sample size requirements of the study (set by the power 
calculation for the larger study and the resources available) and was stopped when 
this sample size was reached and therefore it is likely it is not representative of true 
interest levels in the study.  
Table 2 
Recruitment rates by clinical service 
 
  
Prior to completing the study measures consent was obtained from the parents 
of children aged 8-15 years, with assent obtained from the child. For participants 
aged 16 years consent was obtained from both the child and the parent (see 
Appendices F-I). All study measures were completed in a single research visit to the 
home of the participant (lasting around 90 minutes) in order to minimise the burden 
of taking part in the project. All research visits followed a set order: the child 
completed the CogState battery followed by the acceptability questionnaire and then 
the remainder of the measures required by the construct validity study (listed below) 
were completed.  
Measures 
 CogState 
 Service A Service B Service C Total 
Number of eligible patients 
identified and approached by the 
team 
20 12 66 99 
Number of patients expressing 
interest  
17 10 19 46 
    Percentage of total approached 85% 83% 30% 47% 
Number of patients recruited  15 9 13 37 
    Percentage of total approached 75% 75% 19% 38% 
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 The CogState paediatric battery used in this study was made up of six tasks; 
Detection (DET), Identification (IDN), One Card Learning (OCL), One Back (OBK), 
Continuous Paired Associate Learning (CPAL) and Groton Maze Learning Task 
(GMLT). A description of these tasks and their primary outcome variables is 
presented in Table 3. All tasks were presented on a Toshiba Satelite Pro C850 1K4 
laptop computer. The participant was guided through the tasks by on screen 
instructions with further verbal instructions from the researcher supervising the 
testing. Practice periods were presented prior to the CPAL and GMLT to ensure the 
participant understood the instructions before beginning the scored portion of the 
test. On the other tasks particular attention was given to the participant’s first few 
responses and the instructions of the test were repeated if necessary. Responses to the 
DEC, IDN, OCL and OBK tasks were made using simple keyboard strokes. An 
external mouse was used for the CPAL and GMLT. Participants were encouraged to 
be as quick and accurate as possible in their responses.  Auditory and visual feedback 
was given each time the participant gave an incorrect response.  
Table 3 
CogState Task Descriptions 
Subtest Abbreviation Description Primary Outcome 
Variable 
Detection Task DET The participant must 
press the “yes” key as 
soon as the single card in 
the centre of the screen 
flips over. In the 10-
16years battery a joker is 
used. In the 8-9years 
battery a smiling face is 
used.  
Speed of 
performance 
(Log10 
transformation of 
mean reaction 
time) 
Identification 
Task 
IDN The participant must 
respond “yes” if the card 
presented is red and “no” 
if it is black as soon as it 
Speed of 
performance 
(Log10 
transformation of 
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flips over. In the 10-
16years battery a joker is 
used. In the 8-9years 
battery a smiling face is 
used. 
mean reaction 
time) 
One Card 
Learning Task 
OCL The participant must 
respond “yes” if they 
have seen the card 
presented before in this 
subtest and “no” if they 
have not. There are four 
target cards which repeat 
nine times during task. In 
the 10-16years battery 
standard playing cards 
are used. In the 8-9years 
battery coloured numbers 
and symbols are used.  
Accuracy of 
performance 
(Arcsine 
transformation of 
proportion of 
correct responses)  
One Back 
Memory Task 
OBK The participant must 
respond “yes” if the 
current card is the same 
as the previous card and 
“no” if it not. In the 10-
16years battery standard 
playing cards are used. In 
the 8-9years battery 
coloured numbers and 
symbols are used. 
Speed of 
performance 
(Log10 
transformation of 
mean reaction 
time) 
Continuous 
Paired Associate 
Learning Task 
CPAL After a learning phase 
during which all the 
shapes visible the 
participant must chose 
the matching shape from 
a choice of eight hidden 
locations (six hiding 
shapes and two decoy). 
They continue choosing 
on each trial until the 
correct shape is found.  
Total Errors 
Groton Maze 
Learning Task 
GMLT The participant must find 
the correct path through a 
10x10 grid from a 
starting point to a target 
following three rules. For 
the 10-16years battery the 
previous steps taken are 
hidden, for the 8-9years 
battery they remain 
visible. Five trials are 
presented which the same 
Total Errors 
(Summed across 
the five trials; 
Total Rule Break 
Errors is an 
alternative 
variable) 
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29 step path on each 
occasion.  
 
 Acceptability Questionnaire 
 The acceptability questionnaire (Appendix K) was designed for the study 
based on the dimensions assessed by Pejnovic et al. (2012) in their participant 
survey. Participants were asked to rate the CogState battery on a three point Likert 
scale in the areas of difficulty, enjoyment, interest, length, fatigue and distress. A 
three point scale was used rather than a five point scale (as in Pejnovic et al., 2012) 
to ensure the questionnaire could be understood by participants across the entire age 
range and with potential intellectual impairment. Pejnovic et al. (2012) collapsed 
their five point scale to a three point scale for data analysis so comparison with 
previous research was still possible.  Answer wording was specific to each question 
but with the same three levels across all questions (e.g. “Did the puzzles take a long 
time? Not a very long time; quite a long time; a very long time” and “Did you feel 
tired after doing the puzzles? Not tired at all; A little bit tired; Very tired”) to aid 
comprehension but retain comparativeness across domains. Participants were also 
asked if they would be happy to complete the puzzles again. The questionnaire 
included a final question inviting the child to give any further comments they wished 
to.  
 Other measures 
 The other measures completed during the study visit related to the larger 
construct validity study. Participants completed the Wechsler Abbreviated 
Intelligence Scale two-subtest short form (Wechsler, 1999), and the Paediatric 
Inventory of Emotional Distress (O'Connor, Carney, House, Ferguson, & O'Connor, 
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2010) which analysed as covariates in the construct validity study. The standard 
battery of tests used for the main analyses were the Grooved Peg Board (Klove, 
1963), the Symbol Search and Digit Span subtests of the Wechsler Intelligence Scale 
for Children version IV (Wechsler, 2003), the Map Mission and Score! subtests of 
the Test of Everyday Attention for Children (Manly, Robertson, Anderson, & 
Nimmo-Smith, 1999); the Dot Location subtest of the Children’s Memory Scale 
(Cohen, 1997), the Trail Making Test A and B (Reitan, 1958) and the Behaviour 
Rating Inventory of Executive Functioning (Gioia, Isquith, Guy, & Kenworthy, 
2000). The time taken to complete and score this battery was recorded for 
comparison with the CogState battery with reference to the feasibility of the 
CogState battery.  
Statistical analysis  
 Statistical analyses were conducted using Excel 2013 and SPSS version 19. 
Descriptive statistics were used to describe the results of the acceptability 
questionnaire. Qualitative comments were arranged into themes. Brevity was 
analysed by taking the mean length of time to complete the CogState battery and 
compared to the standard battery using a paired sample t-test. Mean time to score a 
sub-sample of five data sets is reported and was analysed compared to the standard 
battery using an independent samples t-test.  Percentage completion of the battery is 
reported.   
Results 
Acceptability Questionnaire 
 The results of the Acceptability questionnaire are presented in Figure 1. Only 
3% of participants rated the battery as very hard. Similarly only 3% said they had not 
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enjoyed it at all. In total 95% of participants reported finding the tasks ‘a little bit’ or 
‘very’ interesting. Only 8% of participants thought the battery took a ‘very’ long 
time to complete with 43% reporting it took “not a very long time at all”. No 
participants reported that they felt ‘very’ tired or upset after completing the tasks 
with the vast majority of participants (92%) saying the felt “not upset at all”.   
Figure 1 
Acceptability Questionnaire Responses 
 
The responses to the question asking participants if they would be happy to 
do the puzzles again are represented in Figure 2. The vast majority of participants 
responded positively.  
Figure 2. 
Pie chart of answers to the question “Would you be happy to do the puzzles again?” 
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 Of the four participants (11%) who said they would not be happy to complete 
the battery again one child later reported to the researcher that they had actually 
enjoyed the CogState tasks the best of any of the tasks in the testing session as a 
whole. Two of the other children were among the most cognitively impaired children 
in the sample as a whole performing ≥1Standard Deviation below the mean on 8/9 
tasks and 7/9 tasks in the standard battery and 1/4 and 2/4 CogState tasks (of the four 
tasks where this can be assessed) respectively.    
Qualitative comments 
The last question on the acceptability questionnaire invited participants to 
give any additional comments on their experience of completing the measure 
prompting them with the phrase “Is there anything else you would like to say about 
the puzzles? For example, was there a puzzle you liked the best? Or a puzzle you 
really didn’t like?” Of the 37 participants 24 chose to leave a comment in this 
section, with 10 participants commenting on two separate aspects of the measure 
resulting in 34 comments in total.  
Overall 22 positive comments were made (65%), either about the measure as 
a whole (three comments; e.g. “I enjoyed it a lot, I feel I would like to do this again”) 
89%
11%
Yes No
230 
 
or about specific tasks. Of the specific tasks eight participants said they enjoyed the 
GMLT, seven participants said that they enjoyed the CPAL task, and four mentioned 
enjoying the card based tasks ( one singling out the OCL task and one the IDN and 
OBK tasks).  
There were 10 comments made regarding aspects of the battery the 
participants did not like. Six participants reported they did not like specific tasks 
(GMLT (2), card tasks (4) including OCL (1)). Within this three participants gave 
reasons for their dislike. The two participants who referred to the GMLT stated it 
was too hard. The child who referred to the card based takes stated they “went on for 
quite a while”. One participant commented that the keyboard controls for the tasks 
were “a bit annoying to use” and another than the feedback when they answered 
incorrectly on some items left them feeling “a bit demoralised”. Lastly one 
participant commented that in general the tasks need to be made “a bit harder 
because they are too easy”.  
 Lastly one neutral comment was made which stated “some of the tasks took 
longer than others”.  
Feasibility 
 Recruitment and Completion rates  
 The recruitment rates from each of the clinical services were presented in 
Table 2. The expression of interest rate at the two smaller services (A and B) was 
85% and 83% respectively. In Service A three people declined to find out more about 
research. Of these, one family wished their child to have a full neuropsychological 
evaluation; one child had just finished their treatment and did not wish to have any 
further contact with services at that time and one family declined as they could not 
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see the benefit of the project to their child. In Service B two families declined to find 
out more about the research without providing a reason.  In service C the expression 
of interest rate was much lower (46%) however this is likely due to the follow up 
phone calls from the service stopping once the sample size had been achieved.  
In all three services the recruitment and completion rates of those who an 
expressed an interest were high. In Service A only two families who showed an 
interest in the study did not go on to complete the battery. One child was excluded 
prior to consent due to previous neuropsychological assessment in the past year. The 
other child was consented into the study, however during completion of the CogState 
battery asked to stop taking part and was subsequently excluded from the study with 
appropriate clinical support identified. In retrospect this child should have been 
excluded from recruitment due to motor impairment severe enough to prevent testing 
due to only being able to use one of their hands. This highlights the motor 
requirements of the battery, which may appear minimal but do require the use of both 
hands. In Service B one family expressed an interest but were not consented into the 
study due to difficulty arranging a suitable place to hold the testing visit. If the 
battery were a standard part of clinical practice this issue would not be relevant. In 
Service C six families who expressed an interest were not consented into the study. 
Of these one family had moved out of area, three were not possible to contact due to 
incorrect details, one was excluded due to the severity of their sensory impairment 
and one due to English not being their first language.  
In summary the recruitment rate overall was high when taking into account 
the limitations of the sample size. Families were keen to take part and regularly 
expressed to the researcher their belief that cognitive screening is necessary and 
should be more widely available. Reasons for non-participation, where known, were 
232 
 
generally due to the practical aspects of the research rather than the content or topic 
of the study. All but one child (97%) completed the CogState battery without 
incident.  
 Brevity 
 Data on the time taken to complete and score both the CogState battery and 
the standard battery are presented in Table 4.  
Table 4.  
 Completion and scoring times for the two test batteries 
 
 Three participants did not complete the full standard battery therefore their 
data for both batteries was excluded. Scoring times are taken from a sub sample of 
five participants at the end of the recruitment phase when the researcher was familiar 
with the scoring process for both batteries. For CogState, which is automatically 
scored, this process involved taking the data off the testing computer on a secure 
memory stick, uploading it to the central DataPoint secure server and downloading a 
score profile. For the standard battery this process involved scoring each test and 
compiling the results into a spreadsheet. The time taken to write a report based on the 
scores is not included. The results shown that the CogState battery was significantly 
shorter to complete t(33) = -22.18, p≤.001, with the difference representing a very 
 CogState Battery Standard Subtest 
Battery 
 
Completion time (n=34) 
    Mean 
    SD 
    Range 
 
22.1 
3.1 
17-31 
 
32.6 
2.8 
28-38 
 
p≤.001 
Scoring time (n=5) 
    Mean 
    SD 
    Range 
 
3.8 
0.8 
3-5 
 
31.4 
2.7 
28-35 
 
p≤.001 
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large effect size r=.96. It was also significantly shorter to score, t(8) = -21.82, p≤.001 
with the difference again representing a very large effect size r=.99.  
Discussion 
 In summary the results of this study support the CogState battery as an 
acceptable and feasible measure for use with a paediatric oncology population in the 
areas assessed. Results of the acceptability questionnaire indicate that although 
around three quarters of the sample found the battery at least a little hard the vast 
majority of the participants did not find completing it at all upsetting or tiring and 
almost all found it at least a little interesting and enjoyable. Only three children felt 
the battery took a very long time to complete but around half felt it took quite a long 
time. In comparison with Pejnovic et al. (2012) more children reported finding the 
CogState battery at least a little hard, and quite long to complete but the results for 
fatigue, distress interest and enjoyment are comparably positive.  
 The difference in the children’s impression of the difficulty of the battery 
may be related to the immediate feedback they received during the tasks. This 
feedback is not a common aspect of standard neuropsychological tests and would not 
have occurred on the battery of measures used by Pejnovic et al. (2012). Anecdotally 
the researcher observed several of the participants to show dismay or frustration 
when they received repeated feedback that they were getting items wrong, however 
the converse was also observed with children appearing pleased and motivated by 
positive feedback. One child made an explicit comment about the feedback as 
contributing to them feeling “demoralised” however this was not a common theme in 
the qualitative feedback. Given this and the positive results on the acceptability 
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questionnaire it does not appear that in general the feedback was upsetting to the 
participants even if it did impact their view of the difficulty of the assessment.   
 The difference in the children’s perception of how long the battery took to 
complete is interesting given that the CogState battery was actually significantly 
quicker than the battery reported by Pejnovic et al. (2012), t(81)=12.17, p≤.001, and 
significantly quicker than the battery of standard subtests used in this study. It could 
be hypothesised that this relates to the repetitiveness of the tasks, with up to 80 trials 
being completed in some tasks, or to the fact that all tasks were completed in one 
continuous session on the computer in contrast to the changes of equipment and 
response format when using standard measures. Two children commented 
specifically on this aspect of the battery with one saying the card based tasks in 
particular went on for a long time and another saying that the tasks felt a bit 
repetitive. However it should be remembered that 43% of the children reported 
finding the battery “not long at all” to complete and 89% said they would be happy 
to do the puzzles again indicating that for most of the children the length of the 
battery was not a significant issue.  
 The further analysis of the four children who reported not wanting to do the 
battery again revealed this group included the most impaired children in the sample 
on the standard neuropsychological measures, raising the possibility that for children 
with more significant difficulties the process of assessment is more aversive. This 
possibility is reported as common to all testing environments (Baron, 2004) however 
given the immediate feedback provided within the CogState battery it may be 
something that the examiner needs to be particularly aware of with this assessment. 
However, all but one of the sample successfully completed the entire battery in one 
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sitting without asking for breaks, indicating that the tasks are feasible for most 
children who do not have gross motor impairment.  
 The recruitment rate in this study was high in the two services where it was 
not limited and comparable to similar studies (Pejnovic et al. 2012; 75%; Krull et al. 
2008; 82%). This gives broad support to the acceptability of the assessment to 
families, particularly given that in this study the CogState battery formed part of a 
longer assessment visit. It also suggests that the battery would be feasible to 
incorporate into standard clinical follow up as the reasons for non-participation were 
generally due to the practicalities of the research and would not apply in clinical 
practice.  
 Results regarding the brevity of the battery were strongly in the favour of 
CogState compared to both the brief standard battery used in this study and other 
brief screening measures in the literature. This study also considered scoring time, in 
contrast to other reports, highlighting the large advantage of computerised measures 
in this area for busy clinicians.    
Limitations  
 This study used an appropriate and relevant approach to assessing the 
reported acceptability of the battery to a large and representative sample of children 
at risk of neurocognitive impairment. However there are limitations which should be 
considered. Other areas of feasibility such as the added value of the battery were not 
explicitly considered. Assessment of acceptability relied on self-report by the child 
and did not include structured observations by the examiner. The analysis of the time 
take to score the battery was conducted on a small sub-sample which may have 
limited its reliability, however given the size of the effect observed this is unlikely to 
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have significantly altered the conclusion. Recruitment rates may have been affected 
by the larger requirements of the full research visit and so may be an under 
representation of true interest in and uptake of the CogState assessment. The battery 
was completed in participants’ homes so an evaluation of feasibility specifically in 
the clinic setting is beyond the scope of this project.   
Clinical Implications and Conclusion 
 In conclusion, this study indicates that the CogState battery is acceptable to 
the vast majority of children at risk of neurocognitive impairment followed up 
through paediatric oncology outpatient clinics. In terms of feasibility, the battery was 
quick to complete and especially quick to score. Both of these things mean that it is 
highly suitable as a screening instrument in clinical settings once further research has 
been conducted to ascertain that it shows acceptable construct and criterion validity 
and sensitivity and specificity in this population.  
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Appendix Q 
Scatter Plots of Correlations for Research Questions 1 and 2 
 
Figure Q.1  
Scatterplot of the relationship between Detection and Grooved Peg Board 
(Dominant) 
 
Figure Q.2  
Scatterplot of the relationship between Detection and Symbol Search 
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Figure Q.3 
Scatterplot of the relationship between Identification and Map Mission 
 
 
Figure Q.4  
Scatterplot of the relationship between Identification and Score! 
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Figure Q.5  
Scatterplot of the relationship between Once Card Learning and Dot Location 
 
 
Figure Q.6  
Scatterplot of the relationship between One Card Learning (outlier removed) and 
Dot Location 
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Figure Q.7  
Scatterplot of the relationship between CPAL and Dot Location 
 
 
Figure Q.8 
Scatterplot of the relationship between One Back and Digit Span 
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Figure Q.9 
Scatterplot of the relationship between One Back and Longest Digit Span Backwards 
 
 
Figure Q.10 
Scatterplot of the relationship between the GMLT and the BRIEF GEC in 
participants aged 10-16 years 
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Figure Q.11 
Scatterplot of the relationship between the GMLT and TMT-B in participants aged 
10-16 years 
 
 
 
Figure Q.12  
Scatterplot of the relationship between the GMLT and TMT-B in participants aged 8-
9 years 
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Figure Q.13 
Scatterplot of the relationship between GMLT and the BRIEF GEC in participants 
aged 8-9years 
 
 
Figure Q.14 
Scatterplot of the relationship between time since diagnosis (months) and CogState 
composite score 
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Figure Q.15 
Scatterplot of the relationship between time since diagnosis (months) and IQ 
 
 
 
